Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,28747995,Ki,"Considering a typical dosing regimen and applying the obtained Ki values of 0.72 µM (darifenacin, 15 mg daily) and 7.2 µM [propiverine, 30 mg daily, immediate release (IR)] for the inhibition of CYP2D6 yielded a predicted 1.9-fold and 1.4-fold increase in the area under the curve (AUC) of debrisoquine (CYP2D6 substrate), respectively.",Assessment of inhibitory effects on major human cytochrome P450 enzymes by spasmolytics used in the treatment of overactive bladder syndrome. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28747995/),μM,0.72,620,DB04840,Debrisoquin
,28747995,Ki,"Considering a typical dosing regimen and applying the obtained Ki values of 0.72 µM (darifenacin, 15 mg daily) and 7.2 µM [propiverine, 30 mg daily, immediate release (IR)] for the inhibition of CYP2D6 yielded a predicted 1.9-fold and 1.4-fold increase in the area under the curve (AUC) of debrisoquine (CYP2D6 substrate), respectively.",Assessment of inhibitory effects on major human cytochrome P450 enzymes by spasmolytics used in the treatment of overactive bladder syndrome. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28747995/),μM,7.2,621,DB04840,Debrisoquin
,28747995,Ki,"Due to the inhibition of the particular intestinal CYP3A4, the obtained Ki values of 14 µM of propiverine (30 mg daily, IR) resulted in a predicted doubling of the AUC for midazolam (CYP3A4 substrate).",Assessment of inhibitory effects on major human cytochrome P450 enzymes by spasmolytics used in the treatment of overactive bladder syndrome. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28747995/),μM,14,622,DB04840,Debrisoquin
,2493353,elimination half-life,Estimated mean elimination half-life of glyburide was 3.3 +/- 1.1 hours for EM and 2.5 +/- 0.4 hours for PM.,The metabolism of glyburide in subjects of known debrisoquin phenotype. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2493353/),h,3.3,2489,DB04840,Debrisoquin
,2493353,elimination half-life,Estimated mean elimination half-life of glyburide was 3.3 +/- 1.1 hours for EM and 2.5 +/- 0.4 hours for PM.,The metabolism of glyburide in subjects of known debrisoquin phenotype. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2493353/),h,2.5,2490,DB04840,Debrisoquin
,2493353,apparent elimination half-life,"In one subject (EM), with reduced excretion of 30H, glyburide was detected in plasma at 24 and 30 hours and the apparent elimination half-life was 9.3 hours.",The metabolism of glyburide in subjects of known debrisoquin phenotype. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2493353/),h,9.3,2491,DB04840,Debrisoquin
,3234461,maximum plasma concentrations,"Oxybutynin was rapidly absorbed, maximum plasma concentrations (8 ng.ml-1) being reached in less than 1 h.",The pharmacokinetics of oxybutynin in man. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3234461/),[ng] / [ml],8,8047,DB04840,Debrisoquin
,3234461,absolute systemic availability,The absolute systemic availability averaged 6% and the tablet and solution forms displayed similar relative systemic availability.,The pharmacokinetics of oxybutynin in man. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3234461/),%,6,8048,DB04840,Debrisoquin
,3234461,elimination half-life,"Plasma concentrations of oxybutynin fell biexponentially, the elimination half-life being about 2 h.",The pharmacokinetics of oxybutynin in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3234461/),h,2,8049,DB04840,Debrisoquin
,2861095,systemic availability,In extensive metabolizers the systemic availability of bufuralol was 43%.,Effect of oxidative polymorphism (debrisoquine/sparteine type) on hepatic first-pass metabolism of bufuralol. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2861095/),%,43,9600,DB04840,Debrisoquin
,2702801,total oral clearance,The total oral clearance of propranolol increased about fourfold in both phenotypes from 219.2 +/- 52.8 to 976.7 L/hr in the EMs and from 75.0 +/- 12.6 to 289.8 +/- 78.2 L/hr in the PMs.,Influence of debrisoquin phenotype on the inducibility of propranolol metabolism. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2702801/),[l] / [h],219.2,12007,DB04840,Debrisoquin
,2702801,total oral clearance,The total oral clearance of propranolol increased about fourfold in both phenotypes from 219.2 +/- 52.8 to 976.7 L/hr in the EMs and from 75.0 +/- 12.6 to 289.8 +/- 78.2 L/hr in the PMs.,Influence of debrisoquin phenotype on the inducibility of propranolol metabolism. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2702801/),[l] / [h],976.7,12008,DB04840,Debrisoquin
,2702801,total oral clearance,The total oral clearance of propranolol increased about fourfold in both phenotypes from 219.2 +/- 52.8 to 976.7 L/hr in the EMs and from 75.0 +/- 12.6 to 289.8 +/- 78.2 L/hr in the PMs.,Influence of debrisoquin phenotype on the inducibility of propranolol metabolism. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2702801/),[l] / [h],75.0,12009,DB04840,Debrisoquin
,2702801,total oral clearance,The total oral clearance of propranolol increased about fourfold in both phenotypes from 219.2 +/- 52.8 to 976.7 L/hr in the EMs and from 75.0 +/- 12.6 to 289.8 +/- 78.2 L/hr in the PMs.,Influence of debrisoquin phenotype on the inducibility of propranolol metabolism. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2702801/),[l] / [h],289.8,12010,DB04840,Debrisoquin
,2439789,absolute bioavailability,Bisoprolol exhibits a high absolute bioavailability (90%) because of its nearly complete absorption (greater than 90%) and small first-pass effect (10%).,Balanced pharmacokinetics and metabolism of bisoprolol. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2439789/),%,90,13263,DB04840,Debrisoquin
,2439789,plasma-elimination half-life,A long plasma-elimination half-life (10-11h) allows a once-a-day dose regimen.,Balanced pharmacokinetics and metabolism of bisoprolol. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2439789/),h,10-11,13264,DB04840,Debrisoquin
,2511912,oral clearance,The oral clearance of R-flecainide (467 +/- 109 ml min-1) was less (P less than 0.03) than that of the S-enantiomer (620 +/- 172 ml min-1).,Stereoselective disposition of flecainide in relation to the sparteine/debrisoquine metaboliser phenotype. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2511912/),[ml] / [min],467,14691,DB04840,Debrisoquin
,2511912,oral clearance,The oral clearance of R-flecainide (467 +/- 109 ml min-1) was less (P less than 0.03) than that of the S-enantiomer (620 +/- 172 ml min-1).,Stereoselective disposition of flecainide in relation to the sparteine/debrisoquine metaboliser phenotype. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2511912/),[ml] / [min],620,14692,DB04840,Debrisoquin
,2511912,half-life,The half-life of R-flecainide (12.9 h) was longer (P less than 0.03) than that of S-flecainide (9.8 h).,Stereoselective disposition of flecainide in relation to the sparteine/debrisoquine metaboliser phenotype. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2511912/),h,12.9,14693,DB04840,Debrisoquin
,2511912,half-life,The half-life of R-flecainide (12.9 h) was longer (P less than 0.03) than that of S-flecainide (9.8 h).,Stereoselective disposition of flecainide in relation to the sparteine/debrisoquine metaboliser phenotype. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2511912/),h,9.8,14694,DB04840,Debrisoquin
,2511912,urinary recovery,The urinary recovery of R-flecainide (15.6 +/- 3.7 mg) was greater (P less than 0.03) than that of the S-enantiomer (12.0 +/- 3.7 mg).,Stereoselective disposition of flecainide in relation to the sparteine/debrisoquine metaboliser phenotype. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2511912/),mg,15.6,14695,DB04840,Debrisoquin
,2511912,urinary recovery,The urinary recovery of R-flecainide (15.6 +/- 3.7 mg) was greater (P less than 0.03) than that of the S-enantiomer (12.0 +/- 3.7 mg).,Stereoselective disposition of flecainide in relation to the sparteine/debrisoquine metaboliser phenotype. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2511912/),mg,12.0,14696,DB04840,Debrisoquin
,2511912,urinary recoveries,"4. The urinary recoveries of two major metabolites of flecainide, meta-O-dealkylated flecainide (MODF) and the meta-O-dealkylated lactam of flecainide (MODLF) were lower (P less than 0.05) in PMs, 12.0% +/- 3.1% and 8.2% +/- 3.2% of the dose administered, respectively, than in EMs of 17.7% +/- 3.3% and 16.5% +/- 3.3%, respectively.",Stereoselective disposition of flecainide in relation to the sparteine/debrisoquine metaboliser phenotype. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2511912/),%,12.0,14697,DB04840,Debrisoquin
,2511912,urinary recoveries,"4. The urinary recoveries of two major metabolites of flecainide, meta-O-dealkylated flecainide (MODF) and the meta-O-dealkylated lactam of flecainide (MODLF) were lower (P less than 0.05) in PMs, 12.0% +/- 3.1% and 8.2% +/- 3.2% of the dose administered, respectively, than in EMs of 17.7% +/- 3.3% and 16.5% +/- 3.3%, respectively.",Stereoselective disposition of flecainide in relation to the sparteine/debrisoquine metaboliser phenotype. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2511912/),%,8.2,14698,DB04840,Debrisoquin
,2511912,urinary recoveries,"4. The urinary recoveries of two major metabolites of flecainide, meta-O-dealkylated flecainide (MODF) and the meta-O-dealkylated lactam of flecainide (MODLF) were lower (P less than 0.05) in PMs, 12.0% +/- 3.1% and 8.2% +/- 3.2% of the dose administered, respectively, than in EMs of 17.7% +/- 3.3% and 16.5% +/- 3.3%, respectively.",Stereoselective disposition of flecainide in relation to the sparteine/debrisoquine metaboliser phenotype. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2511912/),%,17.7,14699,DB04840,Debrisoquin
,2511912,urinary recoveries,"4. The urinary recoveries of two major metabolites of flecainide, meta-O-dealkylated flecainide (MODF) and the meta-O-dealkylated lactam of flecainide (MODLF) were lower (P less than 0.05) in PMs, 12.0% +/- 3.1% and 8.2% +/- 3.2% of the dose administered, respectively, than in EMs of 17.7% +/- 3.3% and 16.5% +/- 3.3%, respectively.",Stereoselective disposition of flecainide in relation to the sparteine/debrisoquine metaboliser phenotype. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2511912/),%,16.5,14700,DB04840,Debrisoquin
,3081292,elimination t1/2,Extensive metabolizers of debrisoquin had a mean (+/- SD) encainide elimination t1/2 of 1.19 +/- 0.98 hours (range 0.25 to 3.4 hours).,Co-inheritance of the polymorphic metabolism of encainide and debrisoquin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3081292/),h,1.19,18449,DB04840,Debrisoquin
,3081292,t1/2,Poor metabolizers of debrisoquin (two normal subjects and three family members) had a mean t1/2 of 13.2 +/- 0.73 hours (range 7.8 to 22.4 hours).,Co-inheritance of the polymorphic metabolism of encainide and debrisoquin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3081292/),h,13.2,18450,DB04840,Debrisoquin
,1771652,Plasma concentrations,Plasma concentrations of AMI (510 ng/ml) and nortriptyline (NOR; 320 ng/ml) were very high and the half-life of AMI was about 120 h.,Extremely long plasma half-life of amitriptyline in a woman with the cytochrome P450IID6 29/29-kilobase wild-type allele--a slowly reversible interaction with fluoxetine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1771652/),[ng] / [ml],510,21188,DB04840,Debrisoquin
,1771652,Plasma concentrations,Plasma concentrations of AMI (510 ng/ml) and nortriptyline (NOR; 320 ng/ml) were very high and the half-life of AMI was about 120 h.,Extremely long plasma half-life of amitriptyline in a woman with the cytochrome P450IID6 29/29-kilobase wild-type allele--a slowly reversible interaction with fluoxetine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1771652/),[ng] / [ml],320,21189,DB04840,Debrisoquin
,1771652,half-life,Plasma concentrations of AMI (510 ng/ml) and nortriptyline (NOR; 320 ng/ml) were very high and the half-life of AMI was about 120 h.,Extremely long plasma half-life of amitriptyline in a woman with the cytochrome P450IID6 29/29-kilobase wild-type allele--a slowly reversible interaction with fluoxetine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1771652/),h,120,21190,DB04840,Debrisoquin
,1771652,metabolic ratio,"The debrisoquine metabolic ratio was 0.55 and 0.79 on two occasions, which shows that she had no deficiency of cytochrome P450IID6.",Extremely long plasma half-life of amitriptyline in a woman with the cytochrome P450IID6 29/29-kilobase wild-type allele--a slowly reversible interaction with fluoxetine. ,Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1771652/),,0.55,21191,DB04840,Debrisoquin
,1771652,metabolic ratio,"The debrisoquine metabolic ratio was 0.55 and 0.79 on two occasions, which shows that she had no deficiency of cytochrome P450IID6.",Extremely long plasma half-life of amitriptyline in a woman with the cytochrome P450IID6 29/29-kilobase wild-type allele--a slowly reversible interaction with fluoxetine. ,Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1771652/),,0.79,21192,DB04840,Debrisoquin
,2380545,elimination half-line,"Its kinetics were described by a two-compartment open model with an elimination half-line 1.2 h, systemic clearance 1299 l/min, volume of distribution 1321 l and urinary excretion of parent drug less than 1% of the dose.",Tolerability and kinetics of intravenous medifoxamine in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2380545/),h,1.2,22844,DB04840,Debrisoquin
,2380545,systemic clearance,"Its kinetics were described by a two-compartment open model with an elimination half-line 1.2 h, systemic clearance 1299 l/min, volume of distribution 1321 l and urinary excretion of parent drug less than 1% of the dose.",Tolerability and kinetics of intravenous medifoxamine in healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2380545/),[l] / [min],1299,22845,DB04840,Debrisoquin
,2380545,volume of distribution,"Its kinetics were described by a two-compartment open model with an elimination half-line 1.2 h, systemic clearance 1299 l/min, volume of distribution 1321 l and urinary excretion of parent drug less than 1% of the dose.",Tolerability and kinetics of intravenous medifoxamine in healthy volunteers. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2380545/),l,1321,22846,DB04840,Debrisoquin
,8527689,peak serum concentration (Cmax),At the end of infusion a peak serum concentration (Cmax) of 631 +/- 95 ng mL-1 (mean +/- SD) was observed.,Disposition and bioavailability of the beta 1-adrenoceptor antagonist talinolol in man. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8527689/),[ng] / [ml],631,27392,DB04840,Debrisoquin
,8527689,area under the serum concentration-time curve from zero to infinity (AUC0-infinity),The area under the serum concentration-time curve from zero to infinity (AUC0-infinity) was 1433 +/- 153 ng h mL-1.,Disposition and bioavailability of the beta 1-adrenoceptor antagonist talinolol in man. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8527689/),[h·ng] / [ml],1433,27393,DB04840,Debrisoquin
,8527689,terminal elimination half life (t 1/2),"The following parameters were estimated: terminal elimination half life (t 1/2), 10.6 +/- 3.3 h; mean residence time, 11.6 +/- 3.1 h; volume of distribution, 3.3 +/- 0.5 L kg-1; and total body clearance, 4.9 +/- 0.6 mL min-1 kg-1.",Disposition and bioavailability of the beta 1-adrenoceptor antagonist talinolol in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8527689/),h,10.6,27394,DB04840,Debrisoquin
,8527689,mean residence time,"The following parameters were estimated: terminal elimination half life (t 1/2), 10.6 +/- 3.3 h; mean residence time, 11.6 +/- 3.1 h; volume of distribution, 3.3 +/- 0.5 L kg-1; and total body clearance, 4.9 +/- 0.6 mL min-1 kg-1.",Disposition and bioavailability of the beta 1-adrenoceptor antagonist talinolol in man. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8527689/),h,11.6,27395,DB04840,Debrisoquin
,8527689,volume of distribution,"The following parameters were estimated: terminal elimination half life (t 1/2), 10.6 +/- 3.3 h; mean residence time, 11.6 +/- 3.1 h; volume of distribution, 3.3 +/- 0.5 L kg-1; and total body clearance, 4.9 +/- 0.6 mL min-1 kg-1.",Disposition and bioavailability of the beta 1-adrenoceptor antagonist talinolol in man. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8527689/),[l] / [kg],3.3,27396,DB04840,Debrisoquin
,8527689,total body clearance,"The following parameters were estimated: terminal elimination half life (t 1/2), 10.6 +/- 3.3 h; mean residence time, 11.6 +/- 3.1 h; volume of distribution, 3.3 +/- 0.5 L kg-1; and total body clearance, 4.9 +/- 0.6 mL min-1 kg-1.",Disposition and bioavailability of the beta 1-adrenoceptor antagonist talinolol in man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8527689/),[ml] / [kg·min],4.9,27397,DB04840,Debrisoquin
,8527689,Cmax,After oral administration a Cmax of 168 +/- 67 ng mL-1 was reached after 3.2 +/- 0.8 h.,Disposition and bioavailability of the beta 1-adrenoceptor antagonist talinolol in man. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8527689/),[ng] / [ml],168,27398,DB04840,Debrisoquin
,8527689,AUC0-infinity,The AUC0-infinity was 1321 +/- 382 ng h mL-1.,Disposition and bioavailability of the beta 1-adrenoceptor antagonist talinolol in man. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8527689/),[h·ng] / [ml],1321,27399,DB04840,Debrisoquin
,8527689,t 1/2,The t 1/2 was 11.9 +/- 2.4 h. 28.1 +/- 6.8% of the dose or 55.0 +/- 11.0% of the bioavailable talinolol was eliminated as unchanged talinolol and 0.26 +/- 0.17% of the dose as hydroxylated metabolites by kidney.,Disposition and bioavailability of the beta 1-adrenoceptor antagonist talinolol in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8527689/),h,11.9,27400,DB04840,Debrisoquin
,8527689,t 1/2,The t 1/2 was 11.9 +/- 2.4 h. 28.1 +/- 6.8% of the dose or 55.0 +/- 11.0% of the bioavailable talinolol was eliminated as unchanged talinolol and 0.26 +/- 0.17% of the dose as hydroxylated metabolites by kidney.,Disposition and bioavailability of the beta 1-adrenoceptor antagonist talinolol in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8527689/),%,28.1,27401,DB04840,Debrisoquin
,8527689,t 1/2,The t 1/2 was 11.9 +/- 2.4 h. 28.1 +/- 6.8% of the dose or 55.0 +/- 11.0% of the bioavailable talinolol was eliminated as unchanged talinolol and 0.26 +/- 0.17% of the dose as hydroxylated metabolites by kidney.,Disposition and bioavailability of the beta 1-adrenoceptor antagonist talinolol in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8527689/),%,55.0,27402,DB04840,Debrisoquin
,8527689,t 1/2,The t 1/2 was 11.9 +/- 2.4 h. 28.1 +/- 6.8% of the dose or 55.0 +/- 11.0% of the bioavailable talinolol was eliminated as unchanged talinolol and 0.26 +/- 0.17% of the dose as hydroxylated metabolites by kidney.,Disposition and bioavailability of the beta 1-adrenoceptor antagonist talinolol in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8527689/),%,0.26,27403,DB04840,Debrisoquin
,8527689,absolute bioavailability,"The absolute bioavailability of talinolol was 55 +/- 15% (95% confidence interval, 36-69%).",Disposition and bioavailability of the beta 1-adrenoceptor antagonist talinolol in man. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8527689/),%,55,27404,DB04840,Debrisoquin
,2731406,plasma half-lives,The plasma half-lives of both enantiomers were 8 to 9 hours.,Stereoselective disposition of racemic E-10-hydroxynortriptyline in human beings. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2731406/),h,8 to 9,30057,DB04840,Debrisoquin
,2731406,renal clearance,"The renal clearance of unbound (-)E-10-OH-NT (0.57 +/- 0.16 L.kg-1.hr-1), on the other hand, exceeded that of (+)E-10-OH-NT (0.44 +/- 0.14 L.kg-1.hr-1) (p less than 0.005), which suggests enantioselective tubular secretion.",Stereoselective disposition of racemic E-10-hydroxynortriptyline in human beings. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2731406/),[l] / [h·kg],0.57,30058,DB04840,Debrisoquin
,2731406,renal clearance,"The renal clearance of unbound (-)E-10-OH-NT (0.57 +/- 0.16 L.kg-1.hr-1), on the other hand, exceeded that of (+)E-10-OH-NT (0.44 +/- 0.14 L.kg-1.hr-1) (p less than 0.005), which suggests enantioselective tubular secretion.",Stereoselective disposition of racemic E-10-hydroxynortriptyline in human beings. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2731406/),[l] / [h·kg],0.44,30059,DB04840,Debrisoquin
,6641100,peak plasma concentrations,Higher peak plasma concentrations of phenformin (152.2 +/- 12.7 ng/ml; mean +/- SE) and a greater plasma AUC (779 +/- 99 ng X hr X ml-1) were reached in PM than in EM (99.8 +/- 13.7 ng/ml and 549 +/- 47 ng X hr X ml-1).,Influence of oxidation polymorphism on phenformin kinetics and dynamics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6641100/),[ng] / [ml],152.2,33922,DB04840,Debrisoquin
,6641100,plasma AUC,Higher peak plasma concentrations of phenformin (152.2 +/- 12.7 ng/ml; mean +/- SE) and a greater plasma AUC (779 +/- 99 ng X hr X ml-1) were reached in PM than in EM (99.8 +/- 13.7 ng/ml and 549 +/- 47 ng X hr X ml-1).,Influence of oxidation polymorphism on phenformin kinetics and dynamics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6641100/),[h·ng] / [ml],779,33923,DB04840,Debrisoquin
,6641100,plasma AUC,Higher peak plasma concentrations of phenformin (152.2 +/- 12.7 ng/ml; mean +/- SE) and a greater plasma AUC (779 +/- 99 ng X hr X ml-1) were reached in PM than in EM (99.8 +/- 13.7 ng/ml and 549 +/- 47 ng X hr X ml-1).,Influence of oxidation polymorphism on phenformin kinetics and dynamics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6641100/),[ng] / [ml],99.8,33924,DB04840,Debrisoquin
,6641100,plasma AUC,Higher peak plasma concentrations of phenformin (152.2 +/- 12.7 ng/ml; mean +/- SE) and a greater plasma AUC (779 +/- 99 ng X hr X ml-1) were reached in PM than in EM (99.8 +/- 13.7 ng/ml and 549 +/- 47 ng X hr X ml-1).,Influence of oxidation polymorphism on phenformin kinetics and dynamics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6641100/),[h·ng] / [ml],549,33925,DB04840,Debrisoquin
,3443146,total plasma clearance,"The mean values for total plasma clearance, elimination half-life, and metabolic clearance were 0.26 ml.min-1.kg-1, 3.4 h, and 0.17 ml.min-1.",Lack of relationship between tolbutamide metabolism and debrisoquine oxidation phenotype. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3443146/),[ml] / [kg·min],0.26,37598,DB04840,Debrisoquin
,3443146,elimination half-life,"The mean values for total plasma clearance, elimination half-life, and metabolic clearance were 0.26 ml.min-1.kg-1, 3.4 h, and 0.17 ml.min-1.",Lack of relationship between tolbutamide metabolism and debrisoquine oxidation phenotype. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3443146/),h,3.4,37599,DB04840,Debrisoquin
,3443146,metabolic clearance,"The mean values for total plasma clearance, elimination half-life, and metabolic clearance were 0.26 ml.min-1.kg-1, 3.4 h, and 0.17 ml.min-1.",Lack of relationship between tolbutamide metabolism and debrisoquine oxidation phenotype. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3443146/),[ml] / [min],0.17,37600,DB04840,Debrisoquin
,3443146,Total urinary recovery,Total urinary recovery (% of dose) and ratio of hydroxy- to carboxytolbutamide were 69.4% and 0.219 respectively in PM subjects and 70.9% and 0.226 in EM subjects.,Lack of relationship between tolbutamide metabolism and debrisoquine oxidation phenotype. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3443146/),%,69,37601,DB04840,Debrisoquin
,3443146,Total urinary recovery,Total urinary recovery (% of dose) and ratio of hydroxy- to carboxytolbutamide were 69.4% and 0.219 respectively in PM subjects and 70.9% and 0.226 in EM subjects.,Lack of relationship between tolbutamide metabolism and debrisoquine oxidation phenotype. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3443146/),%,70,37602,DB04840,Debrisoquin
less,2613393,metabolic ratio (MR),"In PM on rifampicin, the debrisoquine metabolic ratio (MR) was significantly reduced, even reaching a value less than 12.6 in 2 subjects but on phenobarbital and cimetidine, the MR was not significantly modified.","Influence of rifampicin, phenobarbital and cimetidine on mixed function monooxygenase in extensive and poor metabolizers of debrisoquine. ",Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2613393/),,12,39596,DB04840,Debrisoquin
,8941024,total amount of,"The total amount of fluoxetine excreted in the urine during 8 days was almost three times higher in poor metabolizers than in extensive metabolizers (719 versus 225 micrograms; p < 0.05), whereas the total amount of norfluoxetine excreted in urine of poor metabolizers was about half of that of extensive metabolizers (524 versus 1047 micrograms; p < 0.05).",The disposition of fluoxetine but not sertraline is altered in poor metabolizers of debrisoquin. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8941024/),μg,524,39866,DB04840,Debrisoquin
,8941024,total amount of,"The total amount of fluoxetine excreted in the urine during 8 days was almost three times higher in poor metabolizers than in extensive metabolizers (719 versus 225 micrograms; p < 0.05), whereas the total amount of norfluoxetine excreted in urine of poor metabolizers was about half of that of extensive metabolizers (524 versus 1047 micrograms; p < 0.05).",The disposition of fluoxetine but not sertraline is altered in poor metabolizers of debrisoquin. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8941024/),μg,1047,39867,DB04840,Debrisoquin
,8941024,excreted,"The total amount of fluoxetine excreted in the urine during 8 days was almost three times higher in poor metabolizers than in extensive metabolizers (719 versus 225 micrograms; p < 0.05), whereas the total amount of norfluoxetine excreted in urine of poor metabolizers was about half of that of extensive metabolizers (524 versus 1047 micrograms; p < 0.05).",The disposition of fluoxetine but not sertraline is altered in poor metabolizers of debrisoquin. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8941024/),μg,524,39868,DB04840,Debrisoquin
,8941024,excreted,"The total amount of fluoxetine excreted in the urine during 8 days was almost three times higher in poor metabolizers than in extensive metabolizers (719 versus 225 micrograms; p < 0.05), whereas the total amount of norfluoxetine excreted in urine of poor metabolizers was about half of that of extensive metabolizers (524 versus 1047 micrograms; p < 0.05).",The disposition of fluoxetine but not sertraline is altered in poor metabolizers of debrisoquin. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8941024/),μg,1047,39869,DB04840,Debrisoquin
,8941024,partial metabolic clearance,"Norfluoxetine Cmax and AUCzero-->t were significantly smaller in poor metabolizers (decreases 55% and decreases 53%, respectively), and the partial metabolic clearance of fluoxetine into norfluoxetine was 10 times smaller in this group (4.3 +/- 1.9 versus 0.4 +/- 0.1 L/hr; p < 0.05).",The disposition of fluoxetine but not sertraline is altered in poor metabolizers of debrisoquin. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8941024/),[l] / [h],4.3,39870,DB04840,Debrisoquin
,8941024,partial metabolic clearance,"Norfluoxetine Cmax and AUCzero-->t were significantly smaller in poor metabolizers (decreases 55% and decreases 53%, respectively), and the partial metabolic clearance of fluoxetine into norfluoxetine was 10 times smaller in this group (4.3 +/- 1.9 versus 0.4 +/- 0.1 L/hr; p < 0.05).",The disposition of fluoxetine but not sertraline is altered in poor metabolizers of debrisoquin. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8941024/),[l] / [h],0.4,39871,DB04840,Debrisoquin
,11907488,clearance,"At the higher but not the lower steady-state dose of fluvoxamine, a significantly lower clearance in PMs compared with EMs was observed (geometric mean, 0.86 versus 1.4 L/h per kilogram; P <.05).",Low daily 10-mg and 20-mg doses of fluvoxamine inhibit the metabolism of both caffeine (cytochrome P4501A2) and omeprazole (cytochrome P4502C19). ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11907488/),[l] / [h·kg],0.86,53686,DB04840,Debrisoquin
,11907488,clearance,"At the higher but not the lower steady-state dose of fluvoxamine, a significantly lower clearance in PMs compared with EMs was observed (geometric mean, 0.86 versus 1.4 L/h per kilogram; P <.05).",Low daily 10-mg and 20-mg doses of fluvoxamine inhibit the metabolism of both caffeine (cytochrome P4501A2) and omeprazole (cytochrome P4502C19). ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11907488/),[l] / [h·kg],1.4,53687,DB04840,Debrisoquin
,9115051,elimination half-lives (t 1/2,"The nonsteroidal antiinflammatory drugs (NSAIDs) oxaprozin and piroxicam have long elimination half-lives (t 1/2 approximately 55 hours), permitting once-daily dose regimens.","Oxaprozin and piroxicam, nonsteroidal antiinflammatory drugs with long half-lives: effect of protein-binding differences on steady-state pharmacokinetics. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9115051/),h,55,55465,DB04840,Debrisoquin
,9115051,t1/2,"Mean single-dose kinetic parameters of oxaprozin versus piroxicam did not differ more than +/-14% (t1/2, 53.0 versus 57.4 hours; apparent oral clearance adjusted for 70-kg body weight [Clpo], 0.139 versus 0.121 L/hr; apparent volume of distribution adjusted for 70-kg body weight [Vd/F]; 10.2 L versus 9.13 L).","Oxaprozin and piroxicam, nonsteroidal antiinflammatory drugs with long half-lives: effect of protein-binding differences on steady-state pharmacokinetics. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9115051/),h,53.0,55466,DB04840,Debrisoquin
,9115051,t1/2,"Mean single-dose kinetic parameters of oxaprozin versus piroxicam did not differ more than +/-14% (t1/2, 53.0 versus 57.4 hours; apparent oral clearance adjusted for 70-kg body weight [Clpo], 0.139 versus 0.121 L/hr; apparent volume of distribution adjusted for 70-kg body weight [Vd/F]; 10.2 L versus 9.13 L).","Oxaprozin and piroxicam, nonsteroidal antiinflammatory drugs with long half-lives: effect of protein-binding differences on steady-state pharmacokinetics. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9115051/),h,57.4,55467,DB04840,Debrisoquin
,9115051,apparent oral clearance,"Mean single-dose kinetic parameters of oxaprozin versus piroxicam did not differ more than +/-14% (t1/2, 53.0 versus 57.4 hours; apparent oral clearance adjusted for 70-kg body weight [Clpo], 0.139 versus 0.121 L/hr; apparent volume of distribution adjusted for 70-kg body weight [Vd/F]; 10.2 L versus 9.13 L).","Oxaprozin and piroxicam, nonsteroidal antiinflammatory drugs with long half-lives: effect of protein-binding differences on steady-state pharmacokinetics. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9115051/),[l] / [h],0.139,55468,DB04840,Debrisoquin
,9115051,apparent oral clearance,"Mean single-dose kinetic parameters of oxaprozin versus piroxicam did not differ more than +/-14% (t1/2, 53.0 versus 57.4 hours; apparent oral clearance adjusted for 70-kg body weight [Clpo], 0.139 versus 0.121 L/hr; apparent volume of distribution adjusted for 70-kg body weight [Vd/F]; 10.2 L versus 9.13 L).","Oxaprozin and piroxicam, nonsteroidal antiinflammatory drugs with long half-lives: effect of protein-binding differences on steady-state pharmacokinetics. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9115051/),[l] / [h],0.121,55469,DB04840,Debrisoquin
,9115051,apparent volume of distribution,"Mean single-dose kinetic parameters of oxaprozin versus piroxicam did not differ more than +/-14% (t1/2, 53.0 versus 57.4 hours; apparent oral clearance adjusted for 70-kg body weight [Clpo], 0.139 versus 0.121 L/hr; apparent volume of distribution adjusted for 70-kg body weight [Vd/F]; 10.2 L versus 9.13 L).","Oxaprozin and piroxicam, nonsteroidal antiinflammatory drugs with long half-lives: effect of protein-binding differences on steady-state pharmacokinetics. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9115051/),l,10.2,55470,DB04840,Debrisoquin
,9115051,apparent volume of distribution,"Mean single-dose kinetic parameters of oxaprozin versus piroxicam did not differ more than +/-14% (t1/2, 53.0 versus 57.4 hours; apparent oral clearance adjusted for 70-kg body weight [Clpo], 0.139 versus 0.121 L/hr; apparent volume of distribution adjusted for 70-kg body weight [Vd/F]; 10.2 L versus 9.13 L).","Oxaprozin and piroxicam, nonsteroidal antiinflammatory drugs with long half-lives: effect of protein-binding differences on steady-state pharmacokinetics. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9115051/),l,9.13,55471,DB04840,Debrisoquin
,9115051,Post-steady-state apparent t 1/2,Post-steady-state apparent t 1/2 of the total and unbound drugs of approximately 62 hours were similarly prolonged with piroxicam but differed substantially with oxaprozin (50.6 hours [total drug] versus 23.8 hours [unbound drug]).,"Oxaprozin and piroxicam, nonsteroidal antiinflammatory drugs with long half-lives: effect of protein-binding differences on steady-state pharmacokinetics. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9115051/),h,62,55472,DB04840,Debrisoquin
,9115051,Post-steady-state apparent t 1/2,Post-steady-state apparent t 1/2 of the total and unbound drugs of approximately 62 hours were similarly prolonged with piroxicam but differed substantially with oxaprozin (50.6 hours [total drug] versus 23.8 hours [unbound drug]).,"Oxaprozin and piroxicam, nonsteroidal antiinflammatory drugs with long half-lives: effect of protein-binding differences on steady-state pharmacokinetics. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9115051/),h,50.6,55473,DB04840,Debrisoquin
,9115051,Post-steady-state apparent t 1/2,Post-steady-state apparent t 1/2 of the total and unbound drugs of approximately 62 hours were similarly prolonged with piroxicam but differed substantially with oxaprozin (50.6 hours [total drug] versus 23.8 hours [unbound drug]).,"Oxaprozin and piroxicam, nonsteroidal antiinflammatory drugs with long half-lives: effect of protein-binding differences on steady-state pharmacokinetics. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9115051/),h,23.8,55474,DB04840,Debrisoquin
,1954076,elimination half-life,The mean elimination half-life of quinine in the PMs (10.2 +/- 1.6 (s.d.)h) was similar to that in the EMs (10.9 +/- 1.7 h).,Lack of relationship between debrisoquine oxidation phenotype and the pharmacokinetics of quinine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1954076/),h,10.2,56523,DB04840,Debrisoquin
,1954076,elimination half-life,The mean elimination half-life of quinine in the PMs (10.2 +/- 1.6 (s.d.)h) was similar to that in the EMs (10.9 +/- 1.7 h).,Lack of relationship between debrisoquine oxidation phenotype and the pharmacokinetics of quinine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1954076/),h,10.9,56524,DB04840,Debrisoquin
,1954076,oral clearance,The oral clearance of quinine in the PM subjects was 0.092 +/- 0.021 l h-1 kg-1 and was not significantly different (P greater than 0.05) from that observed in the EM subjects (0.073 +/- 0.019 l h-1 kg-1).,Lack of relationship between debrisoquine oxidation phenotype and the pharmacokinetics of quinine. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1954076/),[l] / [h·kg],0.092,56525,DB04840,Debrisoquin
,1954076,oral clearance,The oral clearance of quinine in the PM subjects was 0.092 +/- 0.021 l h-1 kg-1 and was not significantly different (P greater than 0.05) from that observed in the EM subjects (0.073 +/- 0.019 l h-1 kg-1).,Lack of relationship between debrisoquine oxidation phenotype and the pharmacokinetics of quinine. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1954076/),[l] / [h·kg],0.073,56526,DB04840,Debrisoquin
,12482486,Clearances,"Clearances were 0.41 and 0.25 l/h/kg, respectively, for the (+)-(R)- and (-)-(S)-enantiomers.",Enantioselective determination of metoprolol acidic metabolite in plasma and urine using liquid chromatography chiral columns: applications to pharmacokinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12482486/),[l] / [h·kg],0.41,62447,DB04840,Debrisoquin
,12482486,Clearances,"Clearances were 0.41 and 0.25 l/h/kg, respectively, for the (+)-(R)- and (-)-(S)-enantiomers.",Enantioselective determination of metoprolol acidic metabolite in plasma and urine using liquid chromatography chiral columns: applications to pharmacokinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12482486/),[l] / [h·kg],0.25,62448,DB04840,Debrisoquin
,2018005,lag time,"Well-absorbed, with a lag time of 4.4 to 9.8 minutes, 5-hydroxypropafenone reached peak concentrations of 153 to 337 ng/ml after 20 to 51 minutes.",Concentration-effect relations of 5-hydroxypropafenone in normal subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2018005/),min,4.4 to 9.8,64389,DB04840,Debrisoquin
,2018005,peak concentrations,"Well-absorbed, with a lag time of 4.4 to 9.8 minutes, 5-hydroxypropafenone reached peak concentrations of 153 to 337 ng/ml after 20 to 51 minutes.",Concentration-effect relations of 5-hydroxypropafenone in normal subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2018005/),[ng] / [ml],153 to 337,64390,DB04840,Debrisoquin
,2018005,terminal half-life,The terminal half-life was 506 to 963 minutes.,Concentration-effect relations of 5-hydroxypropafenone in normal subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2018005/),min,506 to 963,64391,DB04840,Debrisoquin
,6849780,areas under the plasma concentration-time curve,"Whilst PM subjects displayed significantly higher plasma levels of debrisoquine at all time points following 1 h post-dosing, and higher values for areas under the plasma concentration-time curve (EM: 105.6 +/- 7.0 ng ml-1 h; PM: 371.4 +/- 22.4 ng ml-1 h, 2P less than 0.0001), neither debrisoquine plasma half-life (EM: 3.0 +/- 0.5 h; PM: 3.3 +/- 0.4 h) nor renal clearance of the drug (EM: 152.8 +/- 30.3 ml min-1; PM: 137 +/- 4.5 ml min-1) displayed significant inter-phenotype differences.",Genetically determined oxidation capacity and the disposition of debrisoquine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6849780/),[h·ng] / [ml],105.6,68050,DB04840,Debrisoquin
,6849780,areas under the plasma concentration-time curve,"Whilst PM subjects displayed significantly higher plasma levels of debrisoquine at all time points following 1 h post-dosing, and higher values for areas under the plasma concentration-time curve (EM: 105.6 +/- 7.0 ng ml-1 h; PM: 371.4 +/- 22.4 ng ml-1 h, 2P less than 0.0001), neither debrisoquine plasma half-life (EM: 3.0 +/- 0.5 h; PM: 3.3 +/- 0.4 h) nor renal clearance of the drug (EM: 152.8 +/- 30.3 ml min-1; PM: 137 +/- 4.5 ml min-1) displayed significant inter-phenotype differences.",Genetically determined oxidation capacity and the disposition of debrisoquine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6849780/),[h·ng] / [ml],371.4,68051,DB04840,Debrisoquin
,6849780,plasma half-life,"Whilst PM subjects displayed significantly higher plasma levels of debrisoquine at all time points following 1 h post-dosing, and higher values for areas under the plasma concentration-time curve (EM: 105.6 +/- 7.0 ng ml-1 h; PM: 371.4 +/- 22.4 ng ml-1 h, 2P less than 0.0001), neither debrisoquine plasma half-life (EM: 3.0 +/- 0.5 h; PM: 3.3 +/- 0.4 h) nor renal clearance of the drug (EM: 152.8 +/- 30.3 ml min-1; PM: 137 +/- 4.5 ml min-1) displayed significant inter-phenotype differences.",Genetically determined oxidation capacity and the disposition of debrisoquine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6849780/),h,3.0,68052,DB04840,Debrisoquin
,6849780,plasma half-life,"Whilst PM subjects displayed significantly higher plasma levels of debrisoquine at all time points following 1 h post-dosing, and higher values for areas under the plasma concentration-time curve (EM: 105.6 +/- 7.0 ng ml-1 h; PM: 371.4 +/- 22.4 ng ml-1 h, 2P less than 0.0001), neither debrisoquine plasma half-life (EM: 3.0 +/- 0.5 h; PM: 3.3 +/- 0.4 h) nor renal clearance of the drug (EM: 152.8 +/- 30.3 ml min-1; PM: 137 +/- 4.5 ml min-1) displayed significant inter-phenotype differences.",Genetically determined oxidation capacity and the disposition of debrisoquine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6849780/),h,3.3,68053,DB04840,Debrisoquin
,6849780,renal clearance of,"Whilst PM subjects displayed significantly higher plasma levels of debrisoquine at all time points following 1 h post-dosing, and higher values for areas under the plasma concentration-time curve (EM: 105.6 +/- 7.0 ng ml-1 h; PM: 371.4 +/- 22.4 ng ml-1 h, 2P less than 0.0001), neither debrisoquine plasma half-life (EM: 3.0 +/- 0.5 h; PM: 3.3 +/- 0.4 h) nor renal clearance of the drug (EM: 152.8 +/- 30.3 ml min-1; PM: 137 +/- 4.5 ml min-1) displayed significant inter-phenotype differences.",Genetically determined oxidation capacity and the disposition of debrisoquine. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6849780/),[ml] / [min],152.8,68054,DB04840,Debrisoquin
,6849780,renal clearance of,"Whilst PM subjects displayed significantly higher plasma levels of debrisoquine at all time points following 1 h post-dosing, and higher values for areas under the plasma concentration-time curve (EM: 105.6 +/- 7.0 ng ml-1 h; PM: 371.4 +/- 22.4 ng ml-1 h, 2P less than 0.0001), neither debrisoquine plasma half-life (EM: 3.0 +/- 0.5 h; PM: 3.3 +/- 0.4 h) nor renal clearance of the drug (EM: 152.8 +/- 30.3 ml min-1; PM: 137 +/- 4.5 ml min-1) displayed significant inter-phenotype differences.",Genetically determined oxidation capacity and the disposition of debrisoquine. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6849780/),[ml] / [min],137,68055,DB04840,Debrisoquin
,2311341,uptake,"The uptake of toluene was about 3 mmol, or 50% of the inhaled dose in both rapid and slow hydroxylators.",Relationship between uptake and elimination of toluene and debrisoquin hydroxylation polymorphism. ,Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2311341/),mM,3,68910,DB04840,Debrisoquin
,10423287,"maximum plasma concentration, C(max)","However, the following differences (p < 0.05) were observed between the (-)-(S) and (+)-(R) enantiomers: maximum plasma concentration, C(max), 179.99 (123. 33-236.64) versus 151.30 (95.04-207.57) ng/mL; area under the plasma concentration versus time curve, AUC(0-24)(SS), 929.85 (458.02-1401. 70) versus 782.11 (329.80-1234.40) ng h/mL; apparent total clearance, Cl(T)/f, 1.70 (0.79-2.61) versus 2.21 (1.06-3.36) L/h/kg, apparent distribution volume, Vd/f, 10.51 (6.35-14.68) versus 13.80 (6.93-20. 68) L/kg, and renal clearance, Cl(R), 0.06 (0.05-0.08) versus 0.07 (0.05-0.09) L/kg.",Enantioselectivity in the steady-state pharmacokinetics of metoprolol in hypertensive patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10423287/),[ng] / [ml],179.99,70730,DB04840,Debrisoquin
,10423287,"maximum plasma concentration, C(max)","However, the following differences (p < 0.05) were observed between the (-)-(S) and (+)-(R) enantiomers: maximum plasma concentration, C(max), 179.99 (123. 33-236.64) versus 151.30 (95.04-207.57) ng/mL; area under the plasma concentration versus time curve, AUC(0-24)(SS), 929.85 (458.02-1401. 70) versus 782.11 (329.80-1234.40) ng h/mL; apparent total clearance, Cl(T)/f, 1.70 (0.79-2.61) versus 2.21 (1.06-3.36) L/h/kg, apparent distribution volume, Vd/f, 10.51 (6.35-14.68) versus 13.80 (6.93-20. 68) L/kg, and renal clearance, Cl(R), 0.06 (0.05-0.08) versus 0.07 (0.05-0.09) L/kg.",Enantioselectivity in the steady-state pharmacokinetics of metoprolol in hypertensive patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10423287/),[ng] / [ml],151.30,70731,DB04840,Debrisoquin
,10423287,"area under the plasma concentration versus time curve, AUC(0-24)","However, the following differences (p < 0.05) were observed between the (-)-(S) and (+)-(R) enantiomers: maximum plasma concentration, C(max), 179.99 (123. 33-236.64) versus 151.30 (95.04-207.57) ng/mL; area under the plasma concentration versus time curve, AUC(0-24)(SS), 929.85 (458.02-1401. 70) versus 782.11 (329.80-1234.40) ng h/mL; apparent total clearance, Cl(T)/f, 1.70 (0.79-2.61) versus 2.21 (1.06-3.36) L/h/kg, apparent distribution volume, Vd/f, 10.51 (6.35-14.68) versus 13.80 (6.93-20. 68) L/kg, and renal clearance, Cl(R), 0.06 (0.05-0.08) versus 0.07 (0.05-0.09) L/kg.",Enantioselectivity in the steady-state pharmacokinetics of metoprolol in hypertensive patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10423287/),[h·ng] / [ml],929.85,70732,DB04840,Debrisoquin
,10423287,"area under the plasma concentration versus time curve, AUC(0-24)","However, the following differences (p < 0.05) were observed between the (-)-(S) and (+)-(R) enantiomers: maximum plasma concentration, C(max), 179.99 (123. 33-236.64) versus 151.30 (95.04-207.57) ng/mL; area under the plasma concentration versus time curve, AUC(0-24)(SS), 929.85 (458.02-1401. 70) versus 782.11 (329.80-1234.40) ng h/mL; apparent total clearance, Cl(T)/f, 1.70 (0.79-2.61) versus 2.21 (1.06-3.36) L/h/kg, apparent distribution volume, Vd/f, 10.51 (6.35-14.68) versus 13.80 (6.93-20. 68) L/kg, and renal clearance, Cl(R), 0.06 (0.05-0.08) versus 0.07 (0.05-0.09) L/kg.",Enantioselectivity in the steady-state pharmacokinetics of metoprolol in hypertensive patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10423287/),[h·ng] / [ml],782.11,70733,DB04840,Debrisoquin
,10423287,"apparent total clearance, Cl(T)/f","However, the following differences (p < 0.05) were observed between the (-)-(S) and (+)-(R) enantiomers: maximum plasma concentration, C(max), 179.99 (123. 33-236.64) versus 151.30 (95.04-207.57) ng/mL; area under the plasma concentration versus time curve, AUC(0-24)(SS), 929.85 (458.02-1401. 70) versus 782.11 (329.80-1234.40) ng h/mL; apparent total clearance, Cl(T)/f, 1.70 (0.79-2.61) versus 2.21 (1.06-3.36) L/h/kg, apparent distribution volume, Vd/f, 10.51 (6.35-14.68) versus 13.80 (6.93-20. 68) L/kg, and renal clearance, Cl(R), 0.06 (0.05-0.08) versus 0.07 (0.05-0.09) L/kg.",Enantioselectivity in the steady-state pharmacokinetics of metoprolol in hypertensive patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10423287/),[l] / [h·kg],1.70,70734,DB04840,Debrisoquin
,10423287,"apparent total clearance, Cl(T)/f","However, the following differences (p < 0.05) were observed between the (-)-(S) and (+)-(R) enantiomers: maximum plasma concentration, C(max), 179.99 (123. 33-236.64) versus 151.30 (95.04-207.57) ng/mL; area under the plasma concentration versus time curve, AUC(0-24)(SS), 929.85 (458.02-1401. 70) versus 782.11 (329.80-1234.40) ng h/mL; apparent total clearance, Cl(T)/f, 1.70 (0.79-2.61) versus 2.21 (1.06-3.36) L/h/kg, apparent distribution volume, Vd/f, 10.51 (6.35-14.68) versus 13.80 (6.93-20. 68) L/kg, and renal clearance, Cl(R), 0.06 (0.05-0.08) versus 0.07 (0.05-0.09) L/kg.",Enantioselectivity in the steady-state pharmacokinetics of metoprolol in hypertensive patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10423287/),[l] / [h·kg],2.21,70735,DB04840,Debrisoquin
,10423287,"apparent distribution volume, Vd/f","However, the following differences (p < 0.05) were observed between the (-)-(S) and (+)-(R) enantiomers: maximum plasma concentration, C(max), 179.99 (123. 33-236.64) versus 151.30 (95.04-207.57) ng/mL; area under the plasma concentration versus time curve, AUC(0-24)(SS), 929.85 (458.02-1401. 70) versus 782.11 (329.80-1234.40) ng h/mL; apparent total clearance, Cl(T)/f, 1.70 (0.79-2.61) versus 2.21 (1.06-3.36) L/h/kg, apparent distribution volume, Vd/f, 10.51 (6.35-14.68) versus 13.80 (6.93-20. 68) L/kg, and renal clearance, Cl(R), 0.06 (0.05-0.08) versus 0.07 (0.05-0.09) L/kg.",Enantioselectivity in the steady-state pharmacokinetics of metoprolol in hypertensive patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10423287/),[l] / [kg],10.51,70736,DB04840,Debrisoquin
,10423287,"apparent distribution volume, Vd/f","However, the following differences (p < 0.05) were observed between the (-)-(S) and (+)-(R) enantiomers: maximum plasma concentration, C(max), 179.99 (123. 33-236.64) versus 151.30 (95.04-207.57) ng/mL; area under the plasma concentration versus time curve, AUC(0-24)(SS), 929.85 (458.02-1401. 70) versus 782.11 (329.80-1234.40) ng h/mL; apparent total clearance, Cl(T)/f, 1.70 (0.79-2.61) versus 2.21 (1.06-3.36) L/h/kg, apparent distribution volume, Vd/f, 10.51 (6.35-14.68) versus 13.80 (6.93-20. 68) L/kg, and renal clearance, Cl(R), 0.06 (0.05-0.08) versus 0.07 (0.05-0.09) L/kg.",Enantioselectivity in the steady-state pharmacokinetics of metoprolol in hypertensive patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10423287/),[l] / [kg],13.80,70737,DB04840,Debrisoquin
,10423287,"renal clearance, Cl","However, the following differences (p < 0.05) were observed between the (-)-(S) and (+)-(R) enantiomers: maximum plasma concentration, C(max), 179.99 (123. 33-236.64) versus 151.30 (95.04-207.57) ng/mL; area under the plasma concentration versus time curve, AUC(0-24)(SS), 929.85 (458.02-1401. 70) versus 782.11 (329.80-1234.40) ng h/mL; apparent total clearance, Cl(T)/f, 1.70 (0.79-2.61) versus 2.21 (1.06-3.36) L/h/kg, apparent distribution volume, Vd/f, 10.51 (6.35-14.68) versus 13.80 (6.93-20. 68) L/kg, and renal clearance, Cl(R), 0.06 (0.05-0.08) versus 0.07 (0.05-0.09) L/kg.",Enantioselectivity in the steady-state pharmacokinetics of metoprolol in hypertensive patients. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10423287/),[l] / [kg],0.06,70738,DB04840,Debrisoquin
,10423287,"renal clearance, Cl","However, the following differences (p < 0.05) were observed between the (-)-(S) and (+)-(R) enantiomers: maximum plasma concentration, C(max), 179.99 (123. 33-236.64) versus 151.30 (95.04-207.57) ng/mL; area under the plasma concentration versus time curve, AUC(0-24)(SS), 929.85 (458.02-1401. 70) versus 782.11 (329.80-1234.40) ng h/mL; apparent total clearance, Cl(T)/f, 1.70 (0.79-2.61) versus 2.21 (1.06-3.36) L/h/kg, apparent distribution volume, Vd/f, 10.51 (6.35-14.68) versus 13.80 (6.93-20. 68) L/kg, and renal clearance, Cl(R), 0.06 (0.05-0.08) versus 0.07 (0.05-0.09) L/kg.",Enantioselectivity in the steady-state pharmacokinetics of metoprolol in hypertensive patients. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10423287/),[l] / [kg],0.07,70739,DB04840,Debrisoquin
,1623909,total plasma clearance,Codeine had a medium to high extraction ratio and a total plasma clearance of 10.8 (4.3) ml.min-1.kg-1.,The postoperative pharmacokinetics of codeine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1623909/),[ml] / [kg·min],10.8,75152,DB04840,Debrisoquin
,1623909,systemic availability,The systemic availability of codeine varied extensively between subjects (range 12-84%).,The postoperative pharmacokinetics of codeine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1623909/),%,12-84,75153,DB04840,Debrisoquin
,8739818,trough concentrations,"Diprafenone caused a statistically significant increase in digoxin trough concentrations [1.4 (SD 0.2) vs 1.6 (0.3) ng.ml-1], AUC(zero)-24 values [41 (7) vs 48 (9) ng.h.ml-1 and Css-max[3.9 (0.6) vs 5.5 (0.9) ng.ml-1].",Effect of diprafenone on the pharmacokinetics of digoxin. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8739818/),[ng] / [ml],1.4,75800,DB04840,Debrisoquin
,8739818,trough concentrations,"Diprafenone caused a statistically significant increase in digoxin trough concentrations [1.4 (SD 0.2) vs 1.6 (0.3) ng.ml-1], AUC(zero)-24 values [41 (7) vs 48 (9) ng.h.ml-1 and Css-max[3.9 (0.6) vs 5.5 (0.9) ng.ml-1].",Effect of diprafenone on the pharmacokinetics of digoxin. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8739818/),[ng] / [ml],1.6,75801,DB04840,Debrisoquin
,8739818,AUC(zero)-24,"Diprafenone caused a statistically significant increase in digoxin trough concentrations [1.4 (SD 0.2) vs 1.6 (0.3) ng.ml-1], AUC(zero)-24 values [41 (7) vs 48 (9) ng.h.ml-1 and Css-max[3.9 (0.6) vs 5.5 (0.9) ng.ml-1].",Effect of diprafenone on the pharmacokinetics of digoxin. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8739818/),[h·ng] / [ml],41,75802,DB04840,Debrisoquin
,8739818,AUC(zero)-24,"Diprafenone caused a statistically significant increase in digoxin trough concentrations [1.4 (SD 0.2) vs 1.6 (0.3) ng.ml-1], AUC(zero)-24 values [41 (7) vs 48 (9) ng.h.ml-1 and Css-max[3.9 (0.6) vs 5.5 (0.9) ng.ml-1].",Effect of diprafenone on the pharmacokinetics of digoxin. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8739818/),[h·ng] / [ml],48,75803,DB04840,Debrisoquin
,8739818,Css-max,"Diprafenone caused a statistically significant increase in digoxin trough concentrations [1.4 (SD 0.2) vs 1.6 (0.3) ng.ml-1], AUC(zero)-24 values [41 (7) vs 48 (9) ng.h.ml-1 and Css-max[3.9 (0.6) vs 5.5 (0.9) ng.ml-1].",Effect of diprafenone on the pharmacokinetics of digoxin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8739818/),[ng] / [ml],3.9,75804,DB04840,Debrisoquin
,8739818,Css-max,"Diprafenone caused a statistically significant increase in digoxin trough concentrations [1.4 (SD 0.2) vs 1.6 (0.3) ng.ml-1], AUC(zero)-24 values [41 (7) vs 48 (9) ng.h.ml-1 and Css-max[3.9 (0.6) vs 5.5 (0.9) ng.ml-1].",Effect of diprafenone on the pharmacokinetics of digoxin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8739818/),[ng] / [ml],5.5,75805,DB04840,Debrisoquin
,8739818,trough concentration,"In all volunteers the parameters tended to return to the original values after administration of diprafenone was discontinued [1.4 (0.3) ng.ml-1, 39 (11) ng.h.ml-1, and 3.9 (1.1) ng.ml-1 for trough concentration, AUC(zero)-24 and Cmax respectively].",Effect of diprafenone on the pharmacokinetics of digoxin. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8739818/),[h·ng] / [ml],39,75806,DB04840,Debrisoquin
,8739818,trough concentration,"In all volunteers the parameters tended to return to the original values after administration of diprafenone was discontinued [1.4 (0.3) ng.ml-1, 39 (11) ng.h.ml-1, and 3.9 (1.1) ng.ml-1 for trough concentration, AUC(zero)-24 and Cmax respectively].",Effect of diprafenone on the pharmacokinetics of digoxin. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8739818/),[ng] / [ml],3.9,75807,DB04840,Debrisoquin
,8739818,AUC(zero)-24,"In all volunteers the parameters tended to return to the original values after administration of diprafenone was discontinued [1.4 (0.3) ng.ml-1, 39 (11) ng.h.ml-1, and 3.9 (1.1) ng.ml-1 for trough concentration, AUC(zero)-24 and Cmax respectively].",Effect of diprafenone on the pharmacokinetics of digoxin. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8739818/),[ng] / [ml],3.9,75808,DB04840,Debrisoquin
,8739818,Cmax,"In all volunteers the parameters tended to return to the original values after administration of diprafenone was discontinued [1.4 (0.3) ng.ml-1, 39 (11) ng.h.ml-1, and 3.9 (1.1) ng.ml-1 for trough concentration, AUC(zero)-24 and Cmax respectively].",Effect of diprafenone on the pharmacokinetics of digoxin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8739818/),[ng] / [ml],3.9,75809,DB04840,Debrisoquin
,4042519,distribution half-life (t1/2 alpha),"Following intravenous administration of 10mg to healthy subjects, methimazole had an initial distribution half-life (t1/2 alpha) of 0.10 to 0.23 hours and an elimination half-life (t1/2 beta) of 4.9 to 5.7 hours.",Pharmacokinetic properties and bioavailability of methimazole. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4042519/),h,0.10 to 0.23,78883,DB04840,Debrisoquin
,4042519,elimination half-life (t1/2 beta),"Following intravenous administration of 10mg to healthy subjects, methimazole had an initial distribution half-life (t1/2 alpha) of 0.10 to 0.23 hours and an elimination half-life (t1/2 beta) of 4.9 to 5.7 hours.",Pharmacokinetic properties and bioavailability of methimazole. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/4042519/),h,4.9 to 5.7,78884,DB04840,Debrisoquin
,4042519,absolute bioavailability,"The absolute bioavailability after oral administration of 10mg methimazole in the fasting state was high, with a mean of 93%.",Pharmacokinetic properties and bioavailability of methimazole. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4042519/),%,93,78885,DB04840,Debrisoquin
,4042519,elimination half-life,"The pharmacokinetic profiles showed small interindividual variations, although one of the hypothyroid patients had a rapid elimination half-life, in both the hypothyroid and euthyroid state (2.6 and 2.4 hours, respectively).",Pharmacokinetic properties and bioavailability of methimazole. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/4042519/),h,2.6,78886,DB04840,Debrisoquin
,4042519,elimination half-life,"The pharmacokinetic profiles showed small interindividual variations, although one of the hypothyroid patients had a rapid elimination half-life, in both the hypothyroid and euthyroid state (2.6 and 2.4 hours, respectively).",Pharmacokinetic properties and bioavailability of methimazole. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/4042519/),h,2.4,78887,DB04840,Debrisoquin
,8748391,t1/2,"In addition, the t1/2 of the active moiety was prolonged (19 h in young subjects versus about 25 h in elderly and renal disease patients).","Influence of age, renal and liver impairment on the pharmacokinetics of risperidone in man. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8748391/),h,19,81649,DB04840,Debrisoquin
,8748391,t1/2,"In addition, the t1/2 of the active moiety was prolonged (19 h in young subjects versus about 25 h in elderly and renal disease patients).","Influence of age, renal and liver impairment on the pharmacokinetics of risperidone in man. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8748391/),h,25,81650,DB04840,Debrisoquin
,1848636,IC50,"There was a difference in metoprolol potency with higher racemic metoprolol IC50 values in PMs (72 +/- 7 ng.ml-1) than EMs (42 +/- 8 ng.ml-1, P less than .001).",Debrisoquine phenotype and the pharmacokinetics and beta-2 receptor pharmacodynamics of metoprolol and its enantiomers. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1848636/),[ng] / [ml],72,82447,DB04840,Debrisoquin
,1848636,IC50,"There was a difference in metoprolol potency with higher racemic metoprolol IC50 values in PMs (72 +/- 7 ng.ml-1) than EMs (42 +/- 8 ng.ml-1, P less than .001).",Debrisoquine phenotype and the pharmacokinetics and beta-2 receptor pharmacodynamics of metoprolol and its enantiomers. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1848636/),[ng] / [ml],42,82448,DB04840,Debrisoquin
,7520903,half-life,In poor metabolizers the half-life of risperidone was about 19 hours compared with about 3 hours in extensive metabolizers.,The pharmacokinetics of risperidone in humans: a summary. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7520903/),h,19,83624,DB04840,Debrisoquin
,7520903,half-life,In poor metabolizers the half-life of risperidone was about 19 hours compared with about 3 hours in extensive metabolizers.,The pharmacokinetics of risperidone in humans: a summary. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7520903/),h,3,83625,DB04840,Debrisoquin
,7520903,half-life,"However, becuase the pharmacology of 9-hydroxyrisperidone is very similar to that of risperidone, the half-life for the ""active fraction"" (risperidone +9-hydroxyrisperidone) was found to be approximately 20 hours in extensive and poor metabolizers.",The pharmacokinetics of risperidone in humans: a summary. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7520903/),h,20,83626,DB04840,Debrisoquin
,9797797,Peak serum concentrations,Peak serum concentrations of selegiline were reached rapidly and ranged from 1 to 32 nmol/L.,CYP2D6 polymorphism is not crucial for the disposition of selegiline. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9797797/),[nM] / [l],1 to 32,84693,DB04840,Debrisoquin
,9797797,50% inhibitory concentration,"The inhibitory potency of selegiline, desmethylselegiline, and l-methamphetamine toward dextromethorphan O-demethylase was very low (50% inhibitory concentration values from 160 to 580 mumol/L).",CYP2D6 polymorphism is not crucial for the disposition of selegiline. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9797797/),[μM] / [l],160 to 580,84694,DB04840,Debrisoquin
,8803526,AUCzero-last ratio,The only slow hydroxylator in this trial had an AUCzero-last ratio (with food/fasting) of 1.54.,Influence of food on the bioavailability and some pharmacokinetic parameters of diprafenone--a novel antiarrhythmic agent. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8803526/),,1.54,86801,DB04840,Debrisoquin
,9643621,terminal half-life,"However, subjects with atypical cholinesterase had a shorter terminal half-life of bambuterol (a measure of uptake rate), 4.8-12.6 h vs 8.3-22.3 h in N, and slightly higher plasma concentrations of bambuterol (average concentrations 1.9-3.7 nmol l(-1) vs 1.5-3.1 nmol l(-1) in N).",Pharmacokinetics of bambuterol in subjects homozygous for the atypical gene for plasma cholinesterase. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9643621/),h,4.8-12.6,88509,DB04840,Debrisoquin
,9643621,terminal half-life,"However, subjects with atypical cholinesterase had a shorter terminal half-life of bambuterol (a measure of uptake rate), 4.8-12.6 h vs 8.3-22.3 h in N, and slightly higher plasma concentrations of bambuterol (average concentrations 1.9-3.7 nmol l(-1) vs 1.5-3.1 nmol l(-1) in N).",Pharmacokinetics of bambuterol in subjects homozygous for the atypical gene for plasma cholinesterase. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9643621/),h,8.3-22.3,88510,DB04840,Debrisoquin
,9643621,Peak/trough terbutaline plasma concentrations ratios,"Peak/trough terbutaline plasma concentrations ratios (2.1-3.2) were somewhat increased, but average plasma concentrations (8.3-14.5 nmol l(-1)) and terminal half-life (16.5-21.8 h) of terbutaline did not differ.",Pharmacokinetics of bambuterol in subjects homozygous for the atypical gene for plasma cholinesterase. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9643621/),,2.1-3.2,88511,DB04840,Debrisoquin
,9643621,terminal half-life,"Peak/trough terbutaline plasma concentrations ratios (2.1-3.2) were somewhat increased, but average plasma concentrations (8.3-14.5 nmol l(-1)) and terminal half-life (16.5-21.8 h) of terbutaline did not differ.",Pharmacokinetics of bambuterol in subjects homozygous for the atypical gene for plasma cholinesterase. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9643621/),h,16.5-21.8,88512,DB04840,Debrisoquin
,7545821,receptor,"D2 receptor occupancy was 50% and 54% in the two PM, as compared to 40%, 43% and 55% in the EM.",A PET study of D2 and 5-HT2 receptor occupancy induced by risperidone in poor metabolizers of debrisoquin and risperidone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7545821/),%,50,92569,DB04840,Debrisoquin
,7545821,occupancy,"D2 receptor occupancy was 50% and 54% in the two PM, as compared to 40%, 43% and 55% in the EM.",A PET study of D2 and 5-HT2 receptor occupancy induced by risperidone in poor metabolizers of debrisoquin and risperidone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7545821/),%,50,92570,DB04840,Debrisoquin
,7545821,occupancy,"D2 receptor occupancy was 50% and 54% in the two PM, as compared to 40%, 43% and 55% in the EM.",A PET study of D2 and 5-HT2 receptor occupancy induced by risperidone in poor metabolizers of debrisoquin and risperidone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7545821/),%,54,92571,DB04840,Debrisoquin
,7545821,occupancy,"D2 receptor occupancy was 50% and 54% in the two PM, as compared to 40%, 43% and 55% in the EM.",A PET study of D2 and 5-HT2 receptor occupancy induced by risperidone in poor metabolizers of debrisoquin and risperidone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7545821/),%,40,92572,DB04840,Debrisoquin
,7545821,occupancy,"D2 receptor occupancy was 50% and 54% in the two PM, as compared to 40%, 43% and 55% in the EM.",A PET study of D2 and 5-HT2 receptor occupancy induced by risperidone in poor metabolizers of debrisoquin and risperidone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7545821/),%,43,92573,DB04840,Debrisoquin
,7545821,occupancy,"D2 receptor occupancy was 50% and 54% in the two PM, as compared to 40%, 43% and 55% in the EM.",A PET study of D2 and 5-HT2 receptor occupancy induced by risperidone in poor metabolizers of debrisoquin and risperidone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7545821/),%,55,92574,DB04840,Debrisoquin
,7545821,occupancy,"5-HT2 receptor occupancy was 63% and 73%, as compared to 45%, 56% and 68% in the EM.",A PET study of D2 and 5-HT2 receptor occupancy induced by risperidone in poor metabolizers of debrisoquin and risperidone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7545821/),%,63,92575,DB04840,Debrisoquin
,7545821,occupancy,"5-HT2 receptor occupancy was 63% and 73%, as compared to 45%, 56% and 68% in the EM.",A PET study of D2 and 5-HT2 receptor occupancy induced by risperidone in poor metabolizers of debrisoquin and risperidone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7545821/),%,73,92576,DB04840,Debrisoquin
,7545821,occupancy,"5-HT2 receptor occupancy was 63% and 73%, as compared to 45%, 56% and 68% in the EM.",A PET study of D2 and 5-HT2 receptor occupancy induced by risperidone in poor metabolizers of debrisoquin and risperidone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7545821/),%,45,92577,DB04840,Debrisoquin
,7545821,occupancy,"5-HT2 receptor occupancy was 63% and 73%, as compared to 45%, 56% and 68% in the EM.",A PET study of D2 and 5-HT2 receptor occupancy induced by risperidone in poor metabolizers of debrisoquin and risperidone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7545821/),%,56,92578,DB04840,Debrisoquin
,7545821,occupancy,"5-HT2 receptor occupancy was 63% and 73%, as compared to 45%, 56% and 68% in the EM.",A PET study of D2 and 5-HT2 receptor occupancy induced by risperidone in poor metabolizers of debrisoquin and risperidone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7545821/),%,68,92579,DB04840,Debrisoquin
,3221745,fu(R),This difference cannot be accounted for by the different degrees of protein binding of the enantiomers (fu(R) = 0.076; fu(S) = 0.049).,Comparative pharmacokinetics and clinical pharmacology of propafenone enantiomers after oral administration to man. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3221745/),,0.,93110,DB04840,Debrisoquin
,3221745,fu(S),This difference cannot be accounted for by the different degrees of protein binding of the enantiomers (fu(R) = 0.076; fu(S) = 0.049).,Comparative pharmacokinetics and clinical pharmacology of propafenone enantiomers after oral administration to man. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3221745/),,0.04,93111,DB04840,Debrisoquin
,2792169,maximum concentrations,2-OH-Imipramine and 2-OH-desipramine were detected in plasma before (maximum concentrations 30-100 nmol.l-1) but not during quinidine.,Quinidine inhibits the 2-hydroxylation of imipramine and desipramine but not the demethylation of imipramine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2792169/),[nM] / [l],30-100,97307,DB04840,Debrisoquin
,1673410,half-life,"The half-life of R-propranolol was increased and its apparent oral clearance decreased significantly in DA rats relative to the SD strain [85 +/- 41 min (DA) vs. 26 +/- 10 min (SD) and 0.020 +/- 0.014 liter/min/kg (DA) vs. 0.31 +/- 0.14 liter/min/kg (SD)], respectively.",Stereoselective differences in propranolol disposition in female Sprague-Dawley and Dark Agouti rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1673410/),min,85,100829,DB04840,Debrisoquin
,1673410,apparent oral clearance,"The half-life of R-propranolol was increased and its apparent oral clearance decreased significantly in DA rats relative to the SD strain [85 +/- 41 min (DA) vs. 26 +/- 10 min (SD) and 0.020 +/- 0.014 liter/min/kg (DA) vs. 0.31 +/- 0.14 liter/min/kg (SD)], respectively.",Stereoselective differences in propranolol disposition in female Sprague-Dawley and Dark Agouti rats. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1673410/),[l] / [kg·min],0.020,100830,DB04840,Debrisoquin
,1673410,apparent oral clearance,"The half-life of R-propranolol was increased and its apparent oral clearance decreased significantly in DA rats relative to the SD strain [85 +/- 41 min (DA) vs. 26 +/- 10 min (SD) and 0.020 +/- 0.014 liter/min/kg (DA) vs. 0.31 +/- 0.14 liter/min/kg (SD)], respectively.",Stereoselective differences in propranolol disposition in female Sprague-Dawley and Dark Agouti rats. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1673410/),[l] / [kg·min],0.31,100831,DB04840,Debrisoquin
,1673410,half-life,"Strain differences in S-propranolol half-life and apparent oral clearance also were observed, but were not as marked [97 +/- 36 min (DA) vs. 52 +/- 35 min (SD) and 0.20 +/- 0.13 liter/min/kg (DA) vs. 0.70 +/- 0.68 liter/min/kg (SD)], respectively.",Stereoselective differences in propranolol disposition in female Sprague-Dawley and Dark Agouti rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1673410/),min,97,100832,DB04840,Debrisoquin
,1673410,half-life,"Strain differences in S-propranolol half-life and apparent oral clearance also were observed, but were not as marked [97 +/- 36 min (DA) vs. 52 +/- 35 min (SD) and 0.20 +/- 0.13 liter/min/kg (DA) vs. 0.70 +/- 0.68 liter/min/kg (SD)], respectively.",Stereoselective differences in propranolol disposition in female Sprague-Dawley and Dark Agouti rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1673410/),min,52,100833,DB04840,Debrisoquin
,1673410,apparent oral clearance,"Strain differences in S-propranolol half-life and apparent oral clearance also were observed, but were not as marked [97 +/- 36 min (DA) vs. 52 +/- 35 min (SD) and 0.20 +/- 0.13 liter/min/kg (DA) vs. 0.70 +/- 0.68 liter/min/kg (SD)], respectively.",Stereoselective differences in propranolol disposition in female Sprague-Dawley and Dark Agouti rats. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1673410/),[l] / [kg·min],0.20,100834,DB04840,Debrisoquin
,1673410,apparent oral clearance,"Strain differences in S-propranolol half-life and apparent oral clearance also were observed, but were not as marked [97 +/- 36 min (DA) vs. 52 +/- 35 min (SD) and 0.20 +/- 0.13 liter/min/kg (DA) vs. 0.70 +/- 0.68 liter/min/kg (SD)], respectively.",Stereoselective differences in propranolol disposition in female Sprague-Dawley and Dark Agouti rats. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1673410/),[l] / [kg·min],0.70,100835,DB04840,Debrisoquin
,1673410,oral clearance ratio,"Due to a more pronounced effect of rat strain on the disposition of R-propranolol, the stereoselective S-/R- oral clearance ratio for propranolol was also strain-dependent [10 +/- 3 (DA) vs. 2.1 +/- 0.9 (SD)].",Stereoselective differences in propranolol disposition in female Sprague-Dawley and Dark Agouti rats. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1673410/),,10,100836,DB04840,Debrisoquin
,1673410,oral clearance ratio,"Due to a more pronounced effect of rat strain on the disposition of R-propranolol, the stereoselective S-/R- oral clearance ratio for propranolol was also strain-dependent [10 +/- 3 (DA) vs. 2.1 +/- 0.9 (SD)].",Stereoselective differences in propranolol disposition in female Sprague-Dawley and Dark Agouti rats. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1673410/),,2.1,100837,DB04840,Debrisoquin
,2625371,elimination half-life,"Patients with cirrhosis had a prolonged elimination half-life (29.5 +/- 5.9 h) and low clearance (24 +/- 7 ml.kg-1.h-1) of antipyrine and also a considerably higher debrisoquine metabolic ratio (18.8 +/- 3.3) than the controls, whereas the alcoholics without cirrhosis had metabolic patterns for these two test compounds comparable to those seen in the controls (antipyrine half-life: 8.8 +/- 1.1 h and 9.8 +/- 2.0 h; debrisoquine metabolic ratio: 3.6 +/- 0.7 and 3.8 +/- 1.2 for alcoholics and controls respectively).",Quinidine disposition in relation to antipyrine elimination and debrisoquine phenotype in alcoholic patients with and without cirrhosis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2625371/),h,29.5,108152,DB04840,Debrisoquin
,2625371,clearance,"Patients with cirrhosis had a prolonged elimination half-life (29.5 +/- 5.9 h) and low clearance (24 +/- 7 ml.kg-1.h-1) of antipyrine and also a considerably higher debrisoquine metabolic ratio (18.8 +/- 3.3) than the controls, whereas the alcoholics without cirrhosis had metabolic patterns for these two test compounds comparable to those seen in the controls (antipyrine half-life: 8.8 +/- 1.1 h and 9.8 +/- 2.0 h; debrisoquine metabolic ratio: 3.6 +/- 0.7 and 3.8 +/- 1.2 for alcoholics and controls respectively).",Quinidine disposition in relation to antipyrine elimination and debrisoquine phenotype in alcoholic patients with and without cirrhosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2625371/),[ml] / [h·kg],24,108153,DB04840,Debrisoquin
,2625371,metabolic ratio,"Patients with cirrhosis had a prolonged elimination half-life (29.5 +/- 5.9 h) and low clearance (24 +/- 7 ml.kg-1.h-1) of antipyrine and also a considerably higher debrisoquine metabolic ratio (18.8 +/- 3.3) than the controls, whereas the alcoholics without cirrhosis had metabolic patterns for these two test compounds comparable to those seen in the controls (antipyrine half-life: 8.8 +/- 1.1 h and 9.8 +/- 2.0 h; debrisoquine metabolic ratio: 3.6 +/- 0.7 and 3.8 +/- 1.2 for alcoholics and controls respectively).",Quinidine disposition in relation to antipyrine elimination and debrisoquine phenotype in alcoholic patients with and without cirrhosis. ,Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2625371/),,18.8,108154,DB04840,Debrisoquin
,2625371,half-life,"Patients with cirrhosis had a prolonged elimination half-life (29.5 +/- 5.9 h) and low clearance (24 +/- 7 ml.kg-1.h-1) of antipyrine and also a considerably higher debrisoquine metabolic ratio (18.8 +/- 3.3) than the controls, whereas the alcoholics without cirrhosis had metabolic patterns for these two test compounds comparable to those seen in the controls (antipyrine half-life: 8.8 +/- 1.1 h and 9.8 +/- 2.0 h; debrisoquine metabolic ratio: 3.6 +/- 0.7 and 3.8 +/- 1.2 for alcoholics and controls respectively).",Quinidine disposition in relation to antipyrine elimination and debrisoquine phenotype in alcoholic patients with and without cirrhosis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2625371/),h,8.8,108155,DB04840,Debrisoquin
,2625371,half-life,"Patients with cirrhosis had a prolonged elimination half-life (29.5 +/- 5.9 h) and low clearance (24 +/- 7 ml.kg-1.h-1) of antipyrine and also a considerably higher debrisoquine metabolic ratio (18.8 +/- 3.3) than the controls, whereas the alcoholics without cirrhosis had metabolic patterns for these two test compounds comparable to those seen in the controls (antipyrine half-life: 8.8 +/- 1.1 h and 9.8 +/- 2.0 h; debrisoquine metabolic ratio: 3.6 +/- 0.7 and 3.8 +/- 1.2 for alcoholics and controls respectively).",Quinidine disposition in relation to antipyrine elimination and debrisoquine phenotype in alcoholic patients with and without cirrhosis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2625371/),h,9.8,108156,DB04840,Debrisoquin
,2625371,metabolic ratio,"Patients with cirrhosis had a prolonged elimination half-life (29.5 +/- 5.9 h) and low clearance (24 +/- 7 ml.kg-1.h-1) of antipyrine and also a considerably higher debrisoquine metabolic ratio (18.8 +/- 3.3) than the controls, whereas the alcoholics without cirrhosis had metabolic patterns for these two test compounds comparable to those seen in the controls (antipyrine half-life: 8.8 +/- 1.1 h and 9.8 +/- 2.0 h; debrisoquine metabolic ratio: 3.6 +/- 0.7 and 3.8 +/- 1.2 for alcoholics and controls respectively).",Quinidine disposition in relation to antipyrine elimination and debrisoquine phenotype in alcoholic patients with and without cirrhosis. ,Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2625371/),,3.6,108157,DB04840,Debrisoquin
,2625371,metabolic ratio,"Patients with cirrhosis had a prolonged elimination half-life (29.5 +/- 5.9 h) and low clearance (24 +/- 7 ml.kg-1.h-1) of antipyrine and also a considerably higher debrisoquine metabolic ratio (18.8 +/- 3.3) than the controls, whereas the alcoholics without cirrhosis had metabolic patterns for these two test compounds comparable to those seen in the controls (antipyrine half-life: 8.8 +/- 1.1 h and 9.8 +/- 2.0 h; debrisoquine metabolic ratio: 3.6 +/- 0.7 and 3.8 +/- 1.2 for alcoholics and controls respectively).",Quinidine disposition in relation to antipyrine elimination and debrisoquine phenotype in alcoholic patients with and without cirrhosis. ,Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2625371/),,3.8,108158,DB04840,Debrisoquin
,2625371,apparent elimination half-life,In patients with cirrhosis the apparent elimination half-life of quinidine was longer (12.8 +/- 1.8 h) whereas after oral administration clearance of quinidine (15.6 +/- 3.5 l.h-1) and quinidine/3-hydroxyquinidine ratio (9.9 +/- 2.1) were not different from controls (quinidine clearance: 13.45 +/- 1.9 l.h-1; quinidine/3-hydroxyquinidine: 10.3 +/- 2.7).,Quinidine disposition in relation to antipyrine elimination and debrisoquine phenotype in alcoholic patients with and without cirrhosis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2625371/),h,12.8,108159,DB04840,Debrisoquin
,2625371,clearance,In patients with cirrhosis the apparent elimination half-life of quinidine was longer (12.8 +/- 1.8 h) whereas after oral administration clearance of quinidine (15.6 +/- 3.5 l.h-1) and quinidine/3-hydroxyquinidine ratio (9.9 +/- 2.1) were not different from controls (quinidine clearance: 13.45 +/- 1.9 l.h-1; quinidine/3-hydroxyquinidine: 10.3 +/- 2.7).,Quinidine disposition in relation to antipyrine elimination and debrisoquine phenotype in alcoholic patients with and without cirrhosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2625371/),[l] / [h],15.6,108160,DB04840,Debrisoquin
,2625371,clearance,In patients with cirrhosis the apparent elimination half-life of quinidine was longer (12.8 +/- 1.8 h) whereas after oral administration clearance of quinidine (15.6 +/- 3.5 l.h-1) and quinidine/3-hydroxyquinidine ratio (9.9 +/- 2.1) were not different from controls (quinidine clearance: 13.45 +/- 1.9 l.h-1; quinidine/3-hydroxyquinidine: 10.3 +/- 2.7).,Quinidine disposition in relation to antipyrine elimination and debrisoquine phenotype in alcoholic patients with and without cirrhosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2625371/),,9.9,108161,DB04840,Debrisoquin
,2625371,clearance,In patients with cirrhosis the apparent elimination half-life of quinidine was longer (12.8 +/- 1.8 h) whereas after oral administration clearance of quinidine (15.6 +/- 3.5 l.h-1) and quinidine/3-hydroxyquinidine ratio (9.9 +/- 2.1) were not different from controls (quinidine clearance: 13.45 +/- 1.9 l.h-1; quinidine/3-hydroxyquinidine: 10.3 +/- 2.7).,Quinidine disposition in relation to antipyrine elimination and debrisoquine phenotype in alcoholic patients with and without cirrhosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2625371/),[l] / [h],13.45,108162,DB04840,Debrisoquin
,2625371,clearance,In patients with cirrhosis the apparent elimination half-life of quinidine was longer (12.8 +/- 1.8 h) whereas after oral administration clearance of quinidine (15.6 +/- 3.5 l.h-1) and quinidine/3-hydroxyquinidine ratio (9.9 +/- 2.1) were not different from controls (quinidine clearance: 13.45 +/- 1.9 l.h-1; quinidine/3-hydroxyquinidine: 10.3 +/- 2.7).,Quinidine disposition in relation to antipyrine elimination and debrisoquine phenotype in alcoholic patients with and without cirrhosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2625371/),,10.3,108163,DB04840,Debrisoquin
,10589372,bioavailability,"Mexiletine, a class Ib antiarrhythmic agent, is rapidly and completely absorbed following oral administration with a bioavailability of about 90%.",Clinical pharmacokinetics of mexiletine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10589372/),%,90,113401,DB04840,Debrisoquin
,10589372,volume of distribution,Its volume of distribution is large and varies from 5 to 9 L/kg in healthy individuals.,Clinical pharmacokinetics of mexiletine. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10589372/),[l] / [kg],5 to 9,113402,DB04840,Debrisoquin
,10589372,elimination half-life,Mexiletine is eliminated slowly in humans (with an elimination half-life of 10 hours).,Clinical pharmacokinetics of mexiletine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10589372/),h,10,113403,DB04840,Debrisoquin
,8513845,clearances,"During paroxetine, the median clearances were 22 l.h-1 and 18 l.h-1 in EMs and PMs respectively.",Inhibition by paroxetine of desipramine metabolism in extensive but not in poor metabolizers of sparteine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8513845/),[l] / [h],22,114647,DB04840,Debrisoquin
,8513845,clearances,"During paroxetine, the median clearances were 22 l.h-1 and 18 l.h-1 in EMs and PMs respectively.",Inhibition by paroxetine of desipramine metabolism in extensive but not in poor metabolizers of sparteine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8513845/),[l] / [h],18,114648,DB04840,Debrisoquin
,8513845,clearance via,"Before paroxetine, the median of desipramine clearance via 2-hydroxylation was 40-times higher in EMs than in PMs (56 and 1.4 l.h-1 respectively), but during paroxetine, it was only 2-times higher (6 and 2.9 l.h-1 respectively).",Inhibition by paroxetine of desipramine metabolism in extensive but not in poor metabolizers of sparteine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8513845/),[l] / [h],56,114649,DB04840,Debrisoquin
,8513845,clearance via,"Before paroxetine, the median of desipramine clearance via 2-hydroxylation was 40-times higher in EMs than in PMs (56 and 1.4 l.h-1 respectively), but during paroxetine, it was only 2-times higher (6 and 2.9 l.h-1 respectively).",Inhibition by paroxetine of desipramine metabolism in extensive but not in poor metabolizers of sparteine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8513845/),[l] / [h],1.4,114650,DB04840,Debrisoquin
,8513845,clearance via,"Before paroxetine, the median of desipramine clearance via 2-hydroxylation was 40-times higher in EMs than in PMs (56 and 1.4 l.h-1 respectively), but during paroxetine, it was only 2-times higher (6 and 2.9 l.h-1 respectively).",Inhibition by paroxetine of desipramine metabolism in extensive but not in poor metabolizers of sparteine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8513845/),[l] / [h],6,114651,DB04840,Debrisoquin
,8513845,clearance via,"Before paroxetine, the median of desipramine clearance via 2-hydroxylation was 40-times higher in EMs than in PMs (56 and 1.4 l.h-1 respectively), but during paroxetine, it was only 2-times higher (6 and 2.9 l.h-1 respectively).",Inhibition by paroxetine of desipramine metabolism in extensive but not in poor metabolizers of sparteine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8513845/),[l] / [h],2.9,114652,DB04840,Debrisoquin
,11985287,AUC,"The mean (+/- SD) AUC of risperidone increased from 83.1 +/- 46.8 ng.h/ml and 398.3 +/- 33.2 ng.h/ml (monotherapy) to 345.1 +/- 158.0 ng.h/ml (p < 0.05) and 514.0 +/- 144.2 ng.h/ml (p < 0.001) when coadministered with fluoxetine in EMs and PMs, respectively.",The effect of fluoxetine on the pharmacokinetics and safety of risperidone in psychotic patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11985287/),[h·ng] / [ml],83.1,116345,DB04840,Debrisoquin
,11985287,AUC,"The mean (+/- SD) AUC of risperidone increased from 83.1 +/- 46.8 ng.h/ml and 398.3 +/- 33.2 ng.h/ml (monotherapy) to 345.1 +/- 158.0 ng.h/ml (p < 0.05) and 514.0 +/- 144.2 ng.h/ml (p < 0.001) when coadministered with fluoxetine in EMs and PMs, respectively.",The effect of fluoxetine on the pharmacokinetics and safety of risperidone in psychotic patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11985287/),[h·ng] / [ml],398.3,116346,DB04840,Debrisoquin
,11985287,AUC,"The mean (+/- SD) AUC of risperidone increased from 83.1 +/- 46.8 ng.h/ml and 398.3 +/- 33.2 ng.h/ml (monotherapy) to 345.1 +/- 158.0 ng.h/ml (p < 0.05) and 514.0 +/- 144.2 ng.h/ml (p < 0.001) when coadministered with fluoxetine in EMs and PMs, respectively.",The effect of fluoxetine on the pharmacokinetics and safety of risperidone in psychotic patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11985287/),[h·ng] / [ml],345.1,116347,DB04840,Debrisoquin
,11985287,AUC,"The mean (+/- SD) AUC of risperidone increased from 83.1 +/- 46.8 ng.h/ml and 398.3 +/- 33.2 ng.h/ml (monotherapy) to 345.1 +/- 158.0 ng.h/ml (p < 0.05) and 514.0 +/- 144.2 ng.h/ml (p < 0.001) when coadministered with fluoxetine in EMs and PMs, respectively.",The effect of fluoxetine on the pharmacokinetics and safety of risperidone in psychotic patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11985287/),[h·ng] / [ml],514.0,116348,DB04840,Debrisoquin
,11985287,AUC,"The AUC of the active moiety (risperidone plus 9-hydroxy-risperidone) increased from 470.0 +/- 170.0 ng.h/ml to 663.0 +/- 243.3 ng.h/ml (p < 0.05)and from 576.3 +/- 19.6 ng.h/ml to 788.0 +/- 89.1 ng.h/ml (ns) in EMs and PMs, respectively.",The effect of fluoxetine on the pharmacokinetics and safety of risperidone in psychotic patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11985287/),[h·ng] / [ml],470.0,116349,DB04840,Debrisoquin
,11985287,AUC,"The AUC of the active moiety (risperidone plus 9-hydroxy-risperidone) increased from 470.0 +/- 170.0 ng.h/ml to 663.0 +/- 243.3 ng.h/ml (p < 0.05)and from 576.3 +/- 19.6 ng.h/ml to 788.0 +/- 89.1 ng.h/ml (ns) in EMs and PMs, respectively.",The effect of fluoxetine on the pharmacokinetics and safety of risperidone in psychotic patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11985287/),[h·ng] / [ml],663.0,116350,DB04840,Debrisoquin
,11985287,AUC,"The AUC of the active moiety (risperidone plus 9-hydroxy-risperidone) increased from 470.0 +/- 170.0 ng.h/ml to 663.0 +/- 243.3 ng.h/ml (p < 0.05)and from 576.3 +/- 19.6 ng.h/ml to 788.0 +/- 89.1 ng.h/ml (ns) in EMs and PMs, respectively.",The effect of fluoxetine on the pharmacokinetics and safety of risperidone in psychotic patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11985287/),[h·ng] / [ml],576.3,116351,DB04840,Debrisoquin
,11985287,AUC,"The AUC of the active moiety (risperidone plus 9-hydroxy-risperidone) increased from 470.0 +/- 170.0 ng.h/ml to 663.0 +/- 243.3 ng.h/ml (p < 0.05)and from 576.3 +/- 19.6 ng.h/ml to 788.0 +/- 89.1 ng.h/ml (ns) in EMs and PMs, respectively.",The effect of fluoxetine on the pharmacokinetics and safety of risperidone in psychotic patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11985287/),[h·ng] / [ml],788.0,116352,DB04840,Debrisoquin
,11985287,AUC,"In EMs, the AUC of 9-hydroxy-risperidone remained similar (monotherapy vs. combination therapy: 386.8 +/- 153.0 ng.h/ml vs. 317.7 +/- 125.2 ng.h/ml, ns),whereas it increased in PMs (178.3 +/- 23.5 ng.h/ml vs. 274.0 +/- 55.1 ng.h/ml (p < 0.05)).",The effect of fluoxetine on the pharmacokinetics and safety of risperidone in psychotic patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11985287/),[h·ng] / [ml],386.8,116353,DB04840,Debrisoquin
,11985287,AUC,"In EMs, the AUC of 9-hydroxy-risperidone remained similar (monotherapy vs. combination therapy: 386.8 +/- 153.0 ng.h/ml vs. 317.7 +/- 125.2 ng.h/ml, ns),whereas it increased in PMs (178.3 +/- 23.5 ng.h/ml vs. 274.0 +/- 55.1 ng.h/ml (p < 0.05)).",The effect of fluoxetine on the pharmacokinetics and safety of risperidone in psychotic patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11985287/),[h·ng] / [ml],317.7,116354,DB04840,Debrisoquin
,11985287,AUC,"In EMs, the AUC of 9-hydroxy-risperidone remained similar (monotherapy vs. combination therapy: 386.8 +/- 153.0 ng.h/ml vs. 317.7 +/- 125.2 ng.h/ml, ns),whereas it increased in PMs (178.3 +/- 23.5 ng.h/ml vs. 274.0 +/- 55.1 ng.h/ml (p < 0.05)).",The effect of fluoxetine on the pharmacokinetics and safety of risperidone in psychotic patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11985287/),[h·ng] / [ml],178.3,116355,DB04840,Debrisoquin
,11985287,AUC,"In EMs, the AUC of 9-hydroxy-risperidone remained similar (monotherapy vs. combination therapy: 386.8 +/- 153.0 ng.h/ml vs. 317.7 +/- 125.2 ng.h/ml, ns),whereas it increased in PMs (178.3 +/- 23.5 ng.h/ml vs. 274.0 +/- 55.1 ng.h/ml (p < 0.05)).",The effect of fluoxetine on the pharmacokinetics and safety of risperidone in psychotic patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11985287/),[h·ng] / [ml],274.0,116356,DB04840,Debrisoquin
,8265519,lag time of absorption,"The lag time of absorption was 0.6 +/- 0.5 hr (mean +/- S.D.), the absorption half-life 0.9 +/- 0.5 hr, the time to maximum serum concentration 5.6 +/- 2.2 hr and the corresponding maximum serum concentration 62 +/- 22 micrograms/l.",Pharmacokinetics of R(+)-terodiline given intravenously and orally to healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8265519/),h,0.6,121667,DB04840,Debrisoquin
,8265519,absorption half-life,"The lag time of absorption was 0.6 +/- 0.5 hr (mean +/- S.D.), the absorption half-life 0.9 +/- 0.5 hr, the time to maximum serum concentration 5.6 +/- 2.2 hr and the corresponding maximum serum concentration 62 +/- 22 micrograms/l.",Pharmacokinetics of R(+)-terodiline given intravenously and orally to healthy volunteers. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8265519/),h,0.9,121668,DB04840,Debrisoquin
,8265519,time to maximum serum concentration,"The lag time of absorption was 0.6 +/- 0.5 hr (mean +/- S.D.), the absorption half-life 0.9 +/- 0.5 hr, the time to maximum serum concentration 5.6 +/- 2.2 hr and the corresponding maximum serum concentration 62 +/- 22 micrograms/l.",Pharmacokinetics of R(+)-terodiline given intravenously and orally to healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8265519/),h,5.6,121669,DB04840,Debrisoquin
,8265519,maximum serum concentration,"The lag time of absorption was 0.6 +/- 0.5 hr (mean +/- S.D.), the absorption half-life 0.9 +/- 0.5 hr, the time to maximum serum concentration 5.6 +/- 2.2 hr and the corresponding maximum serum concentration 62 +/- 22 micrograms/l.",Pharmacokinetics of R(+)-terodiline given intravenously and orally to healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8265519/),[μg] / [l],62,121670,DB04840,Debrisoquin
,8265519,volume of distribution,"The volume of distribution was found to be 372 +/- 84 1, the systemic clearance 86 +/- 29 ml/min., the mean residence time 81 +/- 38 hr and the observed terminal half-life of elimination 56 +/- 26 hr.",Pharmacokinetics of R(+)-terodiline given intravenously and orally to healthy volunteers. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8265519/),1,372,121671,DB04840,Debrisoquin
,8265519,systemic clearance,"The volume of distribution was found to be 372 +/- 84 1, the systemic clearance 86 +/- 29 ml/min., the mean residence time 81 +/- 38 hr and the observed terminal half-life of elimination 56 +/- 26 hr.",Pharmacokinetics of R(+)-terodiline given intravenously and orally to healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8265519/),[ml] / [min],86,121672,DB04840,Debrisoquin
,8265519,mean residence time,"The volume of distribution was found to be 372 +/- 84 1, the systemic clearance 86 +/- 29 ml/min., the mean residence time 81 +/- 38 hr and the observed terminal half-life of elimination 56 +/- 26 hr.",Pharmacokinetics of R(+)-terodiline given intravenously and orally to healthy volunteers. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8265519/),h,81,121673,DB04840,Debrisoquin
,8265519,terminal half-life of elimination,"The volume of distribution was found to be 372 +/- 84 1, the systemic clearance 86 +/- 29 ml/min., the mean residence time 81 +/- 38 hr and the observed terminal half-life of elimination 56 +/- 26 hr.",Pharmacokinetics of R(+)-terodiline given intravenously and orally to healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8265519/),h,56,121674,DB04840,Debrisoquin
,8265519,urinary excretion,The urinary excretion of the intravenous dose was 12 +/- 6% and the renal clearance 10 +/- 5 ml/min.,Pharmacokinetics of R(+)-terodiline given intravenously and orally to healthy volunteers. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8265519/),%,12,121675,DB04840,Debrisoquin
,8265519,renal clearance,The urinary excretion of the intravenous dose was 12 +/- 6% and the renal clearance 10 +/- 5 ml/min.,Pharmacokinetics of R(+)-terodiline given intravenously and orally to healthy volunteers. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8265519/),[ml] / [min],10,121676,DB04840,Debrisoquin
,8265519,bioavailability,The bioavailability of (+)-terodiline was 93 +/- 19%.,Pharmacokinetics of R(+)-terodiline given intravenously and orally to healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8265519/),%,93,121677,DB04840,Debrisoquin
,27580115,Metabolic ratios,"Metabolic ratios for dextromethorphan ranged from 0.03 to 0.46 (mean, 0.12).",Dextromethorphan and debrisoquine metabolism and polymorphism of the gene for cytochrome P450 isozyme 2D50 in Thoroughbreds. ,Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27580115/),,0.12,125070,DB04840,Debrisoquin
,2910639,R/S ratios,"The R/S ratios for the clearance to 4-OH-P were similar between EM and PMD (2.5 +/- 0.5 vs 2.5 +/- 0.4, respectively), implying that the different enzymes involved in ring hydroxylation (i.e., the debrisoquin isozyme and other hydroxylases) have similar stereoselective preferences.",Propranolol's metabolism is determined by both mephenytoin and debrisoquin hydroxylase activities. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2910639/),,2.5,125387,DB04840,Debrisoquin
,2910639,R/S ratios,"The R/S ratios for the clearance to 4-OH-P were similar between EM and PMD (2.5 +/- 0.5 vs 2.5 +/- 0.4, respectively), implying that the different enzymes involved in ring hydroxylation (i.e., the debrisoquin isozyme and other hydroxylases) have similar stereoselective preferences.",Propranolol's metabolism is determined by both mephenytoin and debrisoquin hydroxylase activities. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2910639/),,2.5,125388,DB04840,Debrisoquin
,2719900,steady-state plasma,"3. In patients with the extensive metabolizer phenotype, quinidine increased mean steady-state plasma propafenone concentrations more than two fold, from 408 +/- 351 (mean +/- s.d.) to 1096 +/- 644 ng ml-1 (P less than 0.001), decreased 5-hydroxypropafenone concentrations from 242 +/- 196 to 125 +/- 97 ng ml-1 (P less than 0.02) and reduced propafenone oral clearance by 58 +/- 23%.",Genetically-determined interaction between propafenone and low dose quinidine: role of active metabolites in modulating net drug effect. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2719900/),[ng] / [ml],408,126193,DB04840,Debrisoquin
,2719900,steady-state plasma,"3. In patients with the extensive metabolizer phenotype, quinidine increased mean steady-state plasma propafenone concentrations more than two fold, from 408 +/- 351 (mean +/- s.d.) to 1096 +/- 644 ng ml-1 (P less than 0.001), decreased 5-hydroxypropafenone concentrations from 242 +/- 196 to 125 +/- 97 ng ml-1 (P less than 0.02) and reduced propafenone oral clearance by 58 +/- 23%.",Genetically-determined interaction between propafenone and low dose quinidine: role of active metabolites in modulating net drug effect. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2719900/),[ng] / [ml],1096,126194,DB04840,Debrisoquin
,1937348,area under the plasma concentration-time curve (AUC,"Due to the small number of subjects, comparison of the NF pharmacokinetics at dose 1 and 26 failed to show a bimodality in the frequency distribution of its area under the plasma concentration-time curve (AUC 274.5 to 317.1 ng ml-1 h, NS).",Lack of effect by nifedipine on hepatic mixed function oxidase in man. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1937348/),[h·ng] / [ml],274.5 to 317.1,128876,DB04840,Debrisoquin
,1937348,t1/2,"Hepatic microsomal autoinduction (t1/2 2.87 to 3.06 h, NS) was not found.",Lack of effect by nifedipine on hepatic mixed function oxidase in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1937348/),h,2.87 to 3.06,128877,DB04840,Debrisoquin
,1937348,urinary excretion,"Unlike what has been suggested by in vitro studies, NF treatment did not modify significantly the urinary excretion of 6 beta-hydroxycortisol (318 to 265 micrograms/d, NS).",Lack of effect by nifedipine on hepatic mixed function oxidase in man. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1937348/),[μg] / [d],318 to 265,128878,DB04840,Debrisoquin
,3691597,Cmax,"In PM subjects, mean values of Cmax (158 ng/ml) and AUC(0-24) (2556 ng X h X m-1) for indoramin were substantially elevated and t 1/2 beta (18.5 h) prolonged by comparison with values in the EM subjects (21.6 ng/ml, 151 ng X h X ml-1 and 5.2 h respectively).",The pharmacokinetics of indoramin and 6-hydroxyindoramin in poor and extensive hydroxylators of debrisoquine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3691597/),[ng] / [ml],158,131585,DB04840,Debrisoquin
,3691597,AUC(0-24),"In PM subjects, mean values of Cmax (158 ng/ml) and AUC(0-24) (2556 ng X h X m-1) for indoramin were substantially elevated and t 1/2 beta (18.5 h) prolonged by comparison with values in the EM subjects (21.6 ng/ml, 151 ng X h X ml-1 and 5.2 h respectively).",The pharmacokinetics of indoramin and 6-hydroxyindoramin in poor and extensive hydroxylators of debrisoquine. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3691597/),[h·ng] / [m],2556,131586,DB04840,Debrisoquin
,3691597,t 1/2 beta,"In PM subjects, mean values of Cmax (158 ng/ml) and AUC(0-24) (2556 ng X h X m-1) for indoramin were substantially elevated and t 1/2 beta (18.5 h) prolonged by comparison with values in the EM subjects (21.6 ng/ml, 151 ng X h X ml-1 and 5.2 h respectively).",The pharmacokinetics of indoramin and 6-hydroxyindoramin in poor and extensive hydroxylators of debrisoquine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3691597/),h,18.5,131587,DB04840,Debrisoquin
,3691597,t 1/2 beta,"In PM subjects, mean values of Cmax (158 ng/ml) and AUC(0-24) (2556 ng X h X m-1) for indoramin were substantially elevated and t 1/2 beta (18.5 h) prolonged by comparison with values in the EM subjects (21.6 ng/ml, 151 ng X h X ml-1 and 5.2 h respectively).",The pharmacokinetics of indoramin and 6-hydroxyindoramin in poor and extensive hydroxylators of debrisoquine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3691597/),[ng] / [ml],21.6,131588,DB04840,Debrisoquin
,3691597,t 1/2 beta,"In PM subjects, mean values of Cmax (158 ng/ml) and AUC(0-24) (2556 ng X h X m-1) for indoramin were substantially elevated and t 1/2 beta (18.5 h) prolonged by comparison with values in the EM subjects (21.6 ng/ml, 151 ng X h X ml-1 and 5.2 h respectively).",The pharmacokinetics of indoramin and 6-hydroxyindoramin in poor and extensive hydroxylators of debrisoquine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3691597/),[h·ng] / [ml],151,131589,DB04840,Debrisoquin
,3691597,t 1/2 beta,"In PM subjects, mean values of Cmax (158 ng/ml) and AUC(0-24) (2556 ng X h X m-1) for indoramin were substantially elevated and t 1/2 beta (18.5 h) prolonged by comparison with values in the EM subjects (21.6 ng/ml, 151 ng X h X ml-1 and 5.2 h respectively).",The pharmacokinetics of indoramin and 6-hydroxyindoramin in poor and extensive hydroxylators of debrisoquine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3691597/),h,5.2,131590,DB04840,Debrisoquin
,3691597,Cmax,"For 6-hydroxyindoramin, on the other hand, Cmax (12.4 ng/ml) and AUC (0-8) (47.5 ng X h X ml-1) in PM subjects were significantly lower than in the EM subjects (28.2 ng/ml and 94.7 ng X h X ml-1).",The pharmacokinetics of indoramin and 6-hydroxyindoramin in poor and extensive hydroxylators of debrisoquine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3691597/),[ng] / [ml],12.4,131591,DB04840,Debrisoquin
,3691597,AUC (0-8),"For 6-hydroxyindoramin, on the other hand, Cmax (12.4 ng/ml) and AUC (0-8) (47.5 ng X h X ml-1) in PM subjects were significantly lower than in the EM subjects (28.2 ng/ml and 94.7 ng X h X ml-1).",The pharmacokinetics of indoramin and 6-hydroxyindoramin in poor and extensive hydroxylators of debrisoquine. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3691597/),[h·ng] / [ml],47.5,131592,DB04840,Debrisoquin
,3691597,AUC (0-8),"For 6-hydroxyindoramin, on the other hand, Cmax (12.4 ng/ml) and AUC (0-8) (47.5 ng X h X ml-1) in PM subjects were significantly lower than in the EM subjects (28.2 ng/ml and 94.7 ng X h X ml-1).",The pharmacokinetics of indoramin and 6-hydroxyindoramin in poor and extensive hydroxylators of debrisoquine. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3691597/),[ng] / [ml],28.2,131593,DB04840,Debrisoquin
,3691597,AUC (0-8),"For 6-hydroxyindoramin, on the other hand, Cmax (12.4 ng/ml) and AUC (0-8) (47.5 ng X h X ml-1) in PM subjects were significantly lower than in the EM subjects (28.2 ng/ml and 94.7 ng X h X ml-1).",The pharmacokinetics of indoramin and 6-hydroxyindoramin in poor and extensive hydroxylators of debrisoquine. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3691597/),[h·ng] / [ml],94.7,131594,DB04840,Debrisoquin
,9278194,CL/F,"CL/F was 6.5 +/- 1.8 l h(-1), V(ss)/F 815 +/- 165 l, and k 0.0081 +/- 0.0023 h(-1).",Enantioselective pharmacokinetics of mefloquine during long-term intake of the prophylactic dose. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9278194/),[l] / [h],6.5,140117,DB04840,Debrisoquin
,9278194,V(ss)/F,"CL/F was 6.5 +/- 1.8 l h(-1), V(ss)/F 815 +/- 165 l, and k 0.0081 +/- 0.0023 h(-1).",Enantioselective pharmacokinetics of mefloquine during long-term intake of the prophylactic dose. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9278194/),l,815,140118,DB04840,Debrisoquin
,9278194,k,"CL/F was 6.5 +/- 1.8 l h(-1), V(ss)/F 815 +/- 165 l, and k 0.0081 +/- 0.0023 h(-1).",Enantioselective pharmacokinetics of mefloquine during long-term intake of the prophylactic dose. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9278194/),1/[h],0.0081,140119,DB04840,Debrisoquin
,9278194,oral clearance,"The kinetics of (-)SR-MQ were time- and/or concentration dependent with a lower oral clearance (0.92 +/- 0.25 vs 2.14 +/- 0.63 l h(-1), 95% CI for the difference 0.86-1.60 l h(-1)) and a longer half-life (345 vs 185 h, 95% CI for the difference 47-291 h) after the last dose compared with the first dose.",Enantioselective pharmacokinetics of mefloquine during long-term intake of the prophylactic dose. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9278194/),[l] / [h],0.92,140120,DB04840,Debrisoquin
,9278194,oral clearance,"The kinetics of (-)SR-MQ were time- and/or concentration dependent with a lower oral clearance (0.92 +/- 0.25 vs 2.14 +/- 0.63 l h(-1), 95% CI for the difference 0.86-1.60 l h(-1)) and a longer half-life (345 vs 185 h, 95% CI for the difference 47-291 h) after the last dose compared with the first dose.",Enantioselective pharmacokinetics of mefloquine during long-term intake of the prophylactic dose. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9278194/),[l] / [h],2.14,140121,DB04840,Debrisoquin
,9278194,half-life,"The kinetics of (-)SR-MQ were time- and/or concentration dependent with a lower oral clearance (0.92 +/- 0.25 vs 2.14 +/- 0.63 l h(-1), 95% CI for the difference 0.86-1.60 l h(-1)) and a longer half-life (345 vs 185 h, 95% CI for the difference 47-291 h) after the last dose compared with the first dose.",Enantioselective pharmacokinetics of mefloquine during long-term intake of the prophylactic dose. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9278194/),h,345,140122,DB04840,Debrisoquin
,9278194,half-life,"The kinetics of (-)SR-MQ were time- and/or concentration dependent with a lower oral clearance (0.92 +/- 0.25 vs 2.14 +/- 0.63 l h(-1), 95% CI for the difference 0.86-1.60 l h(-1)) and a longer half-life (345 vs 185 h, 95% CI for the difference 47-291 h) after the last dose compared with the first dose.",Enantioselective pharmacokinetics of mefloquine during long-term intake of the prophylactic dose. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9278194/),h,185,140123,DB04840,Debrisoquin
,9278194,Urinary recovery of unchanged substance,Urinary recovery of unchanged substance was 8.7% for (+)RS-MQ and 12.3% for (-)SR-MQ.,Enantioselective pharmacokinetics of mefloquine during long-term intake of the prophylactic dose. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9278194/),%,8.7,140124,DB04840,Debrisoquin
,9278194,Urinary recovery of unchanged substance,Urinary recovery of unchanged substance was 8.7% for (+)RS-MQ and 12.3% for (-)SR-MQ.,Enantioselective pharmacokinetics of mefloquine during long-term intake of the prophylactic dose. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9278194/),%,12.3,140125,DB04840,Debrisoquin
,7654478,urinary recovery,2. The median urinary recovery of ethylmorphine and measured metabolites was 77% over 48 h.,Biotransformation and pharmacokinetics of ethylmorphine after a single oral dose. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7654478/),%,77,150959,DB04840,Debrisoquin
,7654478,tmax,"The median tmax of unchanged ethylmorphine was 45 min, and the terminal elimination t1/2 was 2 h.",Biotransformation and pharmacokinetics of ethylmorphine after a single oral dose. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7654478/),min,45,150960,DB04840,Debrisoquin
,7654478,terminal elimination t1/2,"The median tmax of unchanged ethylmorphine was 45 min, and the terminal elimination t1/2 was 2 h.",Biotransformation and pharmacokinetics of ethylmorphine after a single oral dose. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7654478/),h,2,150961,DB04840,Debrisoquin
,7654478,urinary recovery,3. Two subjects had significantly lower urinary recovery (0.48 h) of morphine and morphine-glucuronides than the remainder.,Biotransformation and pharmacokinetics of ethylmorphine after a single oral dose. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7654478/),h,0.48,150962,DB04840,Debrisoquin
,8422740,area under the plasma concentration time curve,"In the 11 (92%) subjects phenotyped as extensive metabolizers, propafenone significantly increased the lidocaine area under the plasma concentration time curve (81.7 +/- 16.2 versus 76.3 +/- 15.6 micrograms.hr/ml; p < or = 0.05) and reduced systemic lidocaine clearance (9.53 +/- 1.77 versus 10.27 +/- 2.24 ml/min/kg; p < or = 0.05), but did not significantly affect volume of distribution at steady state (2.48 +/- 0.33 versus 2.64 +/- 0.45 L/kg; p = 0.10) or mean residence time (4.37 +/- 0.92 versus 4.47 +/- 0.87 hours; difference not significant) compared with placebo, respectively.",The pharmacokinetic and pharmacodynamic interaction between propafenone and lidocaine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8422740/),[h·μg] / [ml],81.7,152051,DB04840,Debrisoquin
,8422740,area under the plasma concentration time curve,"In the 11 (92%) subjects phenotyped as extensive metabolizers, propafenone significantly increased the lidocaine area under the plasma concentration time curve (81.7 +/- 16.2 versus 76.3 +/- 15.6 micrograms.hr/ml; p < or = 0.05) and reduced systemic lidocaine clearance (9.53 +/- 1.77 versus 10.27 +/- 2.24 ml/min/kg; p < or = 0.05), but did not significantly affect volume of distribution at steady state (2.48 +/- 0.33 versus 2.64 +/- 0.45 L/kg; p = 0.10) or mean residence time (4.37 +/- 0.92 versus 4.47 +/- 0.87 hours; difference not significant) compared with placebo, respectively.",The pharmacokinetic and pharmacodynamic interaction between propafenone and lidocaine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8422740/),[h·μg] / [ml],76.3,152052,DB04840,Debrisoquin
,8422740,systemic,"In the 11 (92%) subjects phenotyped as extensive metabolizers, propafenone significantly increased the lidocaine area under the plasma concentration time curve (81.7 +/- 16.2 versus 76.3 +/- 15.6 micrograms.hr/ml; p < or = 0.05) and reduced systemic lidocaine clearance (9.53 +/- 1.77 versus 10.27 +/- 2.24 ml/min/kg; p < or = 0.05), but did not significantly affect volume of distribution at steady state (2.48 +/- 0.33 versus 2.64 +/- 0.45 L/kg; p = 0.10) or mean residence time (4.37 +/- 0.92 versus 4.47 +/- 0.87 hours; difference not significant) compared with placebo, respectively.",The pharmacokinetic and pharmacodynamic interaction between propafenone and lidocaine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8422740/),[ml] / [kg·min],9.53,152053,DB04840,Debrisoquin
,8422740,systemic,"In the 11 (92%) subjects phenotyped as extensive metabolizers, propafenone significantly increased the lidocaine area under the plasma concentration time curve (81.7 +/- 16.2 versus 76.3 +/- 15.6 micrograms.hr/ml; p < or = 0.05) and reduced systemic lidocaine clearance (9.53 +/- 1.77 versus 10.27 +/- 2.24 ml/min/kg; p < or = 0.05), but did not significantly affect volume of distribution at steady state (2.48 +/- 0.33 versus 2.64 +/- 0.45 L/kg; p = 0.10) or mean residence time (4.37 +/- 0.92 versus 4.47 +/- 0.87 hours; difference not significant) compared with placebo, respectively.",The pharmacokinetic and pharmacodynamic interaction between propafenone and lidocaine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8422740/),[ml] / [kg·min],10.27,152054,DB04840,Debrisoquin
,8422740,volume of distribution at steady state,"In the 11 (92%) subjects phenotyped as extensive metabolizers, propafenone significantly increased the lidocaine area under the plasma concentration time curve (81.7 +/- 16.2 versus 76.3 +/- 15.6 micrograms.hr/ml; p < or = 0.05) and reduced systemic lidocaine clearance (9.53 +/- 1.77 versus 10.27 +/- 2.24 ml/min/kg; p < or = 0.05), but did not significantly affect volume of distribution at steady state (2.48 +/- 0.33 versus 2.64 +/- 0.45 L/kg; p = 0.10) or mean residence time (4.37 +/- 0.92 versus 4.47 +/- 0.87 hours; difference not significant) compared with placebo, respectively.",The pharmacokinetic and pharmacodynamic interaction between propafenone and lidocaine. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8422740/),[l] / [kg],2.48,152055,DB04840,Debrisoquin
,8422740,volume of distribution at steady state,"In the 11 (92%) subjects phenotyped as extensive metabolizers, propafenone significantly increased the lidocaine area under the plasma concentration time curve (81.7 +/- 16.2 versus 76.3 +/- 15.6 micrograms.hr/ml; p < or = 0.05) and reduced systemic lidocaine clearance (9.53 +/- 1.77 versus 10.27 +/- 2.24 ml/min/kg; p < or = 0.05), but did not significantly affect volume of distribution at steady state (2.48 +/- 0.33 versus 2.64 +/- 0.45 L/kg; p = 0.10) or mean residence time (4.37 +/- 0.92 versus 4.47 +/- 0.87 hours; difference not significant) compared with placebo, respectively.",The pharmacokinetic and pharmacodynamic interaction between propafenone and lidocaine. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8422740/),[l] / [kg],2.64,152056,DB04840,Debrisoquin
,8422740,mean residence time,"In the 11 (92%) subjects phenotyped as extensive metabolizers, propafenone significantly increased the lidocaine area under the plasma concentration time curve (81.7 +/- 16.2 versus 76.3 +/- 15.6 micrograms.hr/ml; p < or = 0.05) and reduced systemic lidocaine clearance (9.53 +/- 1.77 versus 10.27 +/- 2.24 ml/min/kg; p < or = 0.05), but did not significantly affect volume of distribution at steady state (2.48 +/- 0.33 versus 2.64 +/- 0.45 L/kg; p = 0.10) or mean residence time (4.37 +/- 0.92 versus 4.47 +/- 0.87 hours; difference not significant) compared with placebo, respectively.",The pharmacokinetic and pharmacodynamic interaction between propafenone and lidocaine. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8422740/),h,4.37,152057,DB04840,Debrisoquin
,8422740,mean residence time,"In the 11 (92%) subjects phenotyped as extensive metabolizers, propafenone significantly increased the lidocaine area under the plasma concentration time curve (81.7 +/- 16.2 versus 76.3 +/- 15.6 micrograms.hr/ml; p < or = 0.05) and reduced systemic lidocaine clearance (9.53 +/- 1.77 versus 10.27 +/- 2.24 ml/min/kg; p < or = 0.05), but did not significantly affect volume of distribution at steady state (2.48 +/- 0.33 versus 2.64 +/- 0.45 L/kg; p = 0.10) or mean residence time (4.37 +/- 0.92 versus 4.47 +/- 0.87 hours; difference not significant) compared with placebo, respectively.",The pharmacokinetic and pharmacodynamic interaction between propafenone and lidocaine. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8422740/),h,4.47,152058,DB04840,Debrisoquin
,8971425,Cmax,"4. The pharmacokinetic parameters of MMDL and MDL were similar in the ten subjects who were extensive metabolisers of debrisoquine (five of whom were poor metabolisers of S-mephenytoin) (mean MMDL Cmax 59 nmol l-1 and AUC (0, th) 144 nmol l-1h, mean MDL Cmax 183 nmol l-1 and AUC 2627 nmol l-1h) but were markedly different from the five subjects who were poor metabolisers of debrisoquine (mean MMDL Cmax 356 nmol l-1 and AUC 10512 nmol l-1h, MDL concentrations below limit of quantitation).",Involvement of CYP2D6 but not CYP2C19 in nicergoline metabolism in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8971425/),[nM] / [l],59,155308,DB04840,Debrisoquin
,8971425,"AUC (0, th)","4. The pharmacokinetic parameters of MMDL and MDL were similar in the ten subjects who were extensive metabolisers of debrisoquine (five of whom were poor metabolisers of S-mephenytoin) (mean MMDL Cmax 59 nmol l-1 and AUC (0, th) 144 nmol l-1h, mean MDL Cmax 183 nmol l-1 and AUC 2627 nmol l-1h) but were markedly different from the five subjects who were poor metabolisers of debrisoquine (mean MMDL Cmax 356 nmol l-1 and AUC 10512 nmol l-1h, MDL concentrations below limit of quantitation).",Involvement of CYP2D6 but not CYP2C19 in nicergoline metabolism in humans. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8971425/),[nM] / [l],144,155309,DB04840,Debrisoquin
,8971425,Cmax,"4. The pharmacokinetic parameters of MMDL and MDL were similar in the ten subjects who were extensive metabolisers of debrisoquine (five of whom were poor metabolisers of S-mephenytoin) (mean MMDL Cmax 59 nmol l-1 and AUC (0, th) 144 nmol l-1h, mean MDL Cmax 183 nmol l-1 and AUC 2627 nmol l-1h) but were markedly different from the five subjects who were poor metabolisers of debrisoquine (mean MMDL Cmax 356 nmol l-1 and AUC 10512 nmol l-1h, MDL concentrations below limit of quantitation).",Involvement of CYP2D6 but not CYP2C19 in nicergoline metabolism in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8971425/),[nM] / [l],183,155310,DB04840,Debrisoquin
,8971425,AUC,"4. The pharmacokinetic parameters of MMDL and MDL were similar in the ten subjects who were extensive metabolisers of debrisoquine (five of whom were poor metabolisers of S-mephenytoin) (mean MMDL Cmax 59 nmol l-1 and AUC (0, th) 144 nmol l-1h, mean MDL Cmax 183 nmol l-1 and AUC 2627 nmol l-1h) but were markedly different from the five subjects who were poor metabolisers of debrisoquine (mean MMDL Cmax 356 nmol l-1 and AUC 10512 nmol l-1h, MDL concentrations below limit of quantitation).",Involvement of CYP2D6 but not CYP2C19 in nicergoline metabolism in humans. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8971425/),[nM] / [l],2627,155311,DB04840,Debrisoquin
,8971425,Cmax,"4. The pharmacokinetic parameters of MMDL and MDL were similar in the ten subjects who were extensive metabolisers of debrisoquine (five of whom were poor metabolisers of S-mephenytoin) (mean MMDL Cmax 59 nmol l-1 and AUC (0, th) 144 nmol l-1h, mean MDL Cmax 183 nmol l-1 and AUC 2627 nmol l-1h) but were markedly different from the five subjects who were poor metabolisers of debrisoquine (mean MMDL Cmax 356 nmol l-1 and AUC 10512 nmol l-1h, MDL concentrations below limit of quantitation).",Involvement of CYP2D6 but not CYP2C19 in nicergoline metabolism in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8971425/),[nM] / [l],356,155312,DB04840,Debrisoquin
,8971425,AUC,"4. The pharmacokinetic parameters of MMDL and MDL were similar in the ten subjects who were extensive metabolisers of debrisoquine (five of whom were poor metabolisers of S-mephenytoin) (mean MMDL Cmax 59 nmol l-1 and AUC (0, th) 144 nmol l-1h, mean MDL Cmax 183 nmol l-1 and AUC 2627 nmol l-1h) but were markedly different from the five subjects who were poor metabolisers of debrisoquine (mean MMDL Cmax 356 nmol l-1 and AUC 10512 nmol l-1h, MDL concentrations below limit of quantitation).",Involvement of CYP2D6 but not CYP2C19 in nicergoline metabolism in humans. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8971425/),[nM] / [l],10512,155313,DB04840,Debrisoquin
,2125833,oral bioavailability,Over 90% of patients are extensive metabolizers (EM) in whom the oral bioavailability of encainide is only 30% because of extensive first-pass metabolism.,Pharmacokinetics and metabolism of encainide. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2125833/),%,30,156225,DB04840,Debrisoquin
,2125833,elimination t1/2,"In EMs, elimination t1/2 is about 2.5 hours, with a systemic clearance of 1.8 l/min.",Pharmacokinetics and metabolism of encainide. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2125833/),h,2.5,156226,DB04840,Debrisoquin
,2125833,systemic clearance,"In EMs, elimination t1/2 is about 2.5 hours, with a systemic clearance of 1.8 l/min.",Pharmacokinetics and metabolism of encainide. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2125833/),[l] / [min],1.8,156227,DB04840,Debrisoquin
,2125833,oral bioavailability,"The remaining patients (less than 10%) are poor metabolizers (PM), in whom the oral bioavailability is near 88% with an elimination t1/2 of 8-11 hours and a systemic clearance of 0.2 l/min.",Pharmacokinetics and metabolism of encainide. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2125833/),%,88,156228,DB04840,Debrisoquin
,2125833,elimination t1/2,"The remaining patients (less than 10%) are poor metabolizers (PM), in whom the oral bioavailability is near 88% with an elimination t1/2 of 8-11 hours and a systemic clearance of 0.2 l/min.",Pharmacokinetics and metabolism of encainide. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2125833/),h,8-11,156229,DB04840,Debrisoquin
,2125833,systemic clearance,"The remaining patients (less than 10%) are poor metabolizers (PM), in whom the oral bioavailability is near 88% with an elimination t1/2 of 8-11 hours and a systemic clearance of 0.2 l/min.",Pharmacokinetics and metabolism of encainide. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2125833/),[l] / [min],0.2,156230,DB04840,Debrisoquin
,2125833,plasma protein binding,"The conversion to the N-desmethyl-encainide (NDE) metabolite seems to be similar in both metabolizer groups, and plasma protein binding of encainide of 70-78% is also similar.",Pharmacokinetics and metabolism of encainide. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2125833/),%,70-78,156231,DB04840,Debrisoquin
,2125833,Minimally effective plasma concentrations,"Minimally effective plasma concentrations appear to be approximately 300 ng/ml of encainide, 35 ng/ml of ODE, and 100 ng/ml of 3-MODE.",Pharmacokinetics and metabolism of encainide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2125833/),[ng] / [ml],300,156232,DB04840,Debrisoquin
,2125833,Minimally effective plasma concentrations,"Minimally effective plasma concentrations appear to be approximately 300 ng/ml of encainide, 35 ng/ml of ODE, and 100 ng/ml of 3-MODE.",Pharmacokinetics and metabolism of encainide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2125833/),[ng] / [ml],35,156233,DB04840,Debrisoquin
,2125833,Minimally effective plasma concentrations,"Minimally effective plasma concentrations appear to be approximately 300 ng/ml of encainide, 35 ng/ml of ODE, and 100 ng/ml of 3-MODE.",Pharmacokinetics and metabolism of encainide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2125833/),[ng] / [ml],100,156234,DB04840,Debrisoquin
,2357863,area under the plasma concentration-time curve,The coadministration of quinidine resulted in a doubling of the area under the plasma concentration-time curve of (+/-)-propranolol (530 +/- 99 versus 1051 +/- 138 ng.hr/ml; p less than 0.05) and a reduction in the clearance of (+/-)-propranolol from 3087 +/- 648 to 1378 +/- 173 ml/min (p less than 0.05).,Quinidine reduces clearance of (+)-propranolol more than (-)-propranolol through marked reduction in 4-hydroxylation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2357863/),[h·ng] / [ml],530,157270,DB04840,Debrisoquin
,2357863,area under the plasma concentration-time curve,The coadministration of quinidine resulted in a doubling of the area under the plasma concentration-time curve of (+/-)-propranolol (530 +/- 99 versus 1051 +/- 138 ng.hr/ml; p less than 0.05) and a reduction in the clearance of (+/-)-propranolol from 3087 +/- 648 to 1378 +/- 173 ml/min (p less than 0.05).,Quinidine reduces clearance of (+)-propranolol more than (-)-propranolol through marked reduction in 4-hydroxylation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2357863/),[h·ng] / [ml],1051,157271,DB04840,Debrisoquin
,2357863,clearance,The coadministration of quinidine resulted in a doubling of the area under the plasma concentration-time curve of (+/-)-propranolol (530 +/- 99 versus 1051 +/- 138 ng.hr/ml; p less than 0.05) and a reduction in the clearance of (+/-)-propranolol from 3087 +/- 648 to 1378 +/- 173 ml/min (p less than 0.05).,Quinidine reduces clearance of (+)-propranolol more than (-)-propranolol through marked reduction in 4-hydroxylation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2357863/),[ml] / [min],3087,157272,DB04840,Debrisoquin
,2357863,clearance,The coadministration of quinidine resulted in a doubling of the area under the plasma concentration-time curve of (+/-)-propranolol (530 +/- 99 versus 1051 +/- 138 ng.hr/ml; p less than 0.05) and a reduction in the clearance of (+/-)-propranolol from 3087 +/- 648 to 1378 +/- 173 ml/min (p less than 0.05).,Quinidine reduces clearance of (+)-propranolol more than (-)-propranolol through marked reduction in 4-hydroxylation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2357863/),[ml] / [min],1378,157273,DB04840,Debrisoquin
,2357863,partial metabolic clearance,"The metabolism of propranolol by the 4-hydroxylation pathway was almost abolished by quinidine, resulting in a fall in the partial metabolic clearance by this pathway from 678 +/- 246 to 56 +/- 11 ml/min (p less than 0.05).",Quinidine reduces clearance of (+)-propranolol more than (-)-propranolol through marked reduction in 4-hydroxylation. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2357863/),[ml] / [min],678,157274,DB04840,Debrisoquin
,2357863,partial metabolic clearance,"The metabolism of propranolol by the 4-hydroxylation pathway was almost abolished by quinidine, resulting in a fall in the partial metabolic clearance by this pathway from 678 +/- 246 to 56 +/- 11 ml/min (p less than 0.05).",Quinidine reduces clearance of (+)-propranolol more than (-)-propranolol through marked reduction in 4-hydroxylation. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2357863/),[ml] / [min],56,157275,DB04840,Debrisoquin
,1585408,plasma half-life,"PM eliminated haloperidol significantly slower than EM, the plasma half-life being longer (mean 29.4 +/- S.D. 4.2 and 16.3 +/- 6.4 h; p less than 0.01) and the clearance lower (1.16 +/- 0.36 and 2.49 +/- 1.31 L/h/kg; p less than 0.05).",Haloperidol disposition is dependent on debrisoquine hydroxylation phenotype. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1585408/),h,29.4,159562,DB04840,Debrisoquin
,1585408,plasma half-life,"PM eliminated haloperidol significantly slower than EM, the plasma half-life being longer (mean 29.4 +/- S.D. 4.2 and 16.3 +/- 6.4 h; p less than 0.01) and the clearance lower (1.16 +/- 0.36 and 2.49 +/- 1.31 L/h/kg; p less than 0.05).",Haloperidol disposition is dependent on debrisoquine hydroxylation phenotype. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1585408/),h,16.3,159563,DB04840,Debrisoquin
,1585408,clearance,"PM eliminated haloperidol significantly slower than EM, the plasma half-life being longer (mean 29.4 +/- S.D. 4.2 and 16.3 +/- 6.4 h; p less than 0.01) and the clearance lower (1.16 +/- 0.36 and 2.49 +/- 1.31 L/h/kg; p less than 0.05).",Haloperidol disposition is dependent on debrisoquine hydroxylation phenotype. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1585408/),[l] / [h·kg],1.16,159564,DB04840,Debrisoquin
,1585408,clearance,"PM eliminated haloperidol significantly slower than EM, the plasma half-life being longer (mean 29.4 +/- S.D. 4.2 and 16.3 +/- 6.4 h; p less than 0.01) and the clearance lower (1.16 +/- 0.36 and 2.49 +/- 1.31 L/h/kg; p less than 0.05).",Haloperidol disposition is dependent on debrisoquine hydroxylation phenotype. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1585408/),[l] / [h·kg],2.49,159565,DB04840,Debrisoquin
,1910493,elimination half-life,The elimination half-life of intravenous indocyanine green was only 1 hour after oral nifedipine (20 mg) significantly decreased.,[The effects of verapamil and nifedipine on the biotransformation of model substances and on the indocyanine green elimination]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1910493/),h,1,165139,DB04840,Debrisoquin
,1820333,half-time,"The half-time of the toxin depends on both the dose and the animal species, varying from 0.7 h in fish to 840 h in monkeys.",Pharmacokinetics of ochratoxin A in animals. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1820333/),h,0.7,166163,DB04840,Debrisoquin
,1820333,half-time,"The half-time of the toxin depends on both the dose and the animal species, varying from 0.7 h in fish to 840 h in monkeys.",Pharmacokinetics of ochratoxin A in animals. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1820333/),h,840,166164,DB04840,Debrisoquin
,1867958,Cmax,2. Mean values of Cmax (445 nmol l-1) and AUC (1660 nmol l-1 h) of codeine in the Chinese were significantly higher than those in the Caucasians (292 nmol l-1 and 1010 nmol l-1 h).,A comparison of the pharmacokinetics of codeine and its metabolites in healthy Chinese and Caucasian extensive hydroxylators of debrisoquine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1867958/),[nM] / [l],445,166872,DB04840,Debrisoquin
,1867958,AUC,2. Mean values of Cmax (445 nmol l-1) and AUC (1660 nmol l-1 h) of codeine in the Chinese were significantly higher than those in the Caucasians (292 nmol l-1 and 1010 nmol l-1 h).,A comparison of the pharmacokinetics of codeine and its metabolites in healthy Chinese and Caucasian extensive hydroxylators of debrisoquine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1867958/),[h·nM] / [l],1660,166873,DB04840,Debrisoquin
,1867958,AUC,2. Mean values of Cmax (445 nmol l-1) and AUC (1660 nmol l-1 h) of codeine in the Chinese were significantly higher than those in the Caucasians (292 nmol l-1 and 1010 nmol l-1 h).,A comparison of the pharmacokinetics of codeine and its metabolites in healthy Chinese and Caucasian extensive hydroxylators of debrisoquine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1867958/),[nM] / [l],292,166874,DB04840,Debrisoquin
,1867958,AUC,2. Mean values of Cmax (445 nmol l-1) and AUC (1660 nmol l-1 h) of codeine in the Chinese were significantly higher than those in the Caucasians (292 nmol l-1 and 1010 nmol l-1 h).,A comparison of the pharmacokinetics of codeine and its metabolites in healthy Chinese and Caucasian extensive hydroxylators of debrisoquine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1867958/),[h·nM] / [l],1010,166875,DB04840,Debrisoquin
,1867958,Partial clearance,3. Partial clearance by glucuronidation was significantly lower (0.79 +/- 0.14 s.d. vs 1.42 +/- 0.48 s.d. 1 h-1 kg-1) in Chinese than in Caucasians.,A comparison of the pharmacokinetics of codeine and its metabolites in healthy Chinese and Caucasian extensive hydroxylators of debrisoquine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1867958/),,0.79,166876,DB04840,Debrisoquin
,1867958,Partial clearance,3. Partial clearance by glucuronidation was significantly lower (0.79 +/- 0.14 s.d. vs 1.42 +/- 0.48 s.d. 1 h-1 kg-1) in Chinese than in Caucasians.,A comparison of the pharmacokinetics of codeine and its metabolites in healthy Chinese and Caucasian extensive hydroxylators of debrisoquine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1867958/),,1.42,166877,DB04840,Debrisoquin
,1867958,total urinary recovery,4. The total urinary recovery of drug-related material in 48 h urine was similar in Chinese (82.2%) and Caucasians (84.4%).,A comparison of the pharmacokinetics of codeine and its metabolites in healthy Chinese and Caucasian extensive hydroxylators of debrisoquine. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1867958/),%,82.2,166878,DB04840,Debrisoquin
,1867958,total urinary recovery,4. The total urinary recovery of drug-related material in 48 h urine was similar in Chinese (82.2%) and Caucasians (84.4%).,A comparison of the pharmacokinetics of codeine and its metabolites in healthy Chinese and Caucasian extensive hydroxylators of debrisoquine. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1867958/),%,84.4,166879,DB04840,Debrisoquin
,1867958,recovery,The recovery of unchanged codeine was significantly higher in Chinese (5.7%) than in Caucasians (3.3%).,A comparison of the pharmacokinetics of codeine and its metabolites in healthy Chinese and Caucasian extensive hydroxylators of debrisoquine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1867958/),%,5.7,166880,DB04840,Debrisoquin
,1867958,recovery,The recovery of unchanged codeine was significantly higher in Chinese (5.7%) than in Caucasians (3.3%).,A comparison of the pharmacokinetics of codeine and its metabolites in healthy Chinese and Caucasian extensive hydroxylators of debrisoquine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1867958/),%,3.3,166881,DB04840,Debrisoquin
,1867958,AUC ratios,"5. The AUC ratios of codeine relative to its 6-glucuronide, morphine and norcodeine were 1:9, 35:1 and 4:1, respectively in Chinese.",A comparison of the pharmacokinetics of codeine and its metabolites in healthy Chinese and Caucasian extensive hydroxylators of debrisoquine. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1867958/),,1:9,166882,DB04840,Debrisoquin
,1867958,AUC ratios,"5. The AUC ratios of codeine relative to its 6-glucuronide, morphine and norcodeine were 1:9, 35:1 and 4:1, respectively in Chinese.",A comparison of the pharmacokinetics of codeine and its metabolites in healthy Chinese and Caucasian extensive hydroxylators of debrisoquine. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1867958/),,35:1,166883,DB04840,Debrisoquin
,1867958,AUC ratios,"5. The AUC ratios of codeine relative to its 6-glucuronide, morphine and norcodeine were 1:9, 35:1 and 4:1, respectively in Chinese.",A comparison of the pharmacokinetics of codeine and its metabolites in healthy Chinese and Caucasian extensive hydroxylators of debrisoquine. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1867958/),,4:1,166884,DB04840,Debrisoquin
,1632106,total excretion,The total excretion over 5 days ranged from 83% in monkeys to almost 100% in human with a status of extensive hydroxylators.,Disposition of minaprine in animals and in human extensive and limited debrisoquine hydroxylators. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1632106/),%,83,172737,DB04840,Debrisoquin
,1632106,total excretion,The total excretion over 5 days ranged from 83% in monkeys to almost 100% in human with a status of extensive hydroxylators.,Disposition of minaprine in animals and in human extensive and limited debrisoquine hydroxylators. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1632106/),%,100,172738,DB04840,Debrisoquin
,1632106,Cmax,3. In the two limited hydroxylators Cmax values of total radioactivity in plasma were 4.6 and 3.7 mg equiv/l respectively.,Disposition of minaprine in animals and in human extensive and limited debrisoquine hydroxylators. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1632106/),[equiv·mg] / [l],4.6,172739,DB04840,Debrisoquin
,1632106,Cmax,3. In the two limited hydroxylators Cmax values of total radioactivity in plasma were 4.6 and 3.7 mg equiv/l respectively.,Disposition of minaprine in animals and in human extensive and limited debrisoquine hydroxylators. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1632106/),[equiv·mg] / [l],3.7,172740,DB04840,Debrisoquin
,1632106,Plasma Cmax,Plasma Cmax values of minaprine were 4.0 and 1.4 mg/l in limited hydroxylators and 0.35 and 0.23 mg/l in extensive ones.,Disposition of minaprine in animals and in human extensive and limited debrisoquine hydroxylators. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1632106/),[mg] / [l],4.0,172741,DB04840,Debrisoquin
,1632106,Plasma Cmax,Plasma Cmax values of minaprine were 4.0 and 1.4 mg/l in limited hydroxylators and 0.35 and 0.23 mg/l in extensive ones.,Disposition of minaprine in animals and in human extensive and limited debrisoquine hydroxylators. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1632106/),[mg] / [l],1.4,172742,DB04840,Debrisoquin
,1632106,Plasma Cmax,Plasma Cmax values of minaprine were 4.0 and 1.4 mg/l in limited hydroxylators and 0.35 and 0.23 mg/l in extensive ones.,Disposition of minaprine in animals and in human extensive and limited debrisoquine hydroxylators. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1632106/),[mg] / [l],0.35,172743,DB04840,Debrisoquin
,1632106,Plasma Cmax,Plasma Cmax values of minaprine were 4.0 and 1.4 mg/l in limited hydroxylators and 0.35 and 0.23 mg/l in extensive ones.,Disposition of minaprine in animals and in human extensive and limited debrisoquine hydroxylators. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1632106/),[mg] / [l],0.23,172744,DB04840,Debrisoquin
,1632106,t 1/2 beta,"4. In rats and dogs, the ratios of the plasma AUC values for 20 mg/5 mg doses were close to those of the ratios of the doses administered, whereas in the macaque a slower clearance of radioactivity occurred with the higher dose (t 1/2 beta 5.5 h at 5 mg/kg dose versus 25.7 h at 20 mg/kg dose).",Disposition of minaprine in animals and in human extensive and limited debrisoquine hydroxylators. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1632106/),h,5.5,172745,DB04840,Debrisoquin
,1632106,t 1/2 beta,"4. In rats and dogs, the ratios of the plasma AUC values for 20 mg/5 mg doses were close to those of the ratios of the doses administered, whereas in the macaque a slower clearance of radioactivity occurred with the higher dose (t 1/2 beta 5.5 h at 5 mg/kg dose versus 25.7 h at 20 mg/kg dose).",Disposition of minaprine in animals and in human extensive and limited debrisoquine hydroxylators. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1632106/),h,25.7,172746,DB04840,Debrisoquin
,11723233,clearance,"Pharmacokinetic analysis revealed that debrisoquine (DEB) clearance was markedly higher (94.1 +/- 22.3 l/h/kg), and its half-life significantly reduced (6.9 +/- 1.6 h), in CYP2D6 humanized mice compared with wild-type animals (15.2 +/- 0.9 l/h/kg and 16.5 +/- 4.5 h, respectively).",The CYP2D6 humanized mouse: effect of the human CYP2D6 transgene and HNF4alpha on the disposition of debrisoquine in the mouse. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11723233/),[l] / [h·kg],94.1,173509,DB04840,Debrisoquin
,11723233,half-life,"Pharmacokinetic analysis revealed that debrisoquine (DEB) clearance was markedly higher (94.1 +/- 22.3 l/h/kg), and its half-life significantly reduced (6.9 +/- 1.6 h), in CYP2D6 humanized mice compared with wild-type animals (15.2 +/- 0.9 l/h/kg and 16.5 +/- 4.5 h, respectively).",The CYP2D6 humanized mouse: effect of the human CYP2D6 transgene and HNF4alpha on the disposition of debrisoquine in the mouse. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11723233/),h,6.9,173510,DB04840,Debrisoquin
,11723233,half-life,"Pharmacokinetic analysis revealed that debrisoquine (DEB) clearance was markedly higher (94.1 +/- 22.3 l/h/kg), and its half-life significantly reduced (6.9 +/- 1.6 h), in CYP2D6 humanized mice compared with wild-type animals (15.2 +/- 0.9 l/h/kg and 16.5 +/- 4.5 h, respectively).",The CYP2D6 humanized mouse: effect of the human CYP2D6 transgene and HNF4alpha on the disposition of debrisoquine in the mouse. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11723233/),[l] / [h·kg],15.2,173511,DB04840,Debrisoquin
,11723233,half-life,"Pharmacokinetic analysis revealed that debrisoquine (DEB) clearance was markedly higher (94.1 +/- 22.3 l/h/kg), and its half-life significantly reduced (6.9 +/- 1.6 h), in CYP2D6 humanized mice compared with wild-type animals (15.2 +/- 0.9 l/h/kg and 16.5 +/- 4.5 h, respectively).",The CYP2D6 humanized mouse: effect of the human CYP2D6 transgene and HNF4alpha on the disposition of debrisoquine in the mouse. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11723233/),h,16.5,173512,DB04840,Debrisoquin
,2615529,time to peak concentration,"Food intake reduced the time to peak concentration both in plasma, from 1.8 h to 1.1 h (P less than 0.01) and in red blood cells, from 1.8 h to 1.3 h (P less than 0.01).",Variability of 6-mercaptopurine pharmacokinetics during oral maintenance therapy of children with acute leukemia. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2615529/),h,1.8,174119,DB04840,Debrisoquin
,2615529,time to peak concentration,"Food intake reduced the time to peak concentration both in plasma, from 1.8 h to 1.1 h (P less than 0.01) and in red blood cells, from 1.8 h to 1.3 h (P less than 0.01).",Variability of 6-mercaptopurine pharmacokinetics during oral maintenance therapy of children with acute leukemia. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2615529/),h,1.1,174120,DB04840,Debrisoquin
,2615529,time to peak concentration,"Food intake reduced the time to peak concentration both in plasma, from 1.8 h to 1.1 h (P less than 0.01) and in red blood cells, from 1.8 h to 1.3 h (P less than 0.01).",Variability of 6-mercaptopurine pharmacokinetics during oral maintenance therapy of children with acute leukemia. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2615529/),h,1.3,174121,DB04840,Debrisoquin
,2285622,minimal effective concentrations,The minimal effective concentrations were lower after acute oral administration compared with chronic treatment both for propafenone (200 +/- 189 ng/ml vs. 492 +/- 530 ng/ml; p less than 0.05) and for 5-hydroxy-propafenone (82 +/- 40 ng/ml vs. 149 +/- 80 ng/ml; p less than 0.02).,Minimal effective concentration values of propafenone and 5-hydroxy-propafenone in acute and chronic therapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2285622/),[ng] / [ml],200,174259,DB04840,Debrisoquin
,2285622,minimal effective concentrations,The minimal effective concentrations were lower after acute oral administration compared with chronic treatment both for propafenone (200 +/- 189 ng/ml vs. 492 +/- 530 ng/ml; p less than 0.05) and for 5-hydroxy-propafenone (82 +/- 40 ng/ml vs. 149 +/- 80 ng/ml; p less than 0.02).,Minimal effective concentration values of propafenone and 5-hydroxy-propafenone in acute and chronic therapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2285622/),[ng] / [ml],492,174260,DB04840,Debrisoquin
,2285622,minimal effective concentrations,The minimal effective concentrations were lower after acute oral administration compared with chronic treatment both for propafenone (200 +/- 189 ng/ml vs. 492 +/- 530 ng/ml; p less than 0.05) and for 5-hydroxy-propafenone (82 +/- 40 ng/ml vs. 149 +/- 80 ng/ml; p less than 0.02).,Minimal effective concentration values of propafenone and 5-hydroxy-propafenone in acute and chronic therapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2285622/),[ng] / [ml],82,174261,DB04840,Debrisoquin
,2285622,minimal effective concentrations,The minimal effective concentrations were lower after acute oral administration compared with chronic treatment both for propafenone (200 +/- 189 ng/ml vs. 492 +/- 530 ng/ml; p less than 0.05) and for 5-hydroxy-propafenone (82 +/- 40 ng/ml vs. 149 +/- 80 ng/ml; p less than 0.02).,Minimal effective concentration values of propafenone and 5-hydroxy-propafenone in acute and chronic therapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2285622/),[ng] / [ml],149,174262,DB04840,Debrisoquin
,3971637,plasma clearances,"The mean plasma clearances of carbamazepine were 19.8, 54.6 and 113.3 ml/h/kg in groups 1, 2 and 3, respectively.",Carbamazepine metabolism in man. Induction and pharmacogenetic aspects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3971637/),[ml] / [h·kg],19.8,176121,DB04840,Debrisoquin
,3971637,plasma clearances,"The mean plasma clearances of carbamazepine were 19.8, 54.6 and 113.3 ml/h/kg in groups 1, 2 and 3, respectively.",Carbamazepine metabolism in man. Induction and pharmacogenetic aspects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3971637/),[ml] / [h·kg],54.6,176122,DB04840,Debrisoquin
,3971637,plasma clearances,"The mean plasma clearances of carbamazepine were 19.8, 54.6 and 113.3 ml/h/kg in groups 1, 2 and 3, respectively.",Carbamazepine metabolism in man. Induction and pharmacogenetic aspects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3971637/),[ml] / [h·kg],113.3,176123,DB04840,Debrisoquin
,3971637,urinary excretion,"The urinary excretion of 9-OH-CBZ was 1.9, 3.3 and 4.0% of the trans-CBZ-diol excretion during CBZ-E therapy and 23, 32 and 24%, respectively, during carbamazepine administration.",Carbamazepine metabolism in man. Induction and pharmacogenetic aspects. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3971637/),%,1.9,176124,DB04840,Debrisoquin
,3971637,urinary excretion,"The urinary excretion of 9-OH-CBZ was 1.9, 3.3 and 4.0% of the trans-CBZ-diol excretion during CBZ-E therapy and 23, 32 and 24%, respectively, during carbamazepine administration.",Carbamazepine metabolism in man. Induction and pharmacogenetic aspects. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3971637/),%,3.3,176125,DB04840,Debrisoquin
,3971637,urinary excretion,"The urinary excretion of 9-OH-CBZ was 1.9, 3.3 and 4.0% of the trans-CBZ-diol excretion during CBZ-E therapy and 23, 32 and 24%, respectively, during carbamazepine administration.",Carbamazepine metabolism in man. Induction and pharmacogenetic aspects. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3971637/),%,4.0,176126,DB04840,Debrisoquin
,3971637,urinary excretion,"The urinary excretion of 9-OH-CBZ was 1.9, 3.3 and 4.0% of the trans-CBZ-diol excretion during CBZ-E therapy and 23, 32 and 24%, respectively, during carbamazepine administration.",Carbamazepine metabolism in man. Induction and pharmacogenetic aspects. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3971637/),%,23,176127,DB04840,Debrisoquin
,3971637,urinary excretion,"The urinary excretion of 9-OH-CBZ was 1.9, 3.3 and 4.0% of the trans-CBZ-diol excretion during CBZ-E therapy and 23, 32 and 24%, respectively, during carbamazepine administration.",Carbamazepine metabolism in man. Induction and pharmacogenetic aspects. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3971637/),%,32,176128,DB04840,Debrisoquin
,3971637,urinary excretion,"The urinary excretion of 9-OH-CBZ was 1.9, 3.3 and 4.0% of the trans-CBZ-diol excretion during CBZ-E therapy and 23, 32 and 24%, respectively, during carbamazepine administration.",Carbamazepine metabolism in man. Induction and pharmacogenetic aspects. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3971637/),%,24,176129,DB04840,Debrisoquin
,6423808,oral bioavailability,"In the EM group, the oral bioavailability of encainide was only about 25 to 30% because of extensive presystemic (first-pass) metabolism, and no accumulation occurred after multiple oral dosing with 50 mg every 8 hr for 3 days, as the elimination half-life of the drug was about 2.5 hr.",Influence of genetic polymorphism on the metabolism and disposition of encainide in man. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6423808/),%,25 to 30,177156,DB04840,Debrisoquin
,6423808,elimination half-life,"In the EM group, the oral bioavailability of encainide was only about 25 to 30% because of extensive presystemic (first-pass) metabolism, and no accumulation occurred after multiple oral dosing with 50 mg every 8 hr for 3 days, as the elimination half-life of the drug was about 2.5 hr.",Influence of genetic polymorphism on the metabolism and disposition of encainide in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6423808/),h,2.5,177157,DB04840,Debrisoquin
,8803522,total clearance,"The total clearance was 517 ml.min-1, and the absolute bioavailability was 91% for the 30-mg and 81% for the 15-mg enteric-coated formulation.",Pharmacokinetics and absolute bioavailability of lansoprazole. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8803522/),[ml] / [min],517,177431,DB04840,Debrisoquin
,8803522,absolute bioavailability,"The total clearance was 517 ml.min-1, and the absolute bioavailability was 91% for the 30-mg and 81% for the 15-mg enteric-coated formulation.",Pharmacokinetics and absolute bioavailability of lansoprazole. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8803522/),%,91,177432,DB04840,Debrisoquin
,8803522,absolute bioavailability,"The total clearance was 517 ml.min-1, and the absolute bioavailability was 91% for the 30-mg and 81% for the 15-mg enteric-coated formulation.",Pharmacokinetics and absolute bioavailability of lansoprazole. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8803522/),%,81,177433,DB04840,Debrisoquin
,8803522,elimination half-life,The elimination half-life was about 1 h.,Pharmacokinetics and absolute bioavailability of lansoprazole. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8803522/),h,1,177434,DB04840,Debrisoquin
,2495208,plasma half-lives,The plasma half-lives were longer in poor hydroxylators than they were in extensive hydroxylators of mephenytoin for both diazepam (88.3 +/- SD 17.2 and 40.8 +/- 14.0 hours; p = 0.0002) and demethyldiazepam (127.8 +/- 23.0 and 59.0 +/- 16.8 hours; p = 0.0001).,"Importance of genetic factors in the regulation of diazepam metabolism: relationship to S-mephenytoin, but not debrisoquin, hydroxylation phenotype. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2495208/),h,88.3,177475,DB04840,Debrisoquin
,2495208,plasma half-lives,The plasma half-lives were longer in poor hydroxylators than they were in extensive hydroxylators of mephenytoin for both diazepam (88.3 +/- SD 17.2 and 40.8 +/- 14.0 hours; p = 0.0002) and demethyldiazepam (127.8 +/- 23.0 and 59.0 +/- 16.8 hours; p = 0.0001).,"Importance of genetic factors in the regulation of diazepam metabolism: relationship to S-mephenytoin, but not debrisoquin, hydroxylation phenotype. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2495208/),h,40.8,177476,DB04840,Debrisoquin
,2495208,plasma half-lives,The plasma half-lives were longer in poor hydroxylators than they were in extensive hydroxylators of mephenytoin for both diazepam (88.3 +/- SD 17.2 and 40.8 +/- 14.0 hours; p = 0.0002) and demethyldiazepam (127.8 +/- 23.0 and 59.0 +/- 16.8 hours; p = 0.0001).,"Importance of genetic factors in the regulation of diazepam metabolism: relationship to S-mephenytoin, but not debrisoquin, hydroxylation phenotype. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2495208/),h,127.8,177477,DB04840,Debrisoquin
,2495208,plasma half-lives,The plasma half-lives were longer in poor hydroxylators than they were in extensive hydroxylators of mephenytoin for both diazepam (88.3 +/- SD 17.2 and 40.8 +/- 14.0 hours; p = 0.0002) and demethyldiazepam (127.8 +/- 23.0 and 59.0 +/- 16.8 hours; p = 0.0001).,"Importance of genetic factors in the regulation of diazepam metabolism: relationship to S-mephenytoin, but not debrisoquin, hydroxylation phenotype. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2495208/),h,59.0,177478,DB04840,Debrisoquin
,2864157,AUC,"There was a fourfold difference in mean AUC (1590 +/- 1133 vs. 394 +/- 239 ng X hr/ml; P less than 0.01) and a twofold difference in mean t1/2 (7.5 +/- 3 vs. 3.7 +/- 1.7 hours; P less than 0.01), reflecting differences in oral clearance (13.1 +/- 7.8 vs. 48.5 +/- 23.2 L/hr; P less than 0.01).",Pharmacokinetics and beta-blocking effects of timolol in poor and extensive metabolizers of debrisoquin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2864157/),[h·ng] / [ml],1590,178394,DB04840,Debrisoquin
,2864157,AUC,"There was a fourfold difference in mean AUC (1590 +/- 1133 vs. 394 +/- 239 ng X hr/ml; P less than 0.01) and a twofold difference in mean t1/2 (7.5 +/- 3 vs. 3.7 +/- 1.7 hours; P less than 0.01), reflecting differences in oral clearance (13.1 +/- 7.8 vs. 48.5 +/- 23.2 L/hr; P less than 0.01).",Pharmacokinetics and beta-blocking effects of timolol in poor and extensive metabolizers of debrisoquin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2864157/),[h·ng] / [ml],394,178395,DB04840,Debrisoquin
,2864157,t1/2,"There was a fourfold difference in mean AUC (1590 +/- 1133 vs. 394 +/- 239 ng X hr/ml; P less than 0.01) and a twofold difference in mean t1/2 (7.5 +/- 3 vs. 3.7 +/- 1.7 hours; P less than 0.01), reflecting differences in oral clearance (13.1 +/- 7.8 vs. 48.5 +/- 23.2 L/hr; P less than 0.01).",Pharmacokinetics and beta-blocking effects of timolol in poor and extensive metabolizers of debrisoquin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2864157/),h,7.5,178396,DB04840,Debrisoquin
,2864157,t1/2,"There was a fourfold difference in mean AUC (1590 +/- 1133 vs. 394 +/- 239 ng X hr/ml; P less than 0.01) and a twofold difference in mean t1/2 (7.5 +/- 3 vs. 3.7 +/- 1.7 hours; P less than 0.01), reflecting differences in oral clearance (13.1 +/- 7.8 vs. 48.5 +/- 23.2 L/hr; P less than 0.01).",Pharmacokinetics and beta-blocking effects of timolol in poor and extensive metabolizers of debrisoquin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2864157/),h,3.7,178397,DB04840,Debrisoquin
,2864157,oral clearance,"There was a fourfold difference in mean AUC (1590 +/- 1133 vs. 394 +/- 239 ng X hr/ml; P less than 0.01) and a twofold difference in mean t1/2 (7.5 +/- 3 vs. 3.7 +/- 1.7 hours; P less than 0.01), reflecting differences in oral clearance (13.1 +/- 7.8 vs. 48.5 +/- 23.2 L/hr; P less than 0.01).",Pharmacokinetics and beta-blocking effects of timolol in poor and extensive metabolizers of debrisoquin. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2864157/),[l] / [h],13.1,178398,DB04840,Debrisoquin
,2864157,oral clearance,"There was a fourfold difference in mean AUC (1590 +/- 1133 vs. 394 +/- 239 ng X hr/ml; P less than 0.01) and a twofold difference in mean t1/2 (7.5 +/- 3 vs. 3.7 +/- 1.7 hours; P less than 0.01), reflecting differences in oral clearance (13.1 +/- 7.8 vs. 48.5 +/- 23.2 L/hr; P less than 0.01).",Pharmacokinetics and beta-blocking effects of timolol in poor and extensive metabolizers of debrisoquin. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2864157/),[l] / [h],48.5,178399,DB04840,Debrisoquin
,8436157,total area under the curve (AUC),"These subjects showed higher total area under the curve (AUC), (15.7 versus 8.16 micrograms.h.ml-1) prolonged elimination half-lives (in serum and urine) (serum: 18.5 versus 11.6 h, urine: 19.2 versus 11.7 h) and lower total clearance values compared with EM (216 versus 450 ml.min-1).",Influence of debrisoquine hydroxylation phenotype on the pharmacokinetics of mexiletine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8436157/),[h·μg] / [ml],15.7,183186,DB04840,Debrisoquin
,8436157,total area under the curve (AUC),"These subjects showed higher total area under the curve (AUC), (15.7 versus 8.16 micrograms.h.ml-1) prolonged elimination half-lives (in serum and urine) (serum: 18.5 versus 11.6 h, urine: 19.2 versus 11.7 h) and lower total clearance values compared with EM (216 versus 450 ml.min-1).",Influence of debrisoquine hydroxylation phenotype on the pharmacokinetics of mexiletine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8436157/),[h·μg] / [ml],8.16,183187,DB04840,Debrisoquin
,8436157,elimination half-lives,"These subjects showed higher total area under the curve (AUC), (15.7 versus 8.16 micrograms.h.ml-1) prolonged elimination half-lives (in serum and urine) (serum: 18.5 versus 11.6 h, urine: 19.2 versus 11.7 h) and lower total clearance values compared with EM (216 versus 450 ml.min-1).",Influence of debrisoquine hydroxylation phenotype on the pharmacokinetics of mexiletine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8436157/),h,18.5,183188,DB04840,Debrisoquin
,8436157,elimination half-lives,"These subjects showed higher total area under the curve (AUC), (15.7 versus 8.16 micrograms.h.ml-1) prolonged elimination half-lives (in serum and urine) (serum: 18.5 versus 11.6 h, urine: 19.2 versus 11.7 h) and lower total clearance values compared with EM (216 versus 450 ml.min-1).",Influence of debrisoquine hydroxylation phenotype on the pharmacokinetics of mexiletine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8436157/),h,11.6,183189,DB04840,Debrisoquin
,8436157,elimination half-lives,"These subjects showed higher total area under the curve (AUC), (15.7 versus 8.16 micrograms.h.ml-1) prolonged elimination half-lives (in serum and urine) (serum: 18.5 versus 11.6 h, urine: 19.2 versus 11.7 h) and lower total clearance values compared with EM (216 versus 450 ml.min-1).",Influence of debrisoquine hydroxylation phenotype on the pharmacokinetics of mexiletine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8436157/),h,19.2,183190,DB04840,Debrisoquin
,8436157,elimination half-lives,"These subjects showed higher total area under the curve (AUC), (15.7 versus 8.16 micrograms.h.ml-1) prolonged elimination half-lives (in serum and urine) (serum: 18.5 versus 11.6 h, urine: 19.2 versus 11.7 h) and lower total clearance values compared with EM (216 versus 450 ml.min-1).",Influence of debrisoquine hydroxylation phenotype on the pharmacokinetics of mexiletine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8436157/),h,11.7,183191,DB04840,Debrisoquin
,8436157,total clearance,"These subjects showed higher total area under the curve (AUC), (15.7 versus 8.16 micrograms.h.ml-1) prolonged elimination half-lives (in serum and urine) (serum: 18.5 versus 11.6 h, urine: 19.2 versus 11.7 h) and lower total clearance values compared with EM (216 versus 450 ml.min-1).",Influence of debrisoquine hydroxylation phenotype on the pharmacokinetics of mexiletine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8436157/),[ml] / [min],216,183192,DB04840,Debrisoquin
,8436157,total clearance,"These subjects showed higher total area under the curve (AUC), (15.7 versus 8.16 micrograms.h.ml-1) prolonged elimination half-lives (in serum and urine) (serum: 18.5 versus 11.6 h, urine: 19.2 versus 11.7 h) and lower total clearance values compared with EM (216 versus 450 ml.min-1).",Influence of debrisoquine hydroxylation phenotype on the pharmacokinetics of mexiletine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8436157/),[ml] / [min],450,183193,DB04840,Debrisoquin
,12621383,area under the concentration-time curve from time 0 to infinity,"The systemic clearance of atomoxetine was significantly reduced in those with hepatic impairment compared with controls, thereby resulting in increased exposure (area under the concentration-time curve from time 0 to infinity, 1.58 versus 0.85 microg.",Effect of hepatic impairment on the pharmacokinetics of atomoxetine and its metabolites. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12621383/),μg,1.58,186169,DB04840,Debrisoquin
,12621383,area under the concentration-time curve from time 0 to infinity,"The systemic clearance of atomoxetine was significantly reduced in those with hepatic impairment compared with controls, thereby resulting in increased exposure (area under the concentration-time curve from time 0 to infinity, 1.58 versus 0.85 microg.",Effect of hepatic impairment on the pharmacokinetics of atomoxetine and its metabolites. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12621383/),μg,0.85,186170,DB04840,Debrisoquin
,12621383,plasma protein binding,"Mean atomoxetine plasma protein binding was lower in patients with hepatic impairment compared with controls (96.5% versus 98.7%, P =.0008).",Effect of hepatic impairment on the pharmacokinetics of atomoxetine and its metabolites. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12621383/),%,96.5,186171,DB04840,Debrisoquin
,12621383,plasma protein binding,"Mean atomoxetine plasma protein binding was lower in patients with hepatic impairment compared with controls (96.5% versus 98.7%, P =.0008).",Effect of hepatic impairment on the pharmacokinetics of atomoxetine and its metabolites. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12621383/),%,98.7,186172,DB04840,Debrisoquin
,1867957,area under the curve (AUC),"The plasma and urine concentrations of codeine and the metabolites were measured by h.p.l.c. 2. The mean area under the curve (AUC), half-life and total plasma clearance of codeine were 1020 +/- 340 nmol l-1 h, 2.58 +/- 0.57 h and 2.02 +/- 0.73 l h-1 kg-1, respectively.",Pharmacokinetics of codeine and its metabolites in Caucasian healthy volunteers: comparisons between extensive and poor hydroxylators of debrisoquine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1867957/),[h·nM] / [l],1020,190000,DB04840,Debrisoquin
,1867957,half-life,"The plasma and urine concentrations of codeine and the metabolites were measured by h.p.l.c. 2. The mean area under the curve (AUC), half-life and total plasma clearance of codeine were 1020 +/- 340 nmol l-1 h, 2.58 +/- 0.57 h and 2.02 +/- 0.73 l h-1 kg-1, respectively.",Pharmacokinetics of codeine and its metabolites in Caucasian healthy volunteers: comparisons between extensive and poor hydroxylators of debrisoquine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1867957/),h,2.58,190001,DB04840,Debrisoquin
,1867957,total plasma clearance,"The plasma and urine concentrations of codeine and the metabolites were measured by h.p.l.c. 2. The mean area under the curve (AUC), half-life and total plasma clearance of codeine were 1020 +/- 340 nmol l-1 h, 2.58 +/- 0.57 h and 2.02 +/- 0.73 l h-1 kg-1, respectively.",Pharmacokinetics of codeine and its metabolites in Caucasian healthy volunteers: comparisons between extensive and poor hydroxylators of debrisoquine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1867957/),[l] / [h·kg],2.02,190002,DB04840,Debrisoquin
,10885584,absolute bioavailability,"The absolute bioavailability is approximately 50%, mainly because of gut wall and hepatic first-pass metabolism.",Clinical pharmacokinetics of mirtazapine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10885584/),%,50,193151,DB04840,Debrisoquin
,10885584,elimination half-life,"The elimination half-life of mirtazapine ranges from 20 to 40 hours, which is in agreement with the time to reach steady state (4 to 6 days).",Clinical pharmacokinetics of mirtazapine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10885584/),h,20 to 40,193152,DB04840,Debrisoquin
,10885584,time to reach steady state,"The elimination half-life of mirtazapine ranges from 20 to 40 hours, which is in agreement with the time to reach steady state (4 to 6 days).",Clinical pharmacokinetics of mirtazapine. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10885584/),d,4 to 6,193153,DB04840,Debrisoquin
,10885584,Total body clearance,Total body clearance as determined from intravenous administration to young males amounts to 31 L/h.,Clinical pharmacokinetics of mirtazapine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10885584/),[l] / [h],31,193154,DB04840,Debrisoquin
,10885584,half-life,"The pharmacokinetics of mirtazapine appears to be enantioselective, resulting in higher plasma concentrations and longer half-life of the (R)-(-)-enantiomer (18.0 +/-2.5h) compared with that of the (S)-(+)-enantiomer (9.9+/-3. lh).",Clinical pharmacokinetics of mirtazapine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10885584/),h,18.0,193155,DB04840,Debrisoquin
,10885584,half-life,"The pharmacokinetics of mirtazapine appears to be enantioselective, resulting in higher plasma concentrations and longer half-life of the (R)-(-)-enantiomer (18.0 +/-2.5h) compared with that of the (S)-(+)-enantiomer (9.9+/-3. lh).",Clinical pharmacokinetics of mirtazapine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10885584/),h,9.9,193156,DB04840,Debrisoquin
,1981634,bioavailability,"The alpha 1-adrenoceptor antagonist indoramin is rapidly and extensively absorbed after oral administration, but with only low to moderate bioavailability (8-24% median) from the tablet (Baratol).",A review of the clinical pharmacokinetics and metabolism of the alpha 1-adrenoceptor antagonist indoramin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1981634/),%,8-24,195139,DB04840,Debrisoquin
,1981634,plasma protein binding,"Although plasma protein binding is high (72-86%), the drug is widely distributed into tissues (with median Vz 6.3-7.7 l/kg after i.v. dosage).",A review of the clinical pharmacokinetics and metabolism of the alpha 1-adrenoceptor antagonist indoramin. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1981634/),%,72-86,195140,DB04840,Debrisoquin
,1981634,Vz,"Although plasma protein binding is high (72-86%), the drug is widely distributed into tissues (with median Vz 6.3-7.7 l/kg after i.v. dosage).",A review of the clinical pharmacokinetics and metabolism of the alpha 1-adrenoceptor antagonist indoramin. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1981634/),[l] / [kg],6.3-7.7,195141,DB04840,Debrisoquin
,1981634,plasma clearances,"2. Elimination of indoramin is rapid in most healthy volunteers, with median plasma clearances of 18-26 ml/min per kg, after i.v. dosage.",A review of the clinical pharmacokinetics and metabolism of the alpha 1-adrenoceptor antagonist indoramin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1981634/),[ml] / [kg·min],18-26,195142,DB04840,Debrisoquin
,3131058,time required to achieve steady-state concentrations,"The time required to achieve steady-state concentrations of metabolites (in extensive metabolisers) and of encainide itself (in poor metabolisers) is similar (3 to 5 days); therefore, the dosage should be increased no more often than every 3 to 5 days.",Clinical pharmacokinetics of encainide. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3131058/),d,3 to 5,198796,DB04840,Debrisoquin
,8384945,Absolute bioavailability,"Absolute bioavailability of citalopram is almost 100%, whereas it is likely that the other compounds undergo (substantial) first-pass metabolism.",Clinical pharmacokinetics of selective serotonin reuptake inhibitors. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8384945/),%,100,201450,DB04840,Debrisoquin
,8384945,Apparent oral clearance,"Apparent oral clearance values after single doses range from 26 L/h (citalopram) to 167 L/h (paroxetine), while after multiple doses oral clearance is markedly reduced, particularly for fluoxetine and paroxetine.",Clinical pharmacokinetics of selective serotonin reuptake inhibitors. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8384945/),[l] / [h],26,201451,DB04840,Debrisoquin
,8384945,Apparent oral clearance,"Apparent oral clearance values after single doses range from 26 L/h (citalopram) to 167 L/h (paroxetine), while after multiple doses oral clearance is markedly reduced, particularly for fluoxetine and paroxetine.",Clinical pharmacokinetics of selective serotonin reuptake inhibitors. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8384945/),[l] / [h],167,201452,DB04840,Debrisoquin
> or =,8384945,Plasma protein binding,"Plasma protein binding of fluoxetine, paroxetine and sertraline is > or = 95%; values for fluvoxamine (77%) and citalopram (50%) are much lower.",Clinical pharmacokinetics of selective serotonin reuptake inhibitors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8384945/),%,95,201453,DB04840,Debrisoquin
,8384945,Plasma protein binding,"Plasma protein binding of fluoxetine, paroxetine and sertraline is > or = 95%; values for fluvoxamine (77%) and citalopram (50%) are much lower.",Clinical pharmacokinetics of selective serotonin reuptake inhibitors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8384945/),%,77,201454,DB04840,Debrisoquin
,8384945,Plasma protein binding,"Plasma protein binding of fluoxetine, paroxetine and sertraline is > or = 95%; values for fluvoxamine (77%) and citalopram (50%) are much lower.",Clinical pharmacokinetics of selective serotonin reuptake inhibitors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8384945/),%,50,201455,DB04840,Debrisoquin
,8384945,half-lives,"The half-lives of fluvoxamine, paroxetine, sertraline and citalopram are approximately 1 day.",Clinical pharmacokinetics of selective serotonin reuptake inhibitors. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8384945/),d,1,201456,DB04840,Debrisoquin
,8384945,half-life,"The half-life of fluoxetine is approximately 2 days (6 days after multiple doses), and that of the active metabolite norfluoxetine is 7 to 15 days.",Clinical pharmacokinetics of selective serotonin reuptake inhibitors. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8384945/),d,2,201457,DB04840,Debrisoquin
,8384945,half-life,"The half-life of fluoxetine is approximately 2 days (6 days after multiple doses), and that of the active metabolite norfluoxetine is 7 to 15 days.",Clinical pharmacokinetics of selective serotonin reuptake inhibitors. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8384945/),d,6,201458,DB04840,Debrisoquin
,8384945,half-life,"The half-life of fluoxetine is approximately 2 days (6 days after multiple doses), and that of the active metabolite norfluoxetine is 7 to 15 days.",Clinical pharmacokinetics of selective serotonin reuptake inhibitors. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8384945/),d,7 to 15,201459,DB04840,Debrisoquin
less,3988975,"""metabolic ratio""","The ""metabolic ratio"" of urinary debrisoquine to 4-OHD was less than 3 in all 20 subjects, indicating extensive debrisoquine hydroxylation in every volunteer, including two Chinese individuals known to display slow clearance of desipramine.",Interethnic dissociation between debrisoquine and desipramine hydroxylation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3988975/),,3,205156,DB04840,Debrisoquin
,7628184,oral clearance,"In the absence of omeprazole, diazepam oral clearance was marginally greater (mean +/- SEM) (34.4 +/- 2.8 ml/min versus 25.2 +/- 3.5 ml/min, p = 0.057, respectively) and the AUC of desmethyldiazepam was significantly lower (8794 +/- 538 micrograms/L.hr versus 16,358 +/- 2985 mg/L.hr, p = 0.04, respectively) in the white subjects compared with the Chinese subjects.",Interethnic difference in omeprazole's inhibition of diazepam metabolism. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7628184/),[ml] / [min],34.4,207703,DB04840,Debrisoquin
,7628184,oral clearance,"In the absence of omeprazole, diazepam oral clearance was marginally greater (mean +/- SEM) (34.4 +/- 2.8 ml/min versus 25.2 +/- 3.5 ml/min, p = 0.057, respectively) and the AUC of desmethyldiazepam was significantly lower (8794 +/- 538 micrograms/L.hr versus 16,358 +/- 2985 mg/L.hr, p = 0.04, respectively) in the white subjects compared with the Chinese subjects.",Interethnic difference in omeprazole's inhibition of diazepam metabolism. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7628184/),[ml] / [min],25.2,207704,DB04840,Debrisoquin
,7628184,AUC,"In the absence of omeprazole, diazepam oral clearance was marginally greater (mean +/- SEM) (34.4 +/- 2.8 ml/min versus 25.2 +/- 3.5 ml/min, p = 0.057, respectively) and the AUC of desmethyldiazepam was significantly lower (8794 +/- 538 micrograms/L.hr versus 16,358 +/- 2985 mg/L.hr, p = 0.04, respectively) in the white subjects compared with the Chinese subjects.",Interethnic difference in omeprazole's inhibition of diazepam metabolism. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7628184/),[μg] / [h·l],8794,207705,DB04840,Debrisoquin
,7628184,AUC,"In the absence of omeprazole, diazepam oral clearance was marginally greater (mean +/- SEM) (34.4 +/- 2.8 ml/min versus 25.2 +/- 3.5 ml/min, p = 0.057, respectively) and the AUC of desmethyldiazepam was significantly lower (8794 +/- 538 micrograms/L.hr versus 16,358 +/- 2985 mg/L.hr, p = 0.04, respectively) in the white subjects compared with the Chinese subjects.",Interethnic difference in omeprazole's inhibition of diazepam metabolism. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7628184/),[mg] / [h·l],"16,358",207706,DB04840,Debrisoquin
,9630826,systemic clearance,"The mean systemic clearance of tolterodine was significantly lower (p < 0.001) among poor metabolizers (9.0 +/- 2.1 l/hr) compared with extensive metabolizers (44 +/- 13 L/hr), resulting in a fourfold longer elimination half-life (p < 0.001).",Influence of CYP2D6 polymorphism on the pharmacokinetics and pharmacodynamic of tolterodine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9630826/),[l] / [h],9.0,210214,DB04840,Debrisoquin
,9630826,systemic clearance,"The mean systemic clearance of tolterodine was significantly lower (p < 0.001) among poor metabolizers (9.0 +/- 2.1 l/hr) compared with extensive metabolizers (44 +/- 13 L/hr), resulting in a fourfold longer elimination half-life (p < 0.001).",Influence of CYP2D6 polymorphism on the pharmacokinetics and pharmacodynamic of tolterodine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9630826/),[l] / [h],44,210215,DB04840,Debrisoquin
,9630826,terminal half-life,"The terminal half-life of the 5-hydroxymethyl metabolite (2.9 +/- 0.4 hours) was slightly longer than that of the parent compound (2.3 +/- 0.6 hours) among extensive metabolizers, but the 5-hydroxymethyl metabolite was undetectable in the serum of poor metabolizers.",Influence of CYP2D6 polymorphism on the pharmacokinetics and pharmacodynamic of tolterodine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9630826/),h,2.9,210216,DB04840,Debrisoquin
,9630826,terminal half-life,"The terminal half-life of the 5-hydroxymethyl metabolite (2.9 +/- 0.4 hours) was slightly longer than that of the parent compound (2.3 +/- 0.6 hours) among extensive metabolizers, but the 5-hydroxymethyl metabolite was undetectable in the serum of poor metabolizers.",Influence of CYP2D6 polymorphism on the pharmacokinetics and pharmacodynamic of tolterodine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9630826/),h,2.3,210217,DB04840,Debrisoquin
,1906003,half-lives,The half-lives of R- and S-flecainide in PMs (R 19.3 h; S 16.1 h) were approximately twice those observed in EMs (R 8.8 h; S 9.1 h).,Polymorphic flecainide disposition under conditions of uncontrolled urine flow and pH. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1906003/),h,19.3,221014,DB04840,Debrisoquin
,1906003,half-lives,The half-lives of R- and S-flecainide in PMs (R 19.3 h; S 16.1 h) were approximately twice those observed in EMs (R 8.8 h; S 9.1 h).,Polymorphic flecainide disposition under conditions of uncontrolled urine flow and pH. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1906003/),h,16.1,221015,DB04840,Debrisoquin
,1906003,half-lives,The half-lives of R- and S-flecainide in PMs (R 19.3 h; S 16.1 h) were approximately twice those observed in EMs (R 8.8 h; S 9.1 h).,Polymorphic flecainide disposition under conditions of uncontrolled urine flow and pH. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1906003/),h,8.8,221016,DB04840,Debrisoquin
,1906003,half-lives,The half-lives of R- and S-flecainide in PMs (R 19.3 h; S 16.1 h) were approximately twice those observed in EMs (R 8.8 h; S 9.1 h).,Polymorphic flecainide disposition under conditions of uncontrolled urine flow and pH. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1906003/),h,9.1,221017,DB04840,Debrisoquin
,1906003,apparent oral clearances,The apparent oral clearances of R- and S-flecainide were lower in PMs (R 313 ml.min-1; S 379 ml.min-1) than in EMs (R 783 ml.min-1; S 828 ml.min-1).,Polymorphic flecainide disposition under conditions of uncontrolled urine flow and pH. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1906003/),[ml] / [min],313,221018,DB04840,Debrisoquin
,1906003,apparent oral clearances,The apparent oral clearances of R- and S-flecainide were lower in PMs (R 313 ml.min-1; S 379 ml.min-1) than in EMs (R 783 ml.min-1; S 828 ml.min-1).,Polymorphic flecainide disposition under conditions of uncontrolled urine flow and pH. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1906003/),[ml] / [min],379,221019,DB04840,Debrisoquin
,1906003,apparent oral clearances,The apparent oral clearances of R- and S-flecainide were lower in PMs (R 313 ml.min-1; S 379 ml.min-1) than in EMs (R 783 ml.min-1; S 828 ml.min-1).,Polymorphic flecainide disposition under conditions of uncontrolled urine flow and pH. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1906003/),[ml] / [min],783,221020,DB04840,Debrisoquin
,1906003,apparent oral clearances,The apparent oral clearances of R- and S-flecainide were lower in PMs (R 313 ml.min-1; S 379 ml.min-1) than in EMs (R 783 ml.min-1; S 828 ml.min-1).,Polymorphic flecainide disposition under conditions of uncontrolled urine flow and pH. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1906003/),[ml] / [min],828,221021,DB04840,Debrisoquin
,1906003,nonrenal clearance,The nonrenal clearance of both enantiomers was significantly lower in poor (R 123 ml.min-1; S 201 ml.min-1) relative to extensive metabolisers (R 533 ml.min-1; S 586 ml.min-1).,Polymorphic flecainide disposition under conditions of uncontrolled urine flow and pH. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1906003/),[ml] / [min],123,221022,DB04840,Debrisoquin
,1906003,nonrenal clearance,The nonrenal clearance of both enantiomers was significantly lower in poor (R 123 ml.min-1; S 201 ml.min-1) relative to extensive metabolisers (R 533 ml.min-1; S 586 ml.min-1).,Polymorphic flecainide disposition under conditions of uncontrolled urine flow and pH. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1906003/),[ml] / [min],201,221023,DB04840,Debrisoquin
,1906003,nonrenal clearance,The nonrenal clearance of both enantiomers was significantly lower in poor (R 123 ml.min-1; S 201 ml.min-1) relative to extensive metabolisers (R 533 ml.min-1; S 586 ml.min-1).,Polymorphic flecainide disposition under conditions of uncontrolled urine flow and pH. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1906003/),[ml] / [min],533,221024,DB04840,Debrisoquin
,1906003,nonrenal clearance,The nonrenal clearance of both enantiomers was significantly lower in poor (R 123 ml.min-1; S 201 ml.min-1) relative to extensive metabolisers (R 533 ml.min-1; S 586 ml.min-1).,Polymorphic flecainide disposition under conditions of uncontrolled urine flow and pH. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1906003/),[ml] / [min],586,221025,DB04840,Debrisoquin
,1906003,partial clearance,The partial clearance to the two major metabolites meta-O-dealkylated flecainide (MODF) and the meta-O-dealkylated lactam of flecainide (MODLF) was significantly lower in poor (62 ml.min-1) than extensive (267 ml.min-1) metabolisers.,Polymorphic flecainide disposition under conditions of uncontrolled urine flow and pH. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1906003/),[ml] / [min],62,221026,DB04840,Debrisoquin
,1906003,partial clearance,The partial clearance to the two major metabolites meta-O-dealkylated flecainide (MODF) and the meta-O-dealkylated lactam of flecainide (MODLF) was significantly lower in poor (62 ml.min-1) than extensive (267 ml.min-1) metabolisers.,Polymorphic flecainide disposition under conditions of uncontrolled urine flow and pH. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1906003/),[ml] / [min],267,221027,DB04840,Debrisoquin
,10381807,apparent clearance,"Codeine-apparent clearance and partial metabolic clearance by O-demethylation were significantly greater in the Caucasian than in the Chinese subjects (1939 +/- 175 ml/min versus 1301 +/- 193 ml/min, p <.03 and 162.7 +/- 36.6 ml/min versus 52.7 +/- 12.7 ml/min, p <.02, respectively).",Impact of ethnic origin and quinidine coadministration on codeine's disposition and pharmacodynamic effects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10381807/),[ml] / [min],1939,223370,DB04840,Debrisoquin
,10381807,partial metabolic clearance,"Codeine-apparent clearance and partial metabolic clearance by O-demethylation were significantly greater in the Caucasian than in the Chinese subjects (1939 +/- 175 ml/min versus 1301 +/- 193 ml/min, p <.03 and 162.7 +/- 36.6 ml/min versus 52.7 +/- 12.7 ml/min, p <.02, respectively).",Impact of ethnic origin and quinidine coadministration on codeine's disposition and pharmacodynamic effects. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10381807/),[ml] / [min],162.7,223371,DB04840,Debrisoquin
,10381807,partial metabolic clearance,"Codeine-apparent clearance and partial metabolic clearance by O-demethylation were significantly greater in the Caucasian than in the Chinese subjects (1939 +/- 175 ml/min versus 1301 +/- 193 ml/min, p <.03 and 162.7 +/- 36.6 ml/min versus 52.7 +/- 12.7 ml/min, p <.02, respectively).",Impact of ethnic origin and quinidine coadministration on codeine's disposition and pharmacodynamic effects. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10381807/),[ml] / [min],52.7,223372,DB04840,Debrisoquin
,10381807,O,"Codeine O-demethylation was significantly reduced after quinidine in both ethnic groups; however, the absolute decrease was greater in Caucasians (115.8 +/- 25.9 ml/min versus 46.8 +/- 10.6 ml/min, respectively, p <.03).",Impact of ethnic origin and quinidine coadministration on codeine's disposition and pharmacodynamic effects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10381807/),[ml] / [min],115.8,223373,DB04840,Debrisoquin
,1941626,total clearance,"In EM, quinidine decreased mexiletine total clearance from 621 +/- 298 to 471 +/- 214 ml/min (mean +/- S.D.; P less than .05) and mexiletine nonrenal clearance from 583 +/- 292 to 404 +/- 188 ml/min (P less than .05).",Influence of debrisoquine phenotype and of quinidine on mexiletine disposition in man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1941626/),[ml] / [min],621,226923,DB04840,Debrisoquin
,1941626,total clearance,"In EM, quinidine decreased mexiletine total clearance from 621 +/- 298 to 471 +/- 214 ml/min (mean +/- S.D.; P less than .05) and mexiletine nonrenal clearance from 583 +/- 292 to 404 +/- 188 ml/min (P less than .05).",Influence of debrisoquine phenotype and of quinidine on mexiletine disposition in man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1941626/),[ml] / [min],471,226924,DB04840,Debrisoquin
,1941626,nonrenal clearance,"In EM, quinidine decreased mexiletine total clearance from 621 +/- 298 to 471 +/- 214 ml/min (mean +/- S.D.; P less than .05) and mexiletine nonrenal clearance from 583 +/- 292 to 404 +/- 188 ml/min (P less than .05).",Influence of debrisoquine phenotype and of quinidine on mexiletine disposition in man. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1941626/),[ml] / [min],583,226925,DB04840,Debrisoquin
,1941626,nonrenal clearance,"In EM, quinidine decreased mexiletine total clearance from 621 +/- 298 to 471 +/- 214 ml/min (mean +/- S.D.; P less than .05) and mexiletine nonrenal clearance from 583 +/- 292 to 404 +/- 188 ml/min (P less than .05).",Influence of debrisoquine phenotype and of quinidine on mexiletine disposition in man. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1941626/),[ml] / [min],404,226926,DB04840,Debrisoquin
,1941626,elimination half-life,"Moreover, quinidine increased mexiletine elimination half-life in EM from 9 +/- 1 to 11 +/- 2 h (P less than .05).",Influence of debrisoquine phenotype and of quinidine on mexiletine disposition in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1941626/),h,9,226927,DB04840,Debrisoquin
,1941626,elimination half-life,"Moreover, quinidine increased mexiletine elimination half-life in EM from 9 +/- 1 to 11 +/- 2 h (P less than .05).",Influence of debrisoquine phenotype and of quinidine on mexiletine disposition in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1941626/),h,11,226928,DB04840,Debrisoquin
,8148222,Cmax,"The mean (s.d.) Cmax was 117 (81) nmol l-1 and the mean AUC(0,24) value was 890 (711) nmol l-1 h.",Disposition of clozapine in man: lack of association with debrisoquine and S-mephenytoin hydroxylation polymorphisms. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8148222/),[nM] / [l],117,234385,DB04840,Debrisoquin
,8148222,"AUC(0,24)","The mean (s.d.) Cmax was 117 (81) nmol l-1 and the mean AUC(0,24) value was 890 (711) nmol l-1 h.",Disposition of clozapine in man: lack of association with debrisoquine and S-mephenytoin hydroxylation polymorphisms. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8148222/),[h·nM] / [l],890,234386,DB04840,Debrisoquin
,8148222,"t1/2,z","The value of t1/2,z varied 3-fold with a mean (s.d.) of 13.3 (5.0) h.",Disposition of clozapine in man: lack of association with debrisoquine and S-mephenytoin hydroxylation polymorphisms. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8148222/),h,13.3,234387,DB04840,Debrisoquin
,6121708,t 1/2,"Peak plasma concentrations were higher for the parent drug but due to a longer elimination half-life, the metabolite concentrations became higher after a few hours (bufuralol t 1/2 = 2.7 +/- 0.9 h, metabolite t 1/2 = 6.1 +/- 1.5h).",The genetic control of bufuralol metabolism in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6121708/),h,2.7,234409,DB04840,Debrisoquin
,6121708,t 1/2,"Peak plasma concentrations were higher for the parent drug but due to a longer elimination half-life, the metabolite concentrations became higher after a few hours (bufuralol t 1/2 = 2.7 +/- 0.9 h, metabolite t 1/2 = 6.1 +/- 1.5h).",The genetic control of bufuralol metabolism in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6121708/),h,6.1,234410,DB04840,Debrisoquin
,6121708,bioavailability,The bioavailability of the tablet tested was 46 +/- 15%.,The genetic control of bufuralol metabolism in man. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6121708/),%,46,234411,DB04840,Debrisoquin
,11269570,relative bioavailability,"Based on Cmax and AUC(infinity) ratios, relative bioavailability of tolterodine in the presence of food was 1.49 (90% confidence interval [CI], 1.35-1.71) and 1.53 (1.35-1.72), respectively.",Food increases the bioavailability of tolterodine but not effective exposure. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11269570/),,1.49,238499,DB04840,Debrisoquin
,11269570,relative bioavailability,"Based on Cmax and AUC(infinity) ratios, relative bioavailability of tolterodine in the presence of food was 1.49 (90% confidence interval [CI], 1.35-1.71) and 1.53 (1.35-1.72), respectively.",Food increases the bioavailability of tolterodine but not effective exposure. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11269570/),,1.53,238500,DB04840,Debrisoquin
,12968986,CT half-life,"Based on two time points, this subject had a very long CT half-life of 95 h.",Metabolism of citalopram enantiomers in CYP2C19/CYP2D6 phenotyped panels of healthy Swedes. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12968986/),h,95,246479,DB04840,Debrisoquin
,2498026,AUC,"The AUC was higher (1462 +/- 407 versus 860 +/- 256 hr ng/ml), the elimination half-life prolonged (11.8 versus 6.8 hours), and the amount excreted in the urine was higher (26.7 +/- 7.2 versus 15.4 +/- 1.3 mg) in PMs compared with EMs (p less than 0.05).",The influence of the sparteine/debrisoquin phenotype on the disposition of flecainide. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2498026/),[h·ng] / [ml],1462,248880,DB04840,Debrisoquin
,2498026,AUC,"The AUC was higher (1462 +/- 407 versus 860 +/- 256 hr ng/ml), the elimination half-life prolonged (11.8 versus 6.8 hours), and the amount excreted in the urine was higher (26.7 +/- 7.2 versus 15.4 +/- 1.3 mg) in PMs compared with EMs (p less than 0.05).",The influence of the sparteine/debrisoquin phenotype on the disposition of flecainide. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2498026/),[h·ng] / [ml],860,248881,DB04840,Debrisoquin
,2498026,elimination half-life,"The AUC was higher (1462 +/- 407 versus 860 +/- 256 hr ng/ml), the elimination half-life prolonged (11.8 versus 6.8 hours), and the amount excreted in the urine was higher (26.7 +/- 7.2 versus 15.4 +/- 1.3 mg) in PMs compared with EMs (p less than 0.05).",The influence of the sparteine/debrisoquin phenotype on the disposition of flecainide. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2498026/),h,11.8,248882,DB04840,Debrisoquin
,2498026,elimination half-life,"The AUC was higher (1462 +/- 407 versus 860 +/- 256 hr ng/ml), the elimination half-life prolonged (11.8 versus 6.8 hours), and the amount excreted in the urine was higher (26.7 +/- 7.2 versus 15.4 +/- 1.3 mg) in PMs compared with EMs (p less than 0.05).",The influence of the sparteine/debrisoquin phenotype on the disposition of flecainide. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2498026/),h,6.8,248883,DB04840,Debrisoquin
,2498026,amount excreted,"The AUC was higher (1462 +/- 407 versus 860 +/- 256 hr ng/ml), the elimination half-life prolonged (11.8 versus 6.8 hours), and the amount excreted in the urine was higher (26.7 +/- 7.2 versus 15.4 +/- 1.3 mg) in PMs compared with EMs (p less than 0.05).",The influence of the sparteine/debrisoquin phenotype on the disposition of flecainide. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2498026/),mg,26.7,248884,DB04840,Debrisoquin
,2498026,amount excreted,"The AUC was higher (1462 +/- 407 versus 860 +/- 256 hr ng/ml), the elimination half-life prolonged (11.8 versus 6.8 hours), and the amount excreted in the urine was higher (26.7 +/- 7.2 versus 15.4 +/- 1.3 mg) in PMs compared with EMs (p less than 0.05).",The influence of the sparteine/debrisoquin phenotype on the disposition of flecainide. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2498026/),mg,15.4,248885,DB04840,Debrisoquin
,2498026,Oral clearance,Oral clearance of flecainide was reduced (p less than 0.019) in PMs (600 +/- 139 versus 1041 +/- 307 ml/min in EMs).,The influence of the sparteine/debrisoquin phenotype on the disposition of flecainide. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2498026/),[ml] / [min],600,248886,DB04840,Debrisoquin
,2498026,Oral clearance,Oral clearance of flecainide was reduced (p less than 0.019) in PMs (600 +/- 139 versus 1041 +/- 307 ml/min in EMs).,The influence of the sparteine/debrisoquin phenotype on the disposition of flecainide. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2498026/),[ml] / [min],1041,248887,DB04840,Debrisoquin
,2498026,renal clearance,"The renal clearance was similar (p greater than 0.05) in PMs (308 +/- 70 ml/min) and EMs (315 +/- 69 ml/min) and, consequently, PMs had a lower (p less than 0.008) metabolic clearance of flecainide (292 +/- 136 versus 726 +/- 240 ml/min in EMs).",The influence of the sparteine/debrisoquin phenotype on the disposition of flecainide. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2498026/),[ml] / [min],308,248888,DB04840,Debrisoquin
,2498026,renal clearance,"The renal clearance was similar (p greater than 0.05) in PMs (308 +/- 70 ml/min) and EMs (315 +/- 69 ml/min) and, consequently, PMs had a lower (p less than 0.008) metabolic clearance of flecainide (292 +/- 136 versus 726 +/- 240 ml/min in EMs).",The influence of the sparteine/debrisoquin phenotype on the disposition of flecainide. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2498026/),[ml] / [min],315,248889,DB04840,Debrisoquin
,2498026,metabolic clearance,"The renal clearance was similar (p greater than 0.05) in PMs (308 +/- 70 ml/min) and EMs (315 +/- 69 ml/min) and, consequently, PMs had a lower (p less than 0.008) metabolic clearance of flecainide (292 +/- 136 versus 726 +/- 240 ml/min in EMs).",The influence of the sparteine/debrisoquin phenotype on the disposition of flecainide. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2498026/),[ml] / [min],292,248890,DB04840,Debrisoquin
,2498026,metabolic clearance,"The renal clearance was similar (p greater than 0.05) in PMs (308 +/- 70 ml/min) and EMs (315 +/- 69 ml/min) and, consequently, PMs had a lower (p less than 0.008) metabolic clearance of flecainide (292 +/- 136 versus 726 +/- 240 ml/min in EMs).",The influence of the sparteine/debrisoquin phenotype on the disposition of flecainide. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2498026/),[ml] / [min],726,248891,DB04840,Debrisoquin
,2496225,systemic clearance,"In extensive metabolizers, quinidine decreased encainide systemic clearance from 935 +/- 541 to 190 +/- 77 ml/min and encainide nonrenal clearance from 782 +/- 474 to 95 +/- 32 ml/min (both P less than .02).",Effect of low dose quinidine on encainide pharmacokinetics and pharmacodynamics. Influence of genetic polymorphism. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2496225/),[ml] / [min],935,251484,DB04840,Debrisoquin
,2496225,systemic clearance,"In extensive metabolizers, quinidine decreased encainide systemic clearance from 935 +/- 541 to 190 +/- 77 ml/min and encainide nonrenal clearance from 782 +/- 474 to 95 +/- 32 ml/min (both P less than .02).",Effect of low dose quinidine on encainide pharmacokinetics and pharmacodynamics. Influence of genetic polymorphism. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2496225/),[ml] / [min],190,251485,DB04840,Debrisoquin
,2496225,nonrenal clearance,"In extensive metabolizers, quinidine decreased encainide systemic clearance from 935 +/- 541 to 190 +/- 77 ml/min and encainide nonrenal clearance from 782 +/- 474 to 95 +/- 32 ml/min (both P less than .02).",Effect of low dose quinidine on encainide pharmacokinetics and pharmacodynamics. Influence of genetic polymorphism. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2496225/),[ml] / [min],782,251486,DB04840,Debrisoquin
,2496225,nonrenal clearance,"In extensive metabolizers, quinidine decreased encainide systemic clearance from 935 +/- 541 to 190 +/- 77 ml/min and encainide nonrenal clearance from 782 +/- 474 to 95 +/- 32 ml/min (both P less than .02).",Effect of low dose quinidine on encainide pharmacokinetics and pharmacodynamics. Influence of genetic polymorphism. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2496225/),[ml] / [min],95,251487,DB04840,Debrisoquin
,2496225,elimination half-life,"In this population, quinidine significantly increased encainide elimination half-life from 1.8 +/- 1.2 to 7.7 +/- 2.4 hr and fractional urinary recovery of unchanged encainide from 17.5 +/- 7.6 to 47.4 +/- 7.8% (both P less than .001).",Effect of low dose quinidine on encainide pharmacokinetics and pharmacodynamics. Influence of genetic polymorphism. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2496225/),h,1.8,251488,DB04840,Debrisoquin
,2496225,elimination half-life,"In this population, quinidine significantly increased encainide elimination half-life from 1.8 +/- 1.2 to 7.7 +/- 2.4 hr and fractional urinary recovery of unchanged encainide from 17.5 +/- 7.6 to 47.4 +/- 7.8% (both P less than .001).",Effect of low dose quinidine on encainide pharmacokinetics and pharmacodynamics. Influence of genetic polymorphism. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2496225/),h,7.7,251489,DB04840,Debrisoquin
,2496225,fractional urinary recovery,"In this population, quinidine significantly increased encainide elimination half-life from 1.8 +/- 1.2 to 7.7 +/- 2.4 hr and fractional urinary recovery of unchanged encainide from 17.5 +/- 7.6 to 47.4 +/- 7.8% (both P less than .001).",Effect of low dose quinidine on encainide pharmacokinetics and pharmacodynamics. Influence of genetic polymorphism. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2496225/),%,17.5,251490,DB04840,Debrisoquin
,2496225,fractional urinary recovery,"In this population, quinidine significantly increased encainide elimination half-life from 1.8 +/- 1.2 to 7.7 +/- 2.4 hr and fractional urinary recovery of unchanged encainide from 17.5 +/- 7.6 to 47.4 +/- 7.8% (both P less than .001).",Effect of low dose quinidine on encainide pharmacokinetics and pharmacodynamics. Influence of genetic polymorphism. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2496225/),%,47.4,251491,DB04840,Debrisoquin
,2743709,Peak serum concentrations,"Peak serum concentrations of perphenazine were significantly higher in slow hydroxylators than they were in rapid hydroxylators (2.4 +/- 0.6 versus 0.7 +/- 0.3 nmol/L, p less than 0.001).",Disposition of perphenazine is related to polymorphic debrisoquin hydroxylation in human beings. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2743709/),[nM] / [l],2.4,253718,DB04840,Debrisoquin
,2743709,Peak serum concentrations,"Peak serum concentrations of perphenazine were significantly higher in slow hydroxylators than they were in rapid hydroxylators (2.4 +/- 0.6 versus 0.7 +/- 0.3 nmol/L, p less than 0.001).",Disposition of perphenazine is related to polymorphic debrisoquin hydroxylation in human beings. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2743709/),[nM] / [l],0.7,253719,DB04840,Debrisoquin
,2743709,AUC(0-12),"The AUC(0-12) was also higher in slow hydroxylators than it was in rapid hydroxylators (18.5 +/- 6.2 versus 4.5 +/- 2.5 nmol.L-1.hr, p less than 0.001).",Disposition of perphenazine is related to polymorphic debrisoquin hydroxylation in human beings. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2743709/),[h·nM] / [l],18.5,253720,DB04840,Debrisoquin
,2743709,AUC(0-12),"The AUC(0-12) was also higher in slow hydroxylators than it was in rapid hydroxylators (18.5 +/- 6.2 versus 4.5 +/- 2.5 nmol.L-1.hr, p less than 0.001).",Disposition of perphenazine is related to polymorphic debrisoquin hydroxylation in human beings. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2743709/),[h·nM] / [l],4.5,253721,DB04840,Debrisoquin
,1927573,plasma elimination half-life,"The peak plasma concentrations of zuclopenthixol did not differ between the phenotypes, whereas the plasma elimination half-life was significantly longer in poor than in extensive metabolizers (29.9 +/- 6.6 vs 17.6 +/- 6.9 h).",Disposition of the neuroleptic zuclopenthixol cosegregates with the polymorphic hydroxylation of debrisoquine in humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1927573/),h,29.9,256589,DB04840,Debrisoquin
,1927573,plasma elimination half-life,"The peak plasma concentrations of zuclopenthixol did not differ between the phenotypes, whereas the plasma elimination half-life was significantly longer in poor than in extensive metabolizers (29.9 +/- 6.6 vs 17.6 +/- 6.9 h).",Disposition of the neuroleptic zuclopenthixol cosegregates with the polymorphic hydroxylation of debrisoquine in humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1927573/),h,17.6,256590,DB04840,Debrisoquin
,1927573,total oral plasma clearance,"Accordingly, the total oral plasma clearance was lower in poor than in extensive metabolizers (0.78 +/- 0.27 vs 2.12 +/- 0.65 1/h/kg).",Disposition of the neuroleptic zuclopenthixol cosegregates with the polymorphic hydroxylation of debrisoquine in humans. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1927573/),[1] / [h·kg],0.78,256591,DB04840,Debrisoquin
,1927573,total oral plasma clearance,"Accordingly, the total oral plasma clearance was lower in poor than in extensive metabolizers (0.78 +/- 0.27 vs 2.12 +/- 0.65 1/h/kg).",Disposition of the neuroleptic zuclopenthixol cosegregates with the polymorphic hydroxylation of debrisoquine in humans. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1927573/),[1] / [h·kg],2.12,256592,DB04840,Debrisoquin
,12774293,AUC(0-24),We observed stereo-selectivity in the alpha-hydroxymetoprolol formation favoring the new 1'R chiral center from both metoprolol enantiomers (AUC(0-24) (1'R1'S) = 3.02).,Stereoselective metabolism of metoprolol: enantioselectivity of alpha-hydroxymetoprolol in plasma and urine. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12774293/),,3.02,257405,DB04840,Debrisoquin
,12774293,AUC(0-24),"(-)-(S)-metoprolol was slightly more alpha-hydroxylated than its antipode (AUC(0-24) (2S/2R) = 1.19), suggesting that this pathway is not responsible for plasma accumulation of this enantiomer in humans.",Stereoselective metabolism of metoprolol: enantioselectivity of alpha-hydroxymetoprolol in plasma and urine. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12774293/),,1.19,257406,DB04840,Debrisoquin
,22399238,total plasma clearance,"The mean total plasma clearance of pridopidine was 541 and 138 mL/min in EM and PM, respectively (p = 0.003), and was slightly higher in PM than the mean renal plasma clearance (105 mL/min; p = 0.11).",The dopaminergic stabilizer pridopidine is to a major extent N-depropylated by CYP2D6 in humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22399238/),[ml] / [min],541,259617,DB04840,Debrisoquin
,22399238,total plasma clearance,"The mean total plasma clearance of pridopidine was 541 and 138 mL/min in EM and PM, respectively (p = 0.003), and was slightly higher in PM than the mean renal plasma clearance (105 mL/min; p = 0.11).",The dopaminergic stabilizer pridopidine is to a major extent N-depropylated by CYP2D6 in humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22399238/),[ml] / [min],138,259618,DB04840,Debrisoquin
,22399238,renal plasma clearance,"The mean total plasma clearance of pridopidine was 541 and 138 mL/min in EM and PM, respectively (p = 0.003), and was slightly higher in PM than the mean renal plasma clearance (105 mL/min; p = 0.11).",The dopaminergic stabilizer pridopidine is to a major extent N-depropylated by CYP2D6 in humans. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22399238/),[ml] / [min],105,259619,DB04840,Debrisoquin
,22399238,plasma,"The mean plasma area under the time-concentration curve between time zero and 32 h (AUC(0-32 h)) of the N-depropyl metabolite ACR30 was higher in EM than in PM (1,377 vs. 61 nmol h/mL, respectively; p < 0.001).",The dopaminergic stabilizer pridopidine is to a major extent N-depropylated by CYP2D6 in humans. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22399238/),[h·nM] / [ml],"1,377",259620,DB04840,Debrisoquin
,22399238,area under the time-concentration curve between time zero and 32 h (AUC(0-32 h)),"The mean plasma area under the time-concentration curve between time zero and 32 h (AUC(0-32 h)) of the N-depropyl metabolite ACR30 was higher in EM than in PM (1,377 vs. 61 nmol h/mL, respectively; p < 0.001).",The dopaminergic stabilizer pridopidine is to a major extent N-depropylated by CYP2D6 in humans. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22399238/),[h·nM] / [ml],"1,377",259621,DB04840,Debrisoquin
,22399238,area under the time-concentration curve between time zero and 32 h (AUC(0-32 h)),"The mean plasma area under the time-concentration curve between time zero and 32 h (AUC(0-32 h)) of the N-depropyl metabolite ACR30 was higher in EM than in PM (1,377 vs. 61 nmol h/mL, respectively; p < 0.001).",The dopaminergic stabilizer pridopidine is to a major extent N-depropylated by CYP2D6 in humans. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22399238/),[h·nM] / [ml],61,259622,DB04840,Debrisoquin
,22399238,urinary excretion,The urinary excretion of pridopidine + ACR30 was high in both EM (85 %) and PM (78 %).,The dopaminergic stabilizer pridopidine is to a major extent N-depropylated by CYP2D6 in humans. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22399238/),%,85,259623,DB04840,Debrisoquin
,22399238,urinary excretion,The urinary excretion of pridopidine + ACR30 was high in both EM (85 %) and PM (78 %).,The dopaminergic stabilizer pridopidine is to a major extent N-depropylated by CYP2D6 in humans. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22399238/),%,78,259624,DB04840,Debrisoquin
,11936706,clearance,"The mean clearance of R-ketamine, 0.020 l min(-1) kg(-1), was slightly but significantly lower than of S-ketamine, 0.024 l min(-1) kg(-1).",Pharmacokinetics and non-analgesic effects of S- and R-ketamines in healthy volunteers with normal and reduced metabolic capacity. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11936706/),[l] / [kg·min],0.020,260954,DB04840,Debrisoquin
,11936706,clearance,"The mean clearance of R-ketamine, 0.020 l min(-1) kg(-1), was slightly but significantly lower than of S-ketamine, 0.024 l min(-1) kg(-1).",Pharmacokinetics and non-analgesic effects of S- and R-ketamines in healthy volunteers with normal and reduced metabolic capacity. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11936706/),[l] / [kg·min],0.024,260955,DB04840,Debrisoquin
<,7586928,metabolic ratio [MR],"A single oral dose of dihydrocodeine was administered to six extensive (metabolic ratio [MR] < or = 1), two intermediate (1 < MR < 20) and six poor metabolizers (MR > or = 20) of sparteine/debrisoquin.",Dihydrocodeine: a new opioid substrate for the polymorphic CYP2D6 in humans. ,Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7586928/),,1,261923,DB04840,Debrisoquin
<,7586928,1,"A single oral dose of dihydrocodeine was administered to six extensive (metabolic ratio [MR] < or = 1), two intermediate (1 < MR < 20) and six poor metabolizers (MR > or = 20) of sparteine/debrisoquin.",Dihydrocodeine: a new opioid substrate for the polymorphic CYP2D6 in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7586928/),,20,261924,DB04840,Debrisoquin
>,7586928,MR,"A single oral dose of dihydrocodeine was administered to six extensive (metabolic ratio [MR] < or = 1), two intermediate (1 < MR < 20) and six poor metabolizers (MR > or = 20) of sparteine/debrisoquin.",Dihydrocodeine: a new opioid substrate for the polymorphic CYP2D6 in humans. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7586928/),,20,261925,DB04840,Debrisoquin
,7586928,area under the serum concentration-time curve (AUC),"However, the area under the serum concentration-time curve (AUC), partial metabolic clearance, and total urinary recovery of dihydromorphine were significantly lower in poor metabolizers (10.3 +/- 6.1 nmol.hr/L; 7.0 +/- 4.1 ml/min; 1.3% +/- 0.9% of dose) compared with extensive metabolizers (75.5 +/- 42.9 nmol.hr/L; 49.7 +/- 29.9 ml/min; 8.9% +/- 6.2%; p < 0.01).",Dihydrocodeine: a new opioid substrate for the polymorphic CYP2D6 in humans. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7586928/),[h·nM] / [l],10.3,261926,DB04840,Debrisoquin
,7586928,partial metabolic clearance,"However, the area under the serum concentration-time curve (AUC), partial metabolic clearance, and total urinary recovery of dihydromorphine were significantly lower in poor metabolizers (10.3 +/- 6.1 nmol.hr/L; 7.0 +/- 4.1 ml/min; 1.3% +/- 0.9% of dose) compared with extensive metabolizers (75.5 +/- 42.9 nmol.hr/L; 49.7 +/- 29.9 ml/min; 8.9% +/- 6.2%; p < 0.01).",Dihydrocodeine: a new opioid substrate for the polymorphic CYP2D6 in humans. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7586928/),[ml] / [min],7.0,261927,DB04840,Debrisoquin
,7586928,total urinary recovery,"However, the area under the serum concentration-time curve (AUC), partial metabolic clearance, and total urinary recovery of dihydromorphine were significantly lower in poor metabolizers (10.3 +/- 6.1 nmol.hr/L; 7.0 +/- 4.1 ml/min; 1.3% +/- 0.9% of dose) compared with extensive metabolizers (75.5 +/- 42.9 nmol.hr/L; 49.7 +/- 29.9 ml/min; 8.9% +/- 6.2%; p < 0.01).",Dihydrocodeine: a new opioid substrate for the polymorphic CYP2D6 in humans. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7586928/),%,1.3,261928,DB04840,Debrisoquin
,7586928,total urinary recovery,"However, the area under the serum concentration-time curve (AUC), partial metabolic clearance, and total urinary recovery of dihydromorphine were significantly lower in poor metabolizers (10.3 +/- 6.1 nmol.hr/L; 7.0 +/- 4.1 ml/min; 1.3% +/- 0.9% of dose) compared with extensive metabolizers (75.5 +/- 42.9 nmol.hr/L; 49.7 +/- 29.9 ml/min; 8.9% +/- 6.2%; p < 0.01).",Dihydrocodeine: a new opioid substrate for the polymorphic CYP2D6 in humans. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7586928/),%,8.9,261929,DB04840,Debrisoquin
,10583027,apparent oral clearance,"A decrease (P<0.01) in apparent oral clearance of tolterodine, from 10- 12 l h-1 to 4.3-4.7 l h-1, was obtained during concomitant administration of ketoconazole, yielding at least a two-fold increase in the area under the serum concentration-time curve after single as well as after multiple doses following single dose administration of tolterodine.",Ketoconazole inhibits the metabolism of tolterodine in subjects with deficient CYP2D6 activity. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10583027/),[l] / [h],10- 12,263027,DB04840,Debrisoquin
,10583027,apparent oral clearance,"A decrease (P<0.01) in apparent oral clearance of tolterodine, from 10- 12 l h-1 to 4.3-4.7 l h-1, was obtained during concomitant administration of ketoconazole, yielding at least a two-fold increase in the area under the serum concentration-time curve after single as well as after multiple doses following single dose administration of tolterodine.",Ketoconazole inhibits the metabolism of tolterodine in subjects with deficient CYP2D6 activity. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10583027/),[l] / [h],4.3-4.7,263028,DB04840,Debrisoquin
,10583027,terminal half-life,The mean (+/-s.d.) terminal half-life increased by 50% from 9.7+/-2.7 h to 15+/-5.4 h in the presence of ketoconazole.,Ketoconazole inhibits the metabolism of tolterodine in subjects with deficient CYP2D6 activity. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10583027/),h,9.7,263029,DB04840,Debrisoquin
,10583027,terminal half-life,The mean (+/-s.d.) terminal half-life increased by 50% from 9.7+/-2.7 h to 15+/-5.4 h in the presence of ketoconazole.,Ketoconazole inhibits the metabolism of tolterodine in subjects with deficient CYP2D6 activity. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10583027/),h,15,263030,DB04840,Debrisoquin
,3829342,elimination half-life,"EMs were characterized by a shorter propafenone elimination half-life (5.5 +/- 2.1 vs 17.2 +/- 8.0, p less than .001), lower average plasma concentration (Cp) (1.1 +/- 0.6 vs 2.5 +/- 0.5 ng/ml/mg daily dosage, p less than .001), and higher oral clearance (1115 +/- 1238 vs 264 +/- 48 ml/min, p less than .001).",Polymorphism of propafenone metabolism and disposition in man: clinical and pharmacokinetic consequences. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3829342/),,5.5,264409,DB04840,Debrisoquin
,3829342,elimination half-life,"EMs were characterized by a shorter propafenone elimination half-life (5.5 +/- 2.1 vs 17.2 +/- 8.0, p less than .001), lower average plasma concentration (Cp) (1.1 +/- 0.6 vs 2.5 +/- 0.5 ng/ml/mg daily dosage, p less than .001), and higher oral clearance (1115 +/- 1238 vs 264 +/- 48 ml/min, p less than .001).",Polymorphism of propafenone metabolism and disposition in man: clinical and pharmacokinetic consequences. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3829342/),,17.2,264410,DB04840,Debrisoquin
,3829342,plasma concentration (Cp),"EMs were characterized by a shorter propafenone elimination half-life (5.5 +/- 2.1 vs 17.2 +/- 8.0, p less than .001), lower average plasma concentration (Cp) (1.1 +/- 0.6 vs 2.5 +/- 0.5 ng/ml/mg daily dosage, p less than .001), and higher oral clearance (1115 +/- 1238 vs 264 +/- 48 ml/min, p less than .001).",Polymorphism of propafenone metabolism and disposition in man: clinical and pharmacokinetic consequences. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3829342/),[ng] / [daily·dosage·mg·ml],1.1,264411,DB04840,Debrisoquin
,3829342,plasma concentration (Cp),"EMs were characterized by a shorter propafenone elimination half-life (5.5 +/- 2.1 vs 17.2 +/- 8.0, p less than .001), lower average plasma concentration (Cp) (1.1 +/- 0.6 vs 2.5 +/- 0.5 ng/ml/mg daily dosage, p less than .001), and higher oral clearance (1115 +/- 1238 vs 264 +/- 48 ml/min, p less than .001).",Polymorphism of propafenone metabolism and disposition in man: clinical and pharmacokinetic consequences. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3829342/),[ng] / [daily·dosage·mg·ml],2.5,264412,DB04840,Debrisoquin
,3829342,oral clearance,"EMs were characterized by a shorter propafenone elimination half-life (5.5 +/- 2.1 vs 17.2 +/- 8.0, p less than .001), lower average plasma concentration (Cp) (1.1 +/- 0.6 vs 2.5 +/- 0.5 ng/ml/mg daily dosage, p less than .001), and higher oral clearance (1115 +/- 1238 vs 264 +/- 48 ml/min, p less than .001).",Polymorphism of propafenone metabolism and disposition in man: clinical and pharmacokinetic consequences. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3829342/),[ml] / [min],1115,264413,DB04840,Debrisoquin
,3829342,oral clearance,"EMs were characterized by a shorter propafenone elimination half-life (5.5 +/- 2.1 vs 17.2 +/- 8.0, p less than .001), lower average plasma concentration (Cp) (1.1 +/- 0.6 vs 2.5 +/- 0.5 ng/ml/mg daily dosage, p less than .001), and higher oral clearance (1115 +/- 1238 vs 264 +/- 48 ml/min, p less than .001).",Polymorphism of propafenone metabolism and disposition in man: clinical and pharmacokinetic consequences. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3829342/),[ml] / [min],264,264414,DB04840,Debrisoquin
,3780126,clearance,Cirrhosis produced a 50% reduction in pinacidil's clearance (20.7 +/- 1.4 vs. 42.1 +/- 5.1 L/hr; P less than 0.0005) and a prolongation in the elimination t1/2 from 3.9 +/- 0.3 to 6.1 +/- 0.6 hours (P less than 0.01).,Effect of cirrhosis and debrisoquin phenotype on the disposition and effects of pinacidil. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3780126/),[l] / [h],20.7,265659,DB04840,Debrisoquin
,3780126,clearance,Cirrhosis produced a 50% reduction in pinacidil's clearance (20.7 +/- 1.4 vs. 42.1 +/- 5.1 L/hr; P less than 0.0005) and a prolongation in the elimination t1/2 from 3.9 +/- 0.3 to 6.1 +/- 0.6 hours (P less than 0.01).,Effect of cirrhosis and debrisoquin phenotype on the disposition and effects of pinacidil. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3780126/),[l] / [h],42.1,265660,DB04840,Debrisoquin
,3780126,elimination t1/2,Cirrhosis produced a 50% reduction in pinacidil's clearance (20.7 +/- 1.4 vs. 42.1 +/- 5.1 L/hr; P less than 0.0005) and a prolongation in the elimination t1/2 from 3.9 +/- 0.3 to 6.1 +/- 0.6 hours (P less than 0.01).,Effect of cirrhosis and debrisoquin phenotype on the disposition and effects of pinacidil. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3780126/),h,3.9,265661,DB04840,Debrisoquin
,3780126,elimination t1/2,Cirrhosis produced a 50% reduction in pinacidil's clearance (20.7 +/- 1.4 vs. 42.1 +/- 5.1 L/hr; P less than 0.0005) and a prolongation in the elimination t1/2 from 3.9 +/- 0.3 to 6.1 +/- 0.6 hours (P less than 0.01).,Effect of cirrhosis and debrisoquin phenotype on the disposition and effects of pinacidil. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3780126/),h,6.1,265662,DB04840,Debrisoquin
,11736864,AUClast,"The geometric mean AUClast values (with 95% CI) for MDZ were 95.6 (79.0, 115.7) and 160.4 (133.6, 192.6) microg l(-1) h when given alone and as part of the six drug cocktail, respectively.",An interaction between the cytochrome P450 probe substrates chlorzoxazone (CYP2E1) and midazolam (CYP3A). ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11736864/),[h·μg] / [l],95.6,267028,DB04840,Debrisoquin
,11736864,AUClast,"The geometric mean AUClast values (with 95% CI) for MDZ were 95.6 (79.0, 115.7) and 160.4 (133.6, 192.6) microg l(-1) h when given alone and as part of the six drug cocktail, respectively.",An interaction between the cytochrome P450 probe substrates chlorzoxazone (CYP2E1) and midazolam (CYP3A). ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11736864/),[h·μg] / [l],160.4,267029,DB04840,Debrisoquin
,2266495,clearance,"When compared with Wistar rats (n = 10), dark Agouti rats (n = 10) had a higher mean clearance (4.8 ml/min per kg vs. 3.3 ml/min per kg) and a lower mean residence time (606 min vs. 1361 min) after intravenous dosing of CsA.",Pharmacokinetics and chronic toxicity of cyclosporine A in genetic hydroxylation-deficient dark Agouti rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2266495/),[ml] / [kg·min],4.8,272317,DB04840,Debrisoquin
,2266495,clearance,"When compared with Wistar rats (n = 10), dark Agouti rats (n = 10) had a higher mean clearance (4.8 ml/min per kg vs. 3.3 ml/min per kg) and a lower mean residence time (606 min vs. 1361 min) after intravenous dosing of CsA.",Pharmacokinetics and chronic toxicity of cyclosporine A in genetic hydroxylation-deficient dark Agouti rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2266495/),[ml] / [kg·min],3.3,272318,DB04840,Debrisoquin
,2266495,mean residence time,"When compared with Wistar rats (n = 10), dark Agouti rats (n = 10) had a higher mean clearance (4.8 ml/min per kg vs. 3.3 ml/min per kg) and a lower mean residence time (606 min vs. 1361 min) after intravenous dosing of CsA.",Pharmacokinetics and chronic toxicity of cyclosporine A in genetic hydroxylation-deficient dark Agouti rats. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2266495/),min,606,272319,DB04840,Debrisoquin
,2266495,mean residence time,"When compared with Wistar rats (n = 10), dark Agouti rats (n = 10) had a higher mean clearance (4.8 ml/min per kg vs. 3.3 ml/min per kg) and a lower mean residence time (606 min vs. 1361 min) after intravenous dosing of CsA.",Pharmacokinetics and chronic toxicity of cyclosporine A in genetic hydroxylation-deficient dark Agouti rats. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2266495/),min,1361,272320,DB04840,Debrisoquin
,2266495,systemic availability,The systemic availability of subcutaneous CsA was close to 100%.,Pharmacokinetics and chronic toxicity of cyclosporine A in genetic hydroxylation-deficient dark Agouti rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2266495/),%,100,272321,DB04840,Debrisoquin
,2266495,steady state CsA concentrations,The steady state CsA concentrations assessed by HPLC in whole blood after subcutaneous dosing of 20 mg/kg per day for 23 days (n = 10) were about 1000 ng/ml in dark Agouti rats.,Pharmacokinetics and chronic toxicity of cyclosporine A in genetic hydroxylation-deficient dark Agouti rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2266495/),[ng] / [ml],1000,272322,DB04840,Debrisoquin
